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1  In onderzoek naar de rol v
an hepcidine in gezondheid e
n ziekte dient ook de rol van 
de ratio hepcidine/ferritine te
 worden geëvalueerd. [dit proef
schrift]
2  In de algemene Kaukasisc
he populatie komen geen sing
le nucleotide 
polymorfismen voor die meer
 dan 1% van de variatie in de c
oncentratie van serum 
hepcidine verklaren. [dit proefs
chrift]
3  De verdeling van ijzer ove
r het lichaam en niet de absol
ute hoeveelheid ijzer in het 
lichaam lijkt een causale rol t
e spelen in de ontwikkeling va
n atherosclerose.  
[dit proefschrift]
4  Multivariate genoomwijd
e associatieanalyse moet stan
daard worden toegepast bij 
genoomwijde associatieanaly
se van meerdere (gecorreleerd
e) traits om de power 
voor het identificeren van gen
etische determinanten te verg
roten. [dit proefschrift]
5  De resultaten van human
e populatiestudies dienen in s
terkere mate geïntegreerd te 
worden in het design en de in
terpretatie van resultaten van
 cel- en dierstudies.
6  Succes in de wetenschap 
is in te grote mate afhankelijk
 van de uitkomsten van 
wetenschappelijk onderzoek.
7  Om meer grip te krijgen o
p negatieve bevindingen zoud
en alle wetenschappelijke 
studies, en dus niet alleen tria
ls, bij aanvang standaard gere
gistreerd moeten 
worden.
8  De uitspraak ‘de ziel gaat 
te paard’ (Harry Mulisch) is we
tenschappelijk gezien niet 
verdedigbaar, maar als metaf
oor een waarheid als een koe.
 
9 Life is like riding a bicycle.
 To keep your balance you mu
st keep moving. [Albert Einstein]
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CHAPTER 1
General introduction
Hepcidin
In the beginning of the 21st century, a 25-amino acid peptide was discovered and named 
hepcidin, because of its high expression in the liver and antimicrobial activity [1,2]. Hepcidin, 
encoded by the hepcidin antimicrobial peptide gene (HAMP), is predominantly produced 
by hepatocytes, but expression at much lower levels has also been demonstrated for other 
cell types, e.g. cardiomyocytes and kidney tubule [3,4]. Serum hepcidin circulates in the blood-
stream, partly bound to α2-macroglobulin. Reports are inconsistent about the exact per-
centage of hepcidin that is freely circulating [5,6]. Besides the 25-amino acid peptide, three 
smaller hepcidin isoforms of 24, 22 and 20 amino acids exist, but these are only present in 
serum in patients with diseases that are associated with increased hepcidin-25 concentra-
tions [7,8]. Hepcidin has been reported to leave the body via excretion by the kidneys [9,10]. 
Hepcidin is the key regulator of systemic iron homeostasis
Iron (Fe) is an essential trace element for all living organisms, but free iron is highly toxic 
because of its redox activity that catalyzes the formation of reactive oxygen species. For this 
reason, the systemic iron concentration is tightly controlled with hepcidin as key regulator. 
The hepcidin receptor is ferroportin, the major cellular iron exporter in the membrane of 
macrophages, hepatocytes and the basolateral site of enterocytes [11,12]. By binding to ferro-
portin and inducing its internalization and degradation [13], hepcidin regulates the release of 
iron from these cells into the bloodstream: from duodenal enterocytes which absorb  dietary 
iron, from macrophages which are involved in recycling of iron from senescent erythro-
cytes, and from hepatocytes involved in iron storage (Figure 1.1). Thus, hepcidin affects 
body iron distribution, with increased serum hepcidin concentration leading to a decreased 
flow of iron into the bloodstream and an increased amount of iron trapped inside the iron- 
exporting cells, predominantly reticulo-endothelial macrophages [14]. 
Several other parameters that reflect iron status and homeostasis of the human body are 
used in (clinical) practice. In the blood, iron is bound to transferrin, the iron transport pro-
tein. Transferrin can either be directly measured by immunochemical methods or indirectly 
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by the assessment of the total iron-binding capacity (TIBC), a parameter that indicates 
the capacity of the blood to bind iron and thus reflects the transferrin concentration. 
Transferrin saturation (TS) is the ratio of serum iron divided by TIBC times 100% and 
 reflects the percentage of the iron loading places of transferrin that are occupied by iron. 
Intracellular iron is stored in the cytoplasmic protein complex ferritin, from which iron is re-
leased in the circulation during periods of high iron demand. An iron-poor form of ferritin is 
released in the bloodstream, primarily by macrophages [15]. The measurement of circulating 
ferritin is used to quantify body iron stores, since in most circumstances its concentration 
correlates with liver iron concentrations as quantified by magnetic resonance imaging [16,17]. 
 
Little is known about determinants of serum hepcidin in healthy human 
 populations
Most of the current knowledge about hepcidin regulation is based on animal models and in 
vitro research. There have been studies on serum hepcidin concentrations in humans, but 
these are mostly based on patient series. Data on serum hepcidin concentrations in healthy 
individuals are scarce. 
FIGURE 1.1  Systemic iron homeostasis: iron uptake and recycling.
The largest flux of body iron is the recycling of iron from senescent erythrocytes by macrophages and its subsequent 
incorporation in new erythroid precursors in the bone marrow. Only ±1-2 mg of iron is absorbed from the diet and lost 
from the body every day. Hepcidin regulates the systemic iron concentration (Fe-Tf) by inhibiting iron export from 
duodenal enterocytes and reticulo-endothelial macrophages. It is predominantly produced by hepatocytes. Figure 
adapted from Swinkels et al., 2006 [18].
Iron loss
1-2 mg/day 
Iron uptake
1-2 mg/day 
20-25
mg/day 
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Evidence from animal and in vitro studies
The major factor in hepcidin regulation is iron status: when iron is abundant, hepcidin pro-
duction is increased, and vice versa (Figure 1.2). Iron status regulates hepcidin expression via 
circulating iron and iron stores. 
The signal of circulating iron is suggested to be provided by iron-loaded transferrin that 
binds to transferrin receptor 1 and 2 (TfR1 and TfR2) on hepatocytes. The hemochromatosis 
protein Hfe appears to modulate this signal by acting as a bimodal switch between TfR1 
and TfR2 [19]. It is hypothesized that high concentrations of Tf-Fe2 displace Hfe from TfR1 to 
promote its interaction with TfR2. The Hfe-TfR2 complex then activates the transcription 
of HAMP via extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase 
(MAPK) and bone morphogenetic protein (BMP)/son of mothers against decapentaplegic 
(SMAD) signaling [20-22].
Intracellular iron stores have been found to increase hepcidin expression via bone morpho-
genetic proteins (BMP), particularly BMP-6, which bind to BMP receptors and activate SMAD 
signaling [23-25]. Hemojuvelin (HJV), a BMP co-receptor, appears to enhance this signaling [26]. 
HJV is cleaved by matriptase-2 (MT-2), a transmembrane serine protease encoded by the 
transmembrane serine protease 6 gene (TMPRSS6) in case of low iron status, leading to de-
creased BMP signaling [27]. 
Animal models have revealed that mice with a full knockout for positive regulators of hepci-
din transcription, such as HFE and TfR2, present with decreased hepcidin expression leading 
to iron overload [28,29], whereas mice knockout for TMPRSS6 have increased hepcidin expres-
sion leading to anemia [30]. 
Besides iron status, signals reflecting erythropoietic activity, hypoxia and inflammation 
regulate hepcidin expression (Figure 1.2) [8,20-22,31-33]. Hepcidin expression is decreased under 
conditions of increased erythropoiesis, due to the high iron demand of this process [34], and 
during hypoxia, whereas inflammation leads to increased hepcidin expression [35]. Final-
ly, hepcidin mRNA levels were reported to be influenced by various other factors, e.g. tes-
tosterone [36,37], estrogen [38,39], and growth factors [40], but it is not precisely known whether 
these factors affect hepcidin expression directly or via signals of iron status, inflammation, 
 hypoxia and/or erythropoiesis (Figure 1.2).
Evidence from studies in patients
There is some evidence about regulation of serum hepcidin in humans based on studies in 
patients with inherited and acquired disorders associated with either a hepcidin deficiency 
or a hepcidin excess [8]. The first group includes most forms of hereditary hemochromatosis 
(HH), which are characterized by body iron overload, ultimately resulting in iron-mediated 
organ injury like liver cirrhosis [8,18]. The most common form of HH is caused by homozygosity 
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for the single nucleotide polymorphism (SNP) rs1800562 (p.Cys282Tyr) in HFE, but defects 
in other genes that positively regulate hepcidin are also known to cause HH, namely TfR2, 
HJV, and, but rarely, HAMP itself [8,18,41,42]. Also, hepcidin synthesis is decreased in iron-load-
ing anemias, including β-thalassemia intermedia and major and congenital dyserythro-
poietic anemias, due to overactivity of the diseased erythron despite the presence of iron 
loading [33,43,44]. Furthermore, hepcidin concentrations are relatively low for the level of iron 
load in acquired liver diseases such as excessive alcohol consumption and nonalcoholic 
fatty liver disease, and in patients with iron-deficiency anemia or low ferritin concentra-
tions without anemia [8]. 
Hepcidin concentrations are increased relative to TS in patients with iron-refractory iron 
deficiency anemia (IRIDA), an inherited form of iron deficiency anemia that is resistant to 
oral iron therapy and only partially responds to parenteral iron administration, which re-
sults from defects in the TMPRSS6 gene [45]. Furthermore, hepcidin is increased in infectious 
and inflammatory diseases, and in renal diseases due to impaired renal clearance and asso-
ciated (low-grade) inflammation [8,46].
Evidence from studies in healthy volunteers
Evidence about hepcidin regulation in healthy individuals is scarce and mostly based on 
studies that investigated serum hepcidin levels in relatively small groups, ranging from 
23 to 114 individuals [9,10,47-49]. Data from these studies revealed that serum hepcidin con-
centrations vary substantially between healthy persons, and that gender is a major deter-
minant of serum hepcidin at population level, with higher hepcidin levels in men than in 
women  [9,10,47-49]. The largest study showed median (P5-P95) serum hepcidin concentrations 
of 112 (29-254) and 65 (17-286) ng/mL in men and women, respectively [9]. Hepcidin concen-
tration was shown to increase during a working day [9,47,48,50], which was recently described 
to be mediated by an innate diurnal rhythm rather than dietary iron [51]. The influence of 
age was investigated by only one of the studies on healthy subjects, which showed a trend 
of increasing hepcidin with age for both genders. However, this trend was non-significant 
and the authors called for further confirmation [9]. A high correlation between serum hepci-
din and serum ferritin has been reported by several studies on healthy volunteers [9,10,49,52]. In 
addition, oral iron dosing was shown to increase serum hepcidin levels [9,53-56]. These findings 
confirm the evidence from animal and in vitro studies on the role of iron stores and circu-
lating iron in hepcidin regulation (Figure 1.2). 
Studies of hepcidin levels in healthy pregnant women revealed a decreased serum hepci-
din concentration during pregnancy [57,58]. A recent longitudinal study reported that hepci-
din levels decrease gradually during the course of pregnancy and are undetectable (≤0.5 
 nmoles/L) in nearly all women in their third trimester [57]. This is probably a result of maternal 
iron deficiency caused by an increased iron demand due to the growing fetus and placenta, 
and an increased iron need for erythropoiesis to maintain hemoglobin levels (Figure 1.2). 
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Genetic variation influencing serum hepcidin concentration in the general population has 
been unexplored until now, but (common) variants in the genes HFE and TMPRSS6 are likely 
candidates. 
Iron is hypothesized to play a role in the development of atherosclerosis: 
what about hepcidin?
Iron has been linked to multiple diseases, including neurodegenerative disorders [59], type II 
diabetes [60], and atherosclerosis. Atherosclerosis is the gradual process of accumulation of 
fatty substances, cholesterol, cellular waste products, calcium and fibrin in the inner lin-
ing of an artery, leading to a thickening of the arterial wall, a so called ‘plaque’ [61,62]. These 
plaques can rupture or erode, subsequently leading to thrombosis and cardiovascular dis-
eases (CVD) such as myocardial infarcts and cerebrovascular accidents [61]. In 1981, Sullivan 
proposed the ‘iron hypothesis’, which was based on the observation that men have a higher 
risk of heart disease compared to premenopausal women, but not compared to postmeno-
pausal women [63]. He suggested that iron deficiency plays a protective role against heart 
disease and that women are relatively protected because of loss of iron with menstruation. 
Iron, stored in macrophages that reside in the vessel wall, can catalyze the formation of re-
active oxygen species. These oxidize low-density lipoprotein cholesterol, resulting in trans-
formation of the macrophages into foam cells and ultimately atherosclerosis [64,65]. Until 
now, however, epidemiological studies on iron and atherosclerosis or the harder endpoint 
CVD showed inconsistent results [66-73]. In addition, the fact that HH patients with iron over-
load do not show a higher incidence of atherosclerosis provides evidence against the ‘iron 
FIGURE 1.2  Regulation of serum hepcidin.
Increased erythropoiesis and hypoxia 
result in decreased serum hepcidin 
levels, whereas elevated levels of 
circulating iron and increased body 
iron status and inflammation increase 
serum hepcidin. Other factors might 
 either influence hepcidin levels via 
these or other (unknown) processes.
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hypothesis’ [74]. Recently, Sullivan extended the ‘iron hypothesis’ and proposed that hepci-
din plays a role in the development of atherosclerosis via promotion of iron deposition in 
 macrophages, thereby increasing their atherogenic potential (Figure 1.3) [75]. This hypothesis 
has been confirmed by in vitro studies [76,77] and studies in patients on hemodialysis [78,79], but 
has never been tested in the general population. Indeed, if hepcidin proves to be causally 
related to atherosclerosis, it might contribute to CVD risk prediction and offer a new thera-
peutic target for atherosclerosis and CVD. 
 
Additional insight into hepcidin genetics will help to decipher regulation of 
hepcidin and its role in disease
Both iron and hepcidin levels are viewed as multifactorial (or compex) traits that are influ-
enced by many environmental and genetic factors and their interactions. There is a growing 
body of evidence on the genetic variants that affect iron homeostasis in the general popula-
tion. This knowledge has been acquired by application of genome-wide association studies 
(GWAS), in which the entire genome is scanned in a hypothesis-free manner using SNP- 
arrays to identify common genetic variation associated with a trait of interest. GWAS have 
been performed for serum iron, transferrin, TS and ferritin, and revealed associations with 
variants in e.g. HFE, TMPRSS6, the transferrin gene (TF), and the transferrin receptor 2 gene 
(TfR2) [80-84]. On the contrary, relatively little is known about genetic determinants of hepci-
din variation in the general population. No GWAS for serum hepcidin has been performed 
yet, and there are no studies that investigated associations between serum hepcidin and 
FIGURE 1.3   Risk factors of atherosclerosis. 
Established risk factors include diabetes mellitus, low-density lipoprotein cholesterol, hypertension and smoking. 
Iron and hepcidin are hypothesized to play a role in the development of atherosclerosis.
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common variants in plausible candidate genes such as HFE and TMPRSS6. Knowledge on the 
genetic background of hepcidin will increase insight into (potentially modifiable) molecular 
processes that regulate hepcidin production in the general population. Furthermore, it will 
increase insight into its relation with disease phenotypes via enabling so-called Mendelian 
randomization (MR) studies. In this approach, genetic variants are used as proxies for a risk 
factor of interest to test for a causal effect of this risk factor on an outcome of interest (Figure 
1.4) [85]. It allows for evaluation of causality, as the random allocation of genes at conception 
mimics the randomization in a clinical trial, and thus prevents the occurrence of confound-
ing or reverse causation. This approach has originally been proposed almost three decades 
ago by Katan in order to study the causal relation between serum cholesterol and cancer [86]. 
Iron status genetics can be used to identify genetic determinants of serum 
hepcidin
The known correlations between hepcidin and iron metabolism can be exploited in the 
search for genetic determinants of serum hepcidin. The genes that have previously been 
identified via GWAS for iron parameters are likely candidates for hepcidin. In addition, ap-
plication of a multivariate GWAS, in which the association of genetic variants with multiple, 
potentially correlated traits is assessed simultaneously, may lead to improved power to ac-
tually identify associated genetic variants compared to a univariate GWAS [87-90].
 
Objectives of this thesis
The two main objectives are:
1  To identify biochemical correlates and genetic determinants of serum hepcidin in the 
general population (Part I).
2  To elucidate the effect of hepcidin and iron on atherosclerosis in the general population 
(Part II). 
FIGURE 1.4   Mendelian randomization approach.
A genetic variant is used as a proxy for a risk factor to test its effect on an outcome of interest.  This 
 association provides evidence for causality, as confounding or reverse causation are ruled out.
Genetic variant Risk factor Outcome
Confounding factors
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Population 
The epidemiological studies described in this thesis are based on data from the Nijmegen 
Biomedical Study (NBS). The NBS is a population-based study that was initiated in 2001 by 
the Department for Health Evidence and the Department of Laboratory Medicine. It con-
sists of several phases (NBS phase 1 to phase 5) in which detailed information on lifestyle 
and disease status of the participants was collected. Participants of each phase were invited 
to participate in the next phase, provided that they did not object against participation in 
follow-up studies. 
For this thesis we used data from NBS phase 1 (NBS-1, 2003) and the NBS-2-NIMA (non-inva-
sive measurements of atherosclerosis) substudy (2005-2008) (Figure 1.5). NBS-1 comprised 
a limited questionnaire about lifestyle, health status, and medical history and donation of 
a blood sample. A total of 9350 (43%) persons filled out the NBS-1 questionnaire, of which 
6468 (69%) donated blood samples. In the NBS-2-NIMA, all NBS-2 participants aged 50-
70 years (N=2114) were re-invited to fill out an additional QN, donate a fasting blood 
 sample, and undergo anthropometric measurements and non-invasive measurements 
of  atherosclerosis. A total of 1491 subjects participated in NBS-2-NIMA (response 71%). 
 Approval to conduct the NBS and NBS-2-NIMA study was obtained from the Radboud uni-
versity medical center Institutional Review Board. All participants gave written informed 
consent for participation in the NBS.
Outline of this thesis
PART I: Determinants of serum hepcidin
In chapter 2, we assess age- and sex-stratified reference ranges of serum hepcidin and study 
associations between hepcidin and (biochemical) variables in almost 3000 individuals of 
the general population. Chapter 3 describes a candidate-gene association study in which 
we focus on the genes HFE and TMPRSS6 and study the association of SNPs in these genes 
with hepcidin and the iron parameters, i.e. serum iron, ferritin, TIBC and TS. In chapter 4, 
we present a meta-analysis of genome-wide association studies (GWAS) on serum hepcidin. 
A simulation study comparing methods available for multivariate analysis of GWAS is pre-
sented in chapter 5.  
PART II: Effects on atherosclerosis
In chapter 6, we study the associations of hepcidin and the iron parameters with non-inva-
sive measurements of atherosclerosis (i.e. presence of plaque, intima-media thickness (IMT), 
and ankle-brachial index (ABI)). We evaluate these relationships from a genetic perspective 
using an MR approach in chapter 7. 
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A general discussion of the studies presented in this thesis and future perspectives are given 
in chapter 8. 
 
 
FIGURE 1.5   Schematic overview of phase 1 and 2 of the Nijmegen Biomedical Study.
Schematic overview of the data collection within phase 1 and 2 of the Nijmegen Biomedical  Study (NBS) and 
measurements of main variables used in this thesis (hepcidin, iron parameters and  genome-wide single nucleotide 
polymorphism data).
SNP array I was applied to 1980 blood samples of NBS-1 (overlap with NBS-2-NIMA: N=598). 
SNP array II was applied to 1250 blood samples of NBS-1 (overlap with SNP array I: N=200, overlap with NBS-2-NIMA: 
N=384).
NIMA indicates non-invasive measurements of atherosclerosis; SNP array I and II, measurement of  genome-wide 
single nucleotide polymorphism data. 
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ABSTRACT
To date, concentrations of the promising biomarker hepcidin have only been as-
sessed in serum of relatively small series of healthy volunteers and patients. We as-
sessed age and sex stratified reference ranges of serum hepcidin concentration in a 
selected reference set and performed regression analyses to study associations be-
tween hepcidin and (biochemical) variables in a large, well-phenotyped sample of 
the general population (n=2,998). All participants filled out a questionnaire on life-
style, health status and medical history. Serum measurements of iron parameters, 
liver enzyme alanine aminotransferase (ALAT), creatinine and C-reactive protein 
(CRP) were available. Serum hepcidin concentrations were lower for premenopaus-
al than for postmenopausal women (median 4.1 nM vs 8.5 nM, respectively). Hepci-
din concentrations in men were constant over age (median 7.8 nM). Serum hepcidin 
was strongly associated with serum ferritin in men and women [β-coefficient of 
log-transformed variables (95% confidence interval): 0.78 (0.74 – 0.82) and 0.83 (0.78 
– 0.88), respectively]. Additional significant, though less strong, associations were 
observed for CRP and total iron binding capacity (TIBC) in men and for TIBC, ALAT 
and glomerular filtration rate in women. Our study provides age and gender specific 
reference ranges of serum hepcidin concentration and indicates ferritin as the pri-
mary correlate of serum hepcidin concentration. 
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Introduction
Hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis [1,2]. 
It is a 25-amino acid peptide hormone which is produced and secreted predominantly by 
hepatocytes, circulates in the blood stream and is excreted by the kidneys. By binding to the 
cellular iron exporter ferroportin and inducing its internalization and degradation, hepcidin 
regulates cellular iron efflux [3]. In this way, the absorption of dietary iron from the intestine 
and the release of recycled iron derived from senescent erythrocytes is controlled [1,2]. 
The synthesis of hepcidin is regulated by certain physiologic and pathologic processes. 
Hepcidin concentrations are decreased in situations that require increased concentrations 
of circulating iron. In case of increased erythropoiesis, for example in response to hypoxia, 
anemia, iron deficiency or conditions characterized by ineffective erythropoiesis (e.g. thal-
assemia major and intermedia), a decreased hepcidin concentration will result in the re-
lease of stored iron and in an increase in the dietary iron absorption [4-7]. On the other hand, 
infection and inflammation cause an increase in hepcidin synthesis [4,8-10], resulting in de-
creased availability of circulating iron, which is considered to represent a defense mecha-
nism of the human body against extracellularly proliferating (iron-dependent) pathogens [1]. 
In chronic (low grade) inflammatory states, this ultimately leads to a deficiency of iron avail-
able for erythropoiesis called anemia of chronic disease [11]. Finally, hepcidin concentration is 
increased in situations of iron overload [12], except for situations in which mutations in genes 
encoding hepcidin or its upstream positive regulators are responsible for the surplus of iron 
by preventing hepcidin upregulation [6]. Although notable progression has been made in dis-
covering the identities of hepcidin regulators involved in the aforementioned processes, we 
do not yet fully understand the mechanisms by which they influence hepcidin expression.
Since the discovery of hepcidin and the elucidation of its important role in iron  homeostasis 
[1,2], hepcidin has been suggested as a promising diagnostic marker for iron-related dis- 
orders. Determination of serum hepcidin concentration may be a helpful tool in screening 
for hereditary hemochromatosis, thus preventing cumbersome procedures in the search for 
causative (rare) genetic variants. Furthermore, hepcidin concentrations have been suggest-
ed to negatively correlate with the severity of hemochromatosis and to determine the prog-
nosis and need for stringency of the treatment protocol [13]. Hepcidin concentrations may 
also be used in the management of patients with iron loading anemias [5]. In addition, hepci-
din is key in the diagnosis of iron refractory iron deficiency anemia [14], and might contribute 
to the diagnosis of iron deficiency in patients with anemia of chronic diseases [15]. Hepcidin 
might be a potential marker in the prediction of erythropoietin (EPO) response and to guide 
treatment with EPO and intravenous iron [16]. Finally, measurement of serum hepcidin con-
centration is of importance in the monitoring of novel therapies for iron disorders which 
target hepcidin, its upstream regulators or its downstream receptor ferroportin [17]. 
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Until now, knowledge on how hepcidin exerts its regulatory function and on the molecu-
lar processes that regulate hepcidin production is largely based on animal studies and in 
vitro studies which often use hepcidin mRNA expression as a read out [2]. In addition, many 
studies of hepcidin in humans have relied on urinary hepcidin assays and on measurements 
in relatively small groups of healthy subjects or patient series with a variety of iron dis-
orders [2,18], predominantly without making a distinction between gender and age, factors 
that most probably influence hepcidin concentration. Reference ranges of serum hepcidin 
concentration, based on a large subset from the general population, are instructive for the 
use of hepcidin as a diagnostic tool and therapeutic target in the future, but are currently 
not available. Furthermore, knowledge on the association between potential correlates, for 
example markers of infection, inflammation and iron status, and serum hepcidin concen-
tration in humans is relatively scarce, although this information could greatly contribute to 
understanding of the mechanisms by which hepcidin expression is influenced in vivo. There 
are a number of studies which reported a high correlation between serum hepcidin and 
 serum ferritin concentration in small samples of healthy persons [19-22], but other potentially 
important correlates have only been investigated in animal experiments or small healthy 
and diseased human populations. For example, transferrin has been shown to be a major 
determinant of hepcidin expression in hypotransferrinemic mice [23], and in multivariate 
analyses the estimated glomerular filtration rate (eGFR) was reported not to be a major in-
dependent correlate of serum hepcidin concentration in patients with chronic kidney dis-
ease [21]. However, the applicability of these and other findings to the general human popula-
tion is unclear. To increase our insight in the distribution of hepcidin in human populations 
and to pave the way for its use in diagnostic medicine, we studied serum hepcidin concen-
trations and reference ranges and determined its association with selected (biochemical) 
parameters in a large, well-phenotyped sample of the general population.  
Materials and methods
Study population
We included 2,998 participants from the Nijmegen Biomedical Study (NBS). Details of the 
NBS have been described before [24]. Briefly, the NBS is a population-based survey con-
ducted by the Department of Epidemiology, Biostatistics, and HTA and the Department 
of Labora tory Medicine of the Radboud University Nijmegen Medical Centre, The Nether-
lands.  Approval to conduct the study was obtained from the Institutional Review Board. 
Age and gender stratified randomly selected adult inhabitants of Nijmegen (n=22,451), a 
city located in the eastern part of The Netherlands, received an invitation to fill out a postal 
questionnaire on, for example, lifestyle, health status and medical history, and to donate 
an 8.5 ml blood sample in a serum separator tube and a 10 ml EDTA blood sample. A total 
of 9,350 (43%) individuals filled out the questionnaire, of which 6,468 (69%) responders do-
nated blood samples between 8 am and 9 pm; time of blood sampling was recorded. Prior 
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to the procedure described above, a pilot study was performed to optimize the logistical 
procedures of the NBS. The pilot study entailed a random sample of 650 male and female 
inhabitants of Nijmegen aged ≥18 years; 342 subjects (53%) filled out the questionnaire and 
262 (77%) of the responders donated a blood sample. All participants gave written informed 
consent for participation in the NBS.
For this study, serum hepcidin concentration was measured in 2,998 out of the total of 6,730 
available serum samples. Serum measurements of iron, ferritin, total iron binding cap acity 
(TIBC), liver enzyme alanine aminotransferase (ALAT), creatinine and C-reactive protein 
(CRP) were previously performed in all available serum samples. 
The following variables were extracted from the self-administered questionnaire: length, 
weight [used to derive body-mass index (BMI)], age, use of iron supplements at time of blood 
donation for at least six months, presence of anemia determined by a physician, being a 
blood and/or plasma donor, pregnancy and presence of a regular menstruation.   
Laboratory methods
Serum hepcidin concentration was measured with a competitive-ELISA as described be-
fore [25]. In short, 96-well plates were coated overnight at 4°C with goat-anti-rabbit IgG (Fc) 
antibody, washed and then blocked with bovine serum albumin (BSA) (2h, ambient tem-
perature), washed and thereafter incubated with an in-house raised rabbit-anti-human 
hepcidin antibody [26] (2h, ambient temperature) and again washed. Next, the standards, 
study samples (20-fold diluted) and a reference sample were pipetted into the wells. Subse-
quently, biotinylated hepcidin-25 calibrator was added to all wells and the plates were incu-
bated overnight at 4°C. After washing, the plates were incubated with Streptavidin-β-per-
oxidase (Streptavidin-POD) conjugate for 1h at ambient temperature, again washed and 
then o-phenylenediamine (OPD) substrate was added and incubated for 15 minutes in the 
dark. The color reaction was stopped with H2SO4 and optical density was measured at 492 
nm in an automated c-ELISA reader. In each plate a standard curve and the reference prepa-
ration was present. This reference preparation was used for estimation of the accuracy of 
the method. In total, 86 microtiter plates were used in 15 different assay runs. The mean 
hepcidin concentration in this preparation was 6.87 nmol/L (nM), while the intra-assay vari-
ation, the between-plates variation and inter-assay variation were 6.3%, 5.5% and 11.9%, 
respectively. The intra-assay, inter-assay and between-plates variations were calculated 
from the results obtained in the reference preparation. In 86 plates the reference prepara-
tion was measured in duplicate and the calculated concentrations in each plate were used 
to establish the intra-assay variation. The mean hepcidin concentration per plate was used 
for calculation of the between-plates (inter-day) variation and the inter-assay variation. The 
analytical sensitivity, defined as the minimum hepcidin concentration evoking a response 
significantly different from that of the zero calibrator, was 8.96 pM. As the samples were 20-
fold diluted, samples found to have a hepcidin concentration below 179 pM (20 x 8.96 pM) 
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were imputed with a random value out of a uniform distribution with a minimum of 0 nM 
and a maximum of 0.18 nM (n=12). Hepcidin concentrations are expressed in nmol/L; 1 nM 
serum hepcidin equals 2.79 µg/L.
Total serum iron was measured by colorimetric measurement using ascorbate/FerroZine 
reagents (Roche Diagnostics B.V.) on an Abbott Aeroset analyzer. Unsaturated iron binding 
capacity (UIBC) was measured by adding a known quantity of Fe3+ to the serum samples, re-
ducing it with ascorbate to Fe2+ and measuring it with FerroZine as described above (Roche 
reagents on an Aeroset). TIBC was calculated by adding serum iron and UIBC. Serum trans-
ferrin saturation (TS) was computed by dividing serum iron by TIBC. Serum ferritin concen-
tration was determined by a chemiluminescent microparticle immuno-assay on the Abbott 
Architect calibrated against the ferritin assay on the Immulite 2000 of Diagnostic Products 
Corporation (DPC, Los Angeles, CA).
Serum creatinine was measured by a kinetic alkaline picrate method on an Abbott Aeroset 
auto-analyser by exploiting Bromcresol purple (Jaffe method [27]). In view of the importance 
of interlaboratory and methodological differences in the creatinine assays on results of es-
timated glomerular filtration rate (eGFR), our creatinine data obtained by the Jaffe method 
were calibrated against creatinine values traceable to isotope dilution mass spectrome-
try [27,28]. For this purpose, the eGFR was calculated using a re-expressed MDRD (Modification 
of Diet in Renal Disease) formula: 175 x (standardized serum creatinine (in µmol/L) / 88.4)-1.154 
x (age (in years))-0.203 x 0.742 (if female). As this formula is only valid for white individuals and 
we did not have information about race except for country of birth, we used this variable 
as a proxy and calculated the MDRD formula only for subjects born in The Netherlands and 
other western countries. Genetic analyses revealed that country of birth was highly associ-
ated with race (data not shown), supporting our assumption.
ALAT was measured using standard reagents in a reaction rate assay based on the conver-
sion of NADH to NAD (Abbott Reagent on Aeroset). Samples with a measurement result of <3 
U/L were set at 2 U/L.
CRP was quantified by immunologic agglutination detection with latex-coupled polyclonal 
anti-CRP antibodies (Abbott Reagent on Aeroset).  
Statistical analysis
Statistical analyses were performed with SPSS for Windows, release 16.0.2 (SPSS Inc., Chi-
cago, Illinois). Distributions of serum hepcidin, serum ferritin, ALAT and BMI were skewed 
towards higher values; logarithmic transformations were applied to normalize the distribu-
tions. For all continuous variables, median and 2.5th and 97.5th percentiles (P2.5 and P97.5, 
respectively) were calculated from original untransformed values. Blood sampling time and 
CRP were categorized into three groups based on clinically relevant cutoffs. For blood sam-
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pling time, these were <12 pm, 12-5 pm and >5 pm, according to Dutch routine and in line 
with previously reported hepcidin concentration patterns throughout the day [22,29]. For CRP, 
cutoffs of <5 mg/L, 5-20 mg/L and >20 mg/L were used. Categorical variables were expressed 
in numbers and corresponding percentages.
Reference ranges for serum hepcidin concentration, stratified by 5-year age groups and gen-
der, were constructed using the median, P2.5 and P97.5 per category. A reference subset was 
selected by excluding subjects that passed the following criteria at time of blood sampling: 
pregnant, ALAT>50 U/L, CRP>10 mg/L, eGFR<60 mL/min/1.73 m2, use of iron supplements, 
presence of anemia or BMI>30 kg/m2. 
Univariable and multivariable least squares linear regression analyses were used to evalu-
ate the associations between log-transformed serum hepcidin concentrations and selected 
(biochemical) variables, unadjusted and adjusted for age and time of blood sampling. The 
assumption of linearity between serum hepcidin concentrations and independent vari-
ables was confirmed using graphic methods. Resulting regression coefficients (β) express 
the change in log-transformed serum hepcidin that are associated with a 1-unit change in 
the independent variable. Some of the independent variables were log-transformed as well; 
the interpretation of the regression coefficients for these variables is as follows: a 1% change 
in the independent variable corresponds to a β% change in serum hepcidin. The R2 (adjusted 
for the number of explanatory variables in the model) was obtained to indicate the amount 
of variance in hepcidin concentration that was explained by the included variables. All ana-
lyses were stratified by gender.  
Results
Characteristics of the study population
Forty-eight percent of the total study population (n=2,998) was male. Median age of men 
was 63 years; median age of women 54 years. CRP was increased (>20 mg/L) in 2% of the 
population. Serum ferritin concentration was considerably lower in women than in men, 
which is in concordance with the lower median iron concentration, higher TIBC, lower TS 
and larger number of anemic subjects observed in women compared to men. For most sub-
jects, blood sampling was performed between 12 and 5 pm. Blood sampling time distribu-
tion over the age groups was dissimilar: older individuals underwent blood sampling earlier 
during the day (Supplemental Figure 2.1). Additional characteristics of the subjects included 
in the study, stratified by gender, are described in Table 2.1. A total of 1,948 subjects (1,066 
men; 882 women) passed set criteria and were included in the reference set. The character-
istics of the reference set are given in Supplemental Table 2.1.
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Age and gender specific reference ranges for serum hepcidin concentration in the 
reference set
Reference ranges of serum hepcidin concentration in the reference set per 5-year age group 
are given for men and women in Table 2.2 and Supplemental Figure 2.2. Serum hepcidin con-
centration in men was constant over age, with a median of 7.8 nM (P2.5-P97.5, 0.6-23.3 nM). 
Hepcidin concentrations in women trend upwards as they progress through menopause, 
with a median serum hepcidin concentration of 4.1 nM (P2.5-P97.5, 0.4-19.7) for women 
younger than 55 years and 8.5 nM (P2.5-P97.5, 1.2-24.8 nM) for women of 55 years and older. 
These results were confirmed by univariable regression analyses (Supplemental Table 2.2): 
age was not associated with serum hepcidin concentration in men [β 0.003 (95% CI, -0.001; 
0.007)], but it was in women, whether age was defined as a continuous [β 0.029 (95% CI, 
0.025; 0.032)] or dichotomous variable (<55 years vs ≥55 years, based on the distinction be-
tween pre- and postmenopausal state by using age as a proxy in the absence of information 
on menopausal state) [β 0.840 (95% CI, 0.745; 0.935)].
The lowest median hepcidin concentration [2.6 nM (P2.5-P97.5, 0.7-10.5 nM)] was found in 
the category of women aged 18-24 years, while the highest median concentration was ob-
served in the category of women aged 80-84 years [11.9 nM (P2.5-P97.5, 1.6-19.2 nM)]. Serum 
hepcidin concentrations lower than the detection limit of 0.18 nM were observed for both 
men (n=4) and women (n=5). Serum hepcidin concentration varied substantially between 
subjects, which is reflected in wide reference ranges.
As hepcidin concentrations in serum follow a clear circadian rhythm [22,29,30], we considered 
the influence of time of blood sampling on serum hepcidin reference ranges by calculating 
reference ranges stratified for time of blood sampling divided in 3 categories: <12 pm, 12-5 
pm and >5 pm (Supplemental Tables 2.3-2.5). Serum hepcidin concentration in men who un-
derwent blood sampling in the morning (<12 pm) was lower compared to the concentration 
in men who donated blood after 12 pm [12-5 pm vs <12 pm: β 0.427 (95% CI, 0.315; 0.539); >5 
pm vs <12 pm: β 0.366 (95% CI, 0.225; 0.508)] (Supplemental Table 2.2). This effect did not 
change by adjusting for age. In women, a similar effect was observed for hepcidin concen-
tration in blood sampled between 12-5 pm as compared to morning samples [β 0.416 (95% 
CI, 0.287; 0.546)], but the hepcidin concentration was only slightly elevated in samples ob-
tained after 5 pm compared to morning samples [β 0.080 (95% CI, -0.087; 0.247)]. However, 
adjusting for age increased the regression coefficient in women for samples obtained after 
5 pm compared to morning samples to 0.305 (95% CI, 0.150; 0.460) (data not shown). The 
regression coefficient for samples obtained between 12-5 pm compared to morning samples 
did not change by adjusting for age. Hence, time of blood sampling has an effect on serum 
hepcidin concentration that is independent of age and gender.
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Finally, we assessed serum hepcidin reference ranges after the additional exclusion of indi-
viduals with a serum ferritin concentration below 30 µg/L (Supplemental Table 2.6). Hepci-
din reference ranges in these non-iron-deficient subjects were slightly elevated compared 
to the ranges presented in Table 2.2, especially in premenopausal women.   
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Biochemical correlates of serum hepcidin concentration
The results of the univariable linear regression analyses are presented in Supplemental 
Table 2.2. Below, results of regression analyses after adjustment for age and time of blood 
sampling (Table 2.3) are discussed. These analyses revealed ferritin to be most strongly 
associated with serum hepcidin concentration. The relation between serum ferritin and 
 serum hepcidin was positive for both men and women with adjusted regression coefficients 
of 0.806 (95% CI, 0.770; 0.843) and 0.853 (95% CI, 0.813; 0.892), meaning that a 1% change 
in serum ferritin in µg/L is associated with a 0.81% and 0.85% change in serum hepcidin 
concentration (nM), respectively. TIBC demonstrated a negative association with serum 
hepcidin [men: β -0.033 (95% CI, -0.038; -0.028); women: β -0.027 (95% CI, -0.032; -0.022)]. 
A positive association between BMI and serum hepcidin concentration was observed, but 
this association was not statistically significant in men. Additional statistically significant 
associations in men after adjustment for age and time of blood sampling were found for 
increasing serum hepcidin concentration and iron, TS and CRP (Table 2.3). ALAT and eGFR 
were not statistically significantly associated. In women, additional statistically significant 
associations adjusted for age and time of blood sampling were observed for iron, TS, ALAT, 
eGFR and CRP (Table 2.3).
A sex-specific multivariable model was constructed that included age and time of blood 
sampling and those variables that showed a p-value<0.05 for association with hepcidin 
concentration after adjustment for age and time of blood sampling. For men these were 
ferritin, iron, TIBC and CRP; for women these were BMI, ferritin, iron, TIBC, ALAT, eGFR and 
CRP (Table 2.3). TS was omitted as it is derived using TIBC and iron. In men, independent 
correlates in the multivariable model for serum hepcidin concentration were time of blood 
sampling, ferritin, TIBC and CRP (Table 2.4). In women, independent correlates for serum 
hepcidin concentration were age, time of blood sampling, ferritin, TIBC, ALAT and eGFR 
(Table 2.4). ALAT demonstrated a negative association with serum hepcidin concentration, 
which is opposite to the positive association observed by adjusting for age and time of blood 
sampling only, indicating confounding influences by other variables. The models explained 
59.8% and 63.3% of total serum hepcidin variance in men and women, respectively. Note 
that unadjusted, univariable analyses revealed that serum ferritin concentration by itself 
explained 56.0% and 60.2% (Supplemental Table 2.2) for men and women, respectively, in-
dicating that almost all explained variance in the multivariable model was attributable to 
variation in serum ferritin.   
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Discussion
Our data provide age and gender specific reference ranges of serum hepcidin concentration 
in a large reference population. We demonstrated that serum hepcidin concentrations are 
lower for premenopausal than for postmenopausal women, but are constant over age in 
men. In addition, our results confirm previous reports about the circadian rhythm of hep-
cidin. Based on regression analyses results, we report a strong association between serum 
hepcidin concentration and serum ferritin in both men and women, which explained ap-
proximately 60% of total hepcidin variance. This finding withstood adjustment for other 
(biochemical) variables: BMI, age, iron, TIBC, ALAT, eGFR, CRP and time of blood sampling. 
For the calculation of serum hepcidin concentration reference ranges, we selected a refer-
ence subset excluding individuals with characteristics evidently influencing hepcidin con-
centration and thus explicitly warranting specific serum hepcidin reference ranges, namely 
characteristics that indicate conditions with (a) low hepcidin concentration associated with 
increased iron demands or decreased synthesis (ALAT>50 U/L, pregnancy and anemia), and 
(b) increased hepcidin concentration associated with (low grade) inflammation (CRP>10 
mg/L and BMI>30 kg/m2), increased iron concentration (use of iron supplements) or de-
creased elimination (eGFR<60 mL/min/1.73 m2) [1,2,8,10,19,21,31-34]. 
Variation in hepcidin concentration over age differed between men and women. Men 
showed a stable hepcidin concentration, although a non-significant trend for an age-re-
lated increase in serum hepcidin was previously reported based on 65 men [22]. In women, 
serum hepcidin concentration was substantially higher for postmenopausal than for pre-
menopausal women, although we used age as a proxy in the absence of information on 
menopausal state of the women. Nevertheless, higher serum hepcidin concentration in 
postmenopausal women is in agreement with the observation that ferritin concentrations 
tend to increase sharply as women progress through menopause [35,36]. Serum hepcidin con-
centrations were elevated for men older than 85 years, supporting a role of hepcidin in an-
emia of the elderly [37]. However, an opposite effect was observed for women and the number 
of men and women in this age category may be too low (7 and 9, for men and women, re-
spectively) to draw conclusions. 
Our serum hepcidin reference ranges are in concordance with hepcidin concentrations in 
healthy controls previously reported by our group and others [20,26,29,38]. However, Ganz et al. [22] 
reported much higher median hepcidin concentrations for their series of healthy volunteers. 
In addition, they found a significant gender difference in serum hepcidin that was far more 
pronounced than the overall differences between men and women that we observed, which 
might be due to the lower median age for women (32.6 years) in their study compared to that 
in our population (55 years). The difference in absolute hepcidin concentrations between the 
two studies could have been caused by the application of different hepcidin assays [39]. In the 
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past few years, hepcidin assays have been developed on mass spectrometry (MS) platforms 
and more recently also immunochemical (IC) methods have become available. In patients 
with diseases associated with substantially elevated hepcidin concentrations or a decrease 
in renal clearance, we found that our IC assay measured relatively higher concentrations 
than MS methods, most likely because an IC method lacks the selectivity to distinguish 
hepcidin-25 from its isoforms hepcidin-20 and -22 that are prevalent in these diseases [25]. 
 However, in our experience with the exploitation of TOF-MS techniques hepcidin isoforms 
are rare in reference populations [25]. Moreover, the study of Ganz et al. [22] and our current 
study used similar IC methodologies, although antibodies might differ. This apparent differ-
ence in absolute hepcidin concentrations between the various assays around the world [39] 
clearly illustrates the need for harmonization. In this context, it is worth mentioning that 
in the most recent world-wide send-out of samples (the so called round robin 2) which took 
place in the spring of 2010 among 18 centers, including 22 methods for measuring plasma 
hepcidin, we obtained data that will allow us to generate regression equations for hepcidin 
results measured by the various methods in various laboratories and thus to define hepcidin 
reference ranges for universal use (J.J.K., D.W.S., et al., manuscript in preparation).
We observed a trend of increasing hepcidin concentration during the day, consistent with 
previous reports [22,26,29,30,38]. In addition, this is in agreement with the observation that hep-
cidin expression is regulated by transcription factors such as Upstream Stimulatory Factor 
(USF) and c-Myc/Max through E-boxes, as genes that are regulated through E-boxes, includ-
ing the Clock genes period, timeless and clock, tend to be under circadian rhythmic transcrip-
tional control [40]. However, circadian variation in hepcidin could be secondary as well, e.g. 
driven by variation in iron intake during the day. There is currently no evidence to support 
either a primary or secondary circadian variation in hepcidin. Nevertheless, because of the 
daily variations in serum hepcidin concentration, we adjusted for time of blood sampling in 
our association analyses in order to correct for its potential confounding influence.
Serum ferritin was shown to be the most important correlate of serum hepcidin concen-
tration. A positive regression coefficient was found, indicating that increased serum ferritin 
concentration is associated with increased serum hepcidin concentration, which has con-
sistently been reported before [19-22]. Iron, TIBC and TS only showed moderate associations 
with serum hepcidin, but directions of the effects were in accordance with expectations. 
Increasing iron concentration and TS were associated with increased hepcidin concentra-
tions. This may suggest that TS determines hepcidin concentration, confirming hepcidin’s 
proposed role in counter-regulating increased body iron concentration by decreasing iron 
absorption and macrophage iron release. However, the cross-sectional design of our study 
does not allow assessment of causality. TIBC showed a negative relation with serum hep-
cidin, which corresponds to the observation that TIBC increases in situations of low iron 
status. The association between hepcidin on one side and serum iron concentration on the 
other disappeared after incorporation of variables which were significant in a model adjust-
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ed for age and time of blood sampling: ferritin, TIBC and CRP for men and BMI, ferritin, TIBC, 
ALAT, eGFR and CRP for women. Similarly, the association between hepcidin and BMI in 
women became non-significant after inclusion of these variables in the model. CRP showed 
a positive and significant association with serum hepcidin concentration, both in men and 
women, which is in accordance with the theory that inflammation and infection cause an 
increase in hepcidin production [1,2,4,8-11]. However, this effect was substantially reduced in 
women after inclusion of BMI, ferritin, TIBC, ALAT and eGFR, indicating that the association 
between CRP and serum hepcidin was confounded by these variables. ALAT and serum hep-
cidin concentration showed a positive association when adjusted for age and time of blood 
sampling only, but this effect became negative after adjusting for BMI, ferritin, iron, TIBC, 
eGFR and CRP as well. ALAT is a marker of hepatocyte damage, thus it is not surprising that 
increasing ALAT concentrations are associated with decreasing hepcidin concentrations, 
since hepcidin is predominantly produced by these cells [2]. Notably, causal relationships 
cannot be deduced from the regression analyses of the current study.
Our study has some limitations. First, in the absence of a definition of “health” of a reference 
population, the exclusion criteria applied in this study to generate reference ranges could 
be debated, even though carefully selected. Moreover, hemoglobin (Hb) values were not 
measured in our study population, and therefore we used self-reported anemia as a proxy 
for low Hb concentrations as exclusion criterion for the reference set. In addition to data 
on presence or absence of anemia, information about BMI, pregnancy and use of iron sup-
plements was also obtained by using self-administered questionnaires. Thus, individuals 
who were unaware of having one of the characteristics used for exclusion or who reported 
false answers, might mistakenly be included in the reference subset. However, as we used 
a large study population, we expect that this potential misclassification has not influenced 
the hepcidin reference ranges. Furthermore, we applied age as a proxy for menopausal state 
 using a cutoff of 55 years. Finally, we included subjects in the reference set with missing 
 values for exclusion variables, but this did not influence reference ranges (data not shown).
We observed a high degree of interindividual variance in serum hepcidin concentration. 
This implicates that population-based reference ranges may have limitations when used 
for the interpretation of individual hepcidin concentrations. It appears that hepcidin values, 
like other hormones, should be interpreted as (in)appropriate in the context of indices of 
iron metabolism.
In conclusion, we provide age and gender specific reference ranges of serum hepcidin con-
centration. Until reliable (commutable) calibrators become available for harmonization 
of the current differences in hepcidin results obtained by the various assays, our reference 
ranges can be made appropriate for universal use by exploiting algorithms derived from 
regular world-wide assay comparison studies. Universal hepcidin reference ranges en-
able translational scientists as well as physicians in clinical practice around the world to 
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compare hepcidin concentrations and to collectively define criteria for the use of hepcidin 
assays in diagnosis, staging, monitoring and assessing treatment indication of iron dis-
orders. Furthermore, our data provide insight in (biochemical) correlates of serum hepcidin 
concentration, designating serum ferritin as by far the most important associate of serum 
hepcidin concentration. This association was robust to adjustment for other iron param-
eters and biochemical variables measured in this study. However, no inference can be made 
about causality based on our current study, thus it is impossible to state whether it is the 
 serum ferritin concentration that determines the serum hepcidin concentration or the other 
way around. We emphasize the importance of additional studies that do allow elucidation 
of causality between hepcidin, ferritin and other (biochemical) variables that may be asso-
ciated with serum hepcidin concentration but were not evaluated in this study.  
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Men (N=249) Women (N=195)
95% reference range 95% reference range
Age, years N (%) Median P2.5 P97.5 N (%) Median P2.5 P97.5
18-24 3 (1) 5.5 3.1 7.9 6 (3) 1.9 0.8 3.5
25-29 3 (1) 5.7 0.5 6.3 7 (4) 1.9 0.6 6.3
30-34 2 (1) 6.2 5.1 7.3 3 (2) 3.3 1.3 4.5
35-39 5 (2) 3.3 0.7 4.9 6 (3) 3.0 0.7 5.4
40-44 6 (2) 5.3 3.1 14.6 13 (7) 1.9 0.4 6.7
45-49 19 (8) 5.3 0.8 15.6 30 (15) 1.8 0.3 12.9
50-54 21 (8) 6.3 1.1 19.1 32 (16) 4.6 0.0 9.8
55-59 29 (12) 5.2 0.4 16.1 22 (11) 5.8 0.8 17.6
60-64 41 (16) 6.4 0.3 20.8 31 (16) 7.6 2.0 30.2
65-69 39 (16) 6.9 0.2 20.4 20 (10) 6.6 1.3 18.7
70-74 44 (18) 6.1 0.2 15.5 14 (7) 6.4 2.2 18.3
75-79 32 (13) 5.1 1.3 31.3 2 (1) 12.3 7.6 16.9
80-84 4 (2) 6.6 3.8 9.9 5 (3) 11.5 1.6 14.3
≥85 1 (0) NA NA NA 4 (2) 5.7 3.3 10.4
All 249 (100) 5.9 0.5 18.8 195 (100) 4.5 0.4 18.5
N indicates number; P2.5, 2.5th percentile; P97.5, 97.5th percentile; and NA, not applicable.
SUPPLEMENTAL TABLE 2.3   Reference values for serum hepcidin (nM) per 5-year age group for both men 
and women who donated blood before 12 pm.
Men (N=592) Women (N=535)
95% reference range 95% reference range
Age, years N (%) Median P2.5 P97.5 N (%) Median P2.5 P97.5
18-24 3 (1) 11.6 2.3 17.8 8 (1) 2.8 0.7 10.5
25-29 6 (1) 7.5 4.4 18.5 10 (2) 3.7 1.8 10.9
30-34 6 (1) 9.8 0.8 25.0 14 (3) 3.3 0.2 21.0
35-39 7 (1) 7.2 1.1 13.5 22 (4) 3.7 0.5 16.0
40-44 7 (1) 12.8 1.6 17.8 39 (7) 5.1 0.3 27.0
45-49 28 (5) 10.0 2.5 29.3 49 (9) 3.9 0.0 14.2
50-54 48 (8) 7.5 1.4 22.4 79 (15) 5.9 0.5 31.9
55-59 79 (13) 9.7 0.2 26.8 83 (16) 9.1 0.8 27.1
60-64 116 (20) 8.0 0.6 24.1 93 (17) 7.8 1.1 27.3
65-69 130 (22) 9.7 0.8 22.5 68 (13) 9.8 2.2 23.5
70-74 83 (14) 9.2 1.0 28.5 47 (9) 9.6 0.7 40.5
75-79 57 (10) 8.5 0.7 25.1 14 (3) 9.2 2.1 29.0
80-84 17 (3) 6.9 3.5 20.1 5 (1) 13.5 7.5 19.2
≥85 5 (1) 14.1 3.4 20.5 4 (1) 6.4 1.2 24.5
All 592 (100) 9.0 0.8 24.0 535 (100) 7.4 0.5 24.8
N indicates number; P2.5, 2.5th percentile; and P97.5, 97.5th percentile.
SUPPLEMENTAL TABLE 2.4   Reference values for serum hepcidin (nM) per 5-year age group for both men 
and women who donated blood between 12 and 5 pm.
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Men (N=220) Women (N=151)
95% reference range 95% reference range
Age, years N (%) Median P2.5 P97.5 N (%) Median P2.5 P97.5
18-24 4 (2) 10.8 2.9 13.8 7 (5) 2.8 1.1 8.6
25-29 7 (3) 9.8 5.6 24.2 11 (7) 4.8 0.6 11.0
30-34 10 (5) 7.4 2.1 15.8 7 (5) 5.4 1.6 9.0
35-39 10 (5) 9.2 3.4 19.4 8 (5) 2.3 0.9 8.9
40-44 6 (3) 9.3 1.9 15.0 12 (8) 5.0 0.1 11.0
45-49 29 (13) 6.9 1.4 20.4 31 (21) 4.3 0.4 23.4
50-54 37 (17) 6.3 0.0 27.3 29 (19) 7.0 0.6 23.7
55-59 63 (29) 8.2 0.4 27.5 24 (16) 9.0 2.3 21.1
60-64 22 (10) 9.7 0.3 20.7 13 (9) 10.8 5.5 21.2
65-69 16 (7) 11.2 0.3 17.9 7 (5) 3.8 0.5 9.5
70-74 6 (3) 10.7 2.0 18.1 1 (1) NA NA NA
75-79 8 (4) 6.0 1.2 25.5 0 (0) NA NA NA
80-84 1 (0) NA NA NA 0 (0) NA NA NA
≥85 1 (0) NA NA NA 1 (1) NA NA NA
All 220 (100) 8.4 0.4 24.1 151 (100) 6.1 0.6 21.2
N indicates number; P2.5, 2.5th percentile; P97.5, 97.5th percentile; and NA, not applicable.
SUPPLEMENTAL TABLE 2.5   Reference values for serum hepcidin (nM) per 5-year age group for both men 
and women who donated blood after 5 pm.
Men (N=1,003) Women (N=725)
95% reference range 95% reference range
Age, years N (%) Median P2.5 P97.5 N (%) Median P2.5 P97.5
18-24 10 (1) 9.1 2.3 17.8 13 (2) 3.0 1.7 10.5
25-29 15 (1) 9.2 4.4 24.2 16 (2) 5.5 1.1 11.0
30-34 17 (2) 7.5 0.8 25.0 17 (2) 5.4 1.3 21.0
35-39 21 (2) 7.1 0.7 19.4 22 (3) 5.2 1.1 16.0
40-44 18 (2) 10.6 1.9 17.8 43 (6) 5.6 1.7 25.8
45-49 71 (7) 7.1 1.9 22.1 73 (10) 5.2 1.0 16.0
50-54 96 (10) 7.7 1.5 22.2 115 (16) 7.0 1.4 24.6
55-59 161 (16) 8.3 1.9 25.0 120 (17) 9.1 1.8 21.7
60-64 165 (16) 8.3 1.5 23.1 125 (17) 9.1 3.4 27.4
65-69 175 (17) 9.5 1.5 22.3 89 (12) 8.5 2.2 22.8
70-74 129 (13) 8.5 1.5 27.4 58 (8) 9.2 1.7 38.5
75-79 96 (10) 7.4 1.0 25.5 16 (2) 9.2 2.1 29.0
80-84 22 (2) 6.8 3.5 20.1 10 (1) 11.9 1.6 19.2
≥85 7 (1) 11.3 3.4 20.5 8 (1) 7.1 3.3 24.5
All 1,003 (100) 8.4 1.6 23.7 725 (100) 7.6 1.7 23.9
N indicates number; P2.5, 2.5th percentile; P97.5, 97.5th percentile; and NA, not applicable.
SUPPLEMENTAL TABLE 2.6   Reference ranges for serum hepcidin (nM) per 5-year age group for men and 
women in the reference population with additional exclusion of subjects with 
serum ferritin concentration below 30 µg/L.
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SUPPLEMENTAL FIGURE 2.1  Distribution of blood sampling time per 5-year age group.
SUPPLEMENTAL FIGURE 2.2   Serum hepcidin concentration (nM) per 5-year age group. Median values 
with 2.5th and 97.5th percentile are shown. 
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ABSTRACT
Genome-wide association studies have convincingly shown that single nucleotide 
polymorphisms (SNPs) in HFE and TMPRSS6 are associated with iron parameters. It 
was commonly thought that these associations could be explained by the intermedi-
ate effect on hepcidin concentration. A recent study in an isolated Italian population, 
however, concluded that these associations were not exclusively dependent on hep-
cidin values. Here, we are the second to investigate the role of hepcidin in the asso-
ciations between common variants in HFE and TMPRSS6 with iron parameters. We 
extracted 101 SNPs in HFE and TMPRSS6 from genome-wide imputed SNP data of 1832 
individuals from the general population (Nijmegen Biomedical Study). Single locus 
and haplotype associations with serum iron parameters and hepcidin were studied 
using linear regression analyses. We found that HFE rs1800562 and TMPRSS6 rs855791 
are main determinants of HFE and TMPRSS6-related variation in serum iron, ferritin, 
transferrin saturation and total iron binding capacity. These SNPs are associated with 
the ratios hepcidin/ferritin (p<1x10-5) and hepcidin/transferrin saturation (p<1x10-3), 
but not with serum hepcidin (p>0.2). Adjustment for hepcidin or the ratio hepcidin/
ferritin did not decrease the strength of the SNP-iron parameter associations. Our re-
sults do not support an intermediate role for hepcidin in the SNP–iron parameter as-
sociations, which confirms previous findings, and indicate a pleiotropic SNP effect on 
the hepcidin ratios and the iron parameters. Taken together, this suggests that there 
might be other, yet unknown, serum hepcidin-independent mechanisms which play 
a role in the association of HFE and TMPRSS6 variants with serum iron parameters. 
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Introduction
Genome-wide association studies (GWAS) have shown that at a population level single nu-
cleotide polymorphisms (SNPs) in the hemochromatosis gene (HFE) and in the transmem-
brane serine protease 6 gene (TMPRSS6) are associated with ferritin, iron, transferrin and 
transferrin saturation (TS) (i.e. iron parameters). These associations have been found for the 
SNPs rs1800562 in HFE (p.Cys282Tyr), rs855791 in TMPRSS6 (p.Ala736Val) and rs4820268 in 
TMPRSS6 (p.Asp521Asp) [1-6]. The proteins encoded by HFE and TMPRSS6, Hfe and matriptase 
2 (MT2) respectively, have been suggested to play a role in the transcriptional regulation of 
the hepatic peptide hormone hepcidin, key regulator of iron homeostasis [7-12]. It was com-
monly thought that the reported GWAS-associations between the HFE and TMPRSS6 SNPs 
and iron parameters could be explained by this intermediate effect on hepcidin concentra-
tion. However, serum hepcidin concentrations were not measured in these GWAS, preven-
ting a definite evaluation of this assumption. Recently, Traglia and colleagues [3]  analyzed 
 serum hepcidin concentrations, measured by a mass spectrometry based method [13], in 
1657  re lated individuals from the Val Borbera genetic isolate in Northern Italy. They ex-
plored re lationships between hepcidin and a set of anthropometric, haematologic and iron 
 parameters and performed a GWAS for hepcidin. In the same paper, they also focused on 
the association of two common variants HFE rs1800562 and TMPRSS6 rs855791 with iron, 
erythro cyte parameters and hepcidin values in 1545 genotyped individuals. They reported 
that their study allowed to conclude that associations between these SNPs and iron param-
eters were not exclusively dependent on hepcidin values. This unexpected finding has not 
been replicated in other populations yet. 
In this study, we aim to evaluate the role of hepcidin in the association between HFE and 
 TMPRSS6-related SNP variation and iron parameters in a second, independent population. 
We used data from the Nijmegen Biomedical Study (NBS) to analyze the associations be-
tween common variants in and surrounding the HFE and TMPRSS6 genes and iron param-
eters and hepcidin on a population level. More specifically, the first goal of our study was 
to replicate the associations previously found in the iron GWAS and to determine which 
SNPs in both genes are main determinants of iron parameters in our population. These 
ana lyses revealed that out of the studied SNPs, HFE rs1800562 and TMPRSS6 rs855791 were 
most strongly associated with the iron parameters. Secondly, we focused on these SNPs 
and evaluated the role of serum hepcidin in the associations of HFE and TMPRSS6 variants 
with iron parameters. We also included ratios of hepcidin to ferritin and TS given the known 
 dependence of hepcidin expression on stored iron and circulating iron, respectively [14-19]. We 
(i) considered hepcidin and its ratio to ferritin as intermediate variables in the association 
between the SNPs and iron parameters, (ii) explored the presence of pleiotropy, i.e. whether 
the SNPs both independently affect hepcidin and the iron parameters, and (iii) evaluated 
the presence of an effect on iron parameters only (Figure 3.1). 
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Methods
Study population
This study was performed in participants from the Nijmegen Biomedical Study (NBS). 
Details of the NBS have been described before [20]. Briefly, the NBS is a population-based 
survey conducted by the Department for Health Evidence and the Department of Labo-
ratory Medicine of the Radboud University Medical Centre, Nijmegen, The Netherlands. 
Approval to conduct the study was obtained from the Radboud University Medical Centre 
Institutional Review Board. Age- and sex-stratified randomly selected adult inhabitants 
of Nijmegen (n=22,451), a city located in the eastern part of the Netherlands, received an 
invitation to fill out a postal questionnaire including questions about lifestyle, health sta-
tus, and medical history, and to donate a blood sample for DNA isolation and biochemical 
studies. A total of 9350 (43%) persons filled out the questionnaire, of which 6468 (69%) re-
sponders donated blood samples. All participants gave written informed consent for par-
ticipation in the NBS.
Genotype data were available for 1832 out of the 6468 blood samples, because they were 
selected to serve as controls in GWAS [21]. For all these samples, measurements of hepcidin, 
iron parameters (iron, ferritin, TS and TIBC), liver enzyme alanine aminotransferase (ALT), 
creatinine, and C-reactive protein (CRP) were available. In addition, the following variables 
were extracted from the self-administered questionnaire: length, weight (used to derive 
body mass index [BMI]), age, use of iron supplements for at least 6 months at time of blood 
donation, presence of anemia determined by a physician, and pregnancy.
FIGURE 3.1   Hypothetical roles of serum hepcidin in the associations of HFE and TMPRSS6 variants with 
serum iron parameters.
 (i)  Hepcidin and its ratio to ferritin might be intermediate in the association between HFE and TMPRSS6 variants and iron 
parameters (dotted arrow). 
(ii)  The variants might both independently affect hepcidin and the iron parameters (dashed arrows), i.e. presence of pleiotropy. 
(iii) The variants may affect the iron parameters only and not hepcidin (bold arrow).
Iron parameters
Iron uptake from
the intestine
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TMPRSS6
Recycled iron derived
from senescent
erythrocytes
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Laboratory methods
Serum hepcidin, total serum iron, TIBC, TS and ferritin were measured as described before [22].
Serum hepcidin concentration was measured with an in house developed and validated 
competitive enzyme-linked immunosorbent assay [22,23]. In short, 96-well plates were coated 
with goat anti-rabbit IgG, blocked with bovine serum albumin and incubated with an in-
house raised rabbit anti-human hepcidin antibody [24]. Standards, study samples and a ref-
erence sample were added and thereafter incubated with streptavidin-β-peroxidase conju-
gate. A color reaction was started by adding O-phenylenediamine substrate. Optical density 
was measured at 492 nm in an automated c-enzyme-linked immunosorbent assay reader 
as a read out. The analytical sensitivity, defined as the minimum hepcidin concentration 
evoking a response significantly different from that of the zero calibrator, was 8.96 pM. As 
the samples were 20-fold diluted, samples found to have a hepcidin concentration less than 
179 pM (20 x 8.96pM) were imputed with a random value out of a uniform distribution with a 
minimum of 0 nM and a maximum of 0.18 nM (n=9). Hepcidin concentrations are expressed 
in nanomoles per liter; 1 nM serum hepcidin equals 2.79 µg/L.
Genotyping and selection of SNPs
A total of 1980 participants of the NBS were genotyped with the Illumina Human-
HapCNV370-Duo BeadChip [21]. Pre-imputation quality control criteria included sample yield 
≥96%, Caucasian ancestry ≥90% (based on Structure analysis), SNP yield ≥96%, minor allele 
frequency (MAF) ≥1%, and Hardy-Weinberg equilibrium (HWE) p-value >10-6. This resulted 
in 1832 samples and 312,199 SNPs available for imputation, which was performed with CEU 
HapMap Phase II (release 22, NCBI build 36, dbSNP build 126) as a reference sample using 
IMPUTE software [25]. After imputation, a total of 2,542,995 SNPs was available. Genotype 
data for the SNPs within the genes HFE and TMPRSS6 were extracted for the purpose of this 
study, including SNPs within the 10 kB surrounding region on each side of both genes. Im-
puted SNPs were transformed to hard calls using a genotype probability threshold of 0.9: 
genotypes that did not exceed the probability threshold of 0.9 were set to missing. Selection 
of SNPs with MAF ≥1% and a HWE p-value >10-3 resulted in the inclusion of 35 SNPs (7 geno-
typed) for HFE and 66 SNPs (16 genotyped) for TMPRSS6 (Supplemental Table 3.1). All imputed 
SNPs that were included in our study, had a quality of imputation of >0.4 as measured using 
the SNPtest proper-info measure.
Haplotype analyses were applied to uncover allelic interactions. We did not focus on the 
identification of associations with unmeasured variants in LD with the haplotypes for which 
the prior chance is low given the availability of high density imputed SNP data. In the haplo-
type analysis only non-synonymous SNPs and SNPs known to influence expression of HFE 
or TMPRSS6 were included. With regard to the latter, SNPs were selected based on the fol-
lowing expression databases: SCAN [26], the Chicago eQTL browser from the Pritchard lab 
(http://eqtl.uchicago.edu), seeQTL [27] and GTEx (Genotype-Tissue Expression) eQTL  Browser 
(http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.cgi). We only included SNPs that were 
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found to influence expression in liver tissue samples or in blood samples converted into 
cell lines (e.g. HapMap CEU cell lines). The variant selection procedure resulted in the inclu-
sion of the SNPs rs855791 (p.Ala736Val), rs2235324 (p.Lys253Glu) and rs2160906 for TMPRSS6 
and rs1800562 (p.Cys282Tyr), rs1799945 (p.His63Asp) and rs198853 for HFE. These SNPs are 
non-synonymous variants except for rs2160906 and rs198853, which are eQTL located in an 
intron of TMPRSS6 and in the 10 kb flanking region of HFE, respectively. There was no linkage 
disequilibrium between the variants within the genes (r-squared < 0.2).
Statistical analysis
The variables hepcidin, ferritin and the ratios of hepcidin to ferritin and hepcidin to TS were 
skewed towards higher values and therefore log-transformed to normalize their distribu-
tions. Outliers, defined as values that differed more than three times the standard deviation 
(SD) from the mean, were reduced to mean ± 3 SD (maximal number of outliers per trait: 26).
Two different subsets were created. The first one was selected based on the same criteria as 
used by Traglia et al. [3]: exclusion of persons with CRP >10 mg/L or ferritin <30 µg/L. The sec-
ond subset was selected based on the same criteria as previously [22] excluding persons with 
characteristics evidently influencing hepcidin concentration. The exclusion criteria were: 
pregnancy at time of blood sampling, ALT >50 U/L, CRP >10 mg/L, eGFR <60 mL/min/1.73 m2, 
use of iron supplements, presence of anemia, or BMI >30 kg/m2. Results for the subset were 
compared with results for the whole cohort to investigate whether the results for the whole 
cohort were influenced by extreme values on these variables. 
Association analyses were performed using Plink v1.07 (http://pngu.mgh.harvard.edu/pur-
cell/plink/) [28]. The associations between the SNPs and the traits were evaluated using lin-
ear regression analyses adjusted for age, gender and time of blood sampling, since these 
variables are independent determinants of serum hepcidin [22]. We coded the most frequent 
homozygote genotype as 0 (reference), heterozygotes as 1, and the less frequent homozy-
gote genotype as 2 and applied a genotypic (2 degrees of freedom) test to allow for devi-
ation from additivity. The resulting regression coefficients express the mean change in the 
independent variable for the heterozygous and minor homozygous genotype relative to the 
reference genotype. In case of log-transformation of the independent variables, regression 
coefficients express the mean change in the log-transformed variable relative to the refer-
ence genotype.
Haplotypes were constructed based on inclusion of all SNPs fulfilling selection criteria 
in one gene. Haplotypes with estimated frequencies of 1% or higher were included in the 
haplo type analyses. For each trait, a haplotype association model was compared to the 
 allelic effect of TMPRSS6 rs855791 or HFE rs1800562 in order to conclude whether there 
was an additional effect of the haplotypes on top of the marginal allelic effect of TMPRSS6 
rs855791 or HFE rs1800562 alone.
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Conditional analyses to estimate the effect of a gene variant or haplotype independent of 
the effect of another variant was performed by including the latter as covariate in a multi-
variable regression model.
Due to multiple testing issues, the nominal significance level of 0.05 is not sufficient to 
maintain an overall study false-positive rate of 5%. Application of a Bonferroni correction 
for the number of tested SNPs (i.e. 35 + 66 = 101) would lead to a p-value threshold of signifi-
cance of 5x10-4.
Results
Characteristics of the study population
Mean age of the 1832 individuals was 62 years. Additional characteristics of the individuals 
included in the study are shown in Table 3.1. Application of the exclusion criteria resulted in 
the inclusion of 1505 individuals in subset 1 and 1177 individuals in subset 2 (Supplemental 
Table 3.2). Characteristics of the subsets and the whole cohort were similar, except for the 
proportion of females (51% in the whole cohort versus 47% in subset 1 and 44% in subset 2) 
and geometric mean hepcidin and ferritin concentration in subset 1 (6.4 nM and 107.2 µg/L 
in the whole cohort and 7.7 nM and 131.5 µg/L in subset 1, respectively).
N* % Mean (SD)
Gender Males 906 49 NA
Females 926 51 NA
Age, years 1832 100 61.5 (10.3)
Time of blood sampling Before 12 pm 378 21 NA
Between 12 pm and 5 pm 1172 64 NA
After 5 pm 274 15 NA
Unknown 8 0 NA
Hepcidin, nM† 1832 100 6.4 (2.6)
Ferritin, µg/L† 1830 100 107.2 (2.6)
Ratio hepcidin/ferritin, nmoles/µg† 1830 100 59.4 (1.9)
Ratio hepcidin/TS, nM/%† 1812 99 0.23 (2.6)
Iron, µM 1812 99 17.2 (5.6)
TS, % 1812 99 29.6 (10.3)
TIBC, µM 1812 99 59.2 (9.0)
N indicates number; SD, standard deviation; NA, not applicable.
* Numbers are different from the total number of included persons because of missing values.
†  The variables hepcidin, ferritin, ratio hepcidin/ferritin and ratio hepcidin/TS were log-transformed, and 
therefore geometric mean and SD are given.
TABLE 3.1  Characteristics of the total study population (N=1832).
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Associations of common variants in HFE and TMPRSS6 with ferritin, iron, TS and TIBC
Single SNP association analyses revealed that the SNP HFE rs1800562 was the strongest 
associate of ferritin, iron, TS and TIBC of all variants in and surrounding HFE included in 
our study (p between 1x10-18 and 1x10-3) (Supplemental Table 3.3). For TMPRSS6, rs855791 
was most strongly associated with both iron and TS of all variants tested (p=3.4x10-12 and 
 8.5x10-14, respectively). In addition, this SNP was one of the strongest associates of TIBC and 
ferritin, although not significantly associated (p=0.13 and 0.19, respectively) (Supplemental 
Table 3.3). Besides these two SNPs, other common variants in HFE and TMPRSS6 showed 
associations (using the stringent Bonferroni corrected significance threshold of p<5x10-4) 
with iron and TS: 10 SNPs for HFE and iron, 11 SNPs for HFE and TS, 11 SNPs for TMPRSS6 and 
iron and 22 SNPs for TMPRSS6 and TS. However, all of these associations for TMPRSS6 and 
most of the associations for HFE were dependent on TMPRSS6 rs855791 and HFE rs1800562, 
respectively, as shown by conditional analyses (Supplemental Table 3.4). Only rs1799945 
(p.His63Asp), rs6918586, rs198855 and rs198851 (all three in flanking regions) in HFE were sig-
nificantly associated with both iron and TS after conditioning on HFE rs1800562, but their 
strength of association did not approach that of HFE rs1800562.
Evaluation of allelic interaction between non-synonymous and eQTL variants via haplotype 
analysis (Supplemental Tables 3.5-3.6) suggested the presence of a haplotype effect for HFE 
that was independent of the marginal effect of HFE rs1800562. Still, this SNP was the great-
est contributor to the haplotype effect. There was no evidence for allelic interaction within 
TMPRSS6. These results confirm HFE rs1800562 and TMPRSS6 rs855791 as most important 
variants within HFE and TMPRSS6, respectively, in their ability to affect the iron phenotypes.
Table 3.2 shows the associations between TMPRSS6 rs855791 and HFE rs1800562 with the 
iron parameters. Both SNPs are c.G>A SNPs, with a MAF for the A allele of 0.455 for TMPRSS6 
rs855791 and 0.063 for HFE rs1800562 in the total study population. The SNPs showed the 
strongest association with iron and TS. The minor allele A of TMPRSS6 rs855791 showed de-
creased iron concentration [beta (95% CI) AG vs. GG -1.5 (-2.1 to -0.9); AA vs. GG -2.5 (-3.2 to 
-1.8)] and TS [beta (95% CI) AG vs. GG -2.9 (-4.0 to -1.9); AA vs. GG -5.0 (-6.3 to -3.7)], while the 
minor allele A of HFE rs1800562 was associated with both increased iron concentrations 
[beta (95% CI) AG vs. GG 2.3 (1.5 to 3.0); AA vs. GG 10.7 (5.5 to 15.9)] and TS [beta (95% CI) AG vs. 
GG 5.4 (4.0 to 6.8); AA vs. GG 22.6 (13.2 to 32.0)]. Ferritin and TIBC were associated with HFE 
rs1800562, but not with TMPRSS6 rs855791. The A allele of HFE rs1800562 is associated with 
an increase of ferritin and a decrease of TIBC, respectively.
Results for the two subsets were comparable to the results observed for the total study po-
pulation, indicating that our findings are not driven by extremes on the exclusion variables 
(Supplemental Tables 3.7-3.8). 
52 C H A P T E R  3
Role of hepcidin in the associations of HFE rs1800562 and TMPRSS6 rs855791 with the 
iron parameters
Results of the association analyses of HFE rs1800562 and TMPRSS6 rs855791 with serum hep-
cidin, the ratio of hepcidin to ferritin and the ratio of hepcidin to TS are presented in Table 
3.2 (see Supplemental Tables 3.7-3.8 for results in the subsets). The SNPs were not associ-
ated with hepcidin (p>0.2) but were by far the strongest associates of the ratios out of all 
variants tested in our study (Supplemental Table 3.9). TMPRSS6 rs855791 and HFE rs1800562 
were associated with an increase and decrease, respectively, in both log hepcidin/ferritin 
[TMPRSS6 rs855791: beta (95%CI) AG vs. GG 0.04 (0.01 to 0.07), AA vs. GG 0.08 (0.05 to 0.12); 
HFE rs1800562: beta (95% CI) AG vs. GG -0.04 (-0.08 to -0.01), AA vs. GG -0.65 (-0.90 to -0.41)] 
and log hepcidin/TS [TMPRSS6 rs855791: beta (95%CI) AG vs. GG 0.05 (0.01 to 0.09), AA vs. GG 
0.12 (0.07 to 0.17); HFE rs1800562: beta (95% CI) AG vs. GG -0.07 (-0.13 to -0.02), AA vs. GG -0.58 
(-0.96 to -0.20)]. Stratification of the study population by both HFE rs1800562 and TMPRSS6 
rs855791 and subsequent calculation of mean hepcidin concentrations per stratum indi-
cated the presence of statistical interaction, but our sample size was not sufficient to reach 
statistical significance (Supplemental Table 3.10).
The associations of TMPRSS6 rs855791 and HFE rs1800562 with ferritin, iron, TS and TIBC 
were not dependent on serum hepcidin: regression coefficients for the associations did not 
change after inclusion of serum hepcidin concentrations in the regression models  (Table 
3.2). P-values for the associations of the SNPs with iron, TS and TIBC before and after ad-
justment for serum hepcidin were similar, but smaller for the associations of the SNPs with 
log ferritin after adjustment for serum hepcidin. Inclusion of the hepcidin/ferritin ratio 
as covariate in the regression models did not change the associations either and only de-
creased the p- values for the associations of the SNPs with log ferritin (Table 3.2). Identical 
 observations were done for subset 1 and 2 (Supplemental Tables 3.7-3.8). We did not correct 
the asso ciations for the hepcidin/TS ratio, because TS was calculated by dividing serum iron 
by TIBC.
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Discussion
Our results showed that HFE rs1800562 and TMPRSS6 rs855791 are the strongest associates 
of these genes for iron parameters in our study population. These SNPs and their correlated 
SNP variants also emerged from six previously published GWAS on serum iron, transferrin, 
TS and ferritin [1-6]. We found that serum hepcidin was not statistically significantly associ-
ated with HFE rs1800562 or TMPRSS6 rs855791 nor with any other SNP in HFE and TMPRSS6. 
However, the ratios of hepcidin to ferritin and hepcidin to TS did show association with the 
two SNPs. Adjustment for hepcidin did not result in a decrease of the strength of the asso-
ciations between the SNPs and the iron parameters, neither did adjustment for the ratio of 
hepcidin to ferritin in the SNP association analyses for iron, TS and TIBC. Hence, our data do 
not support an intermediate role of hepcidin in the SNP-iron parameter associations nor 
do they support a pleiotropic effect of the HFE and TMPRSS6 SNPs on iron parameters and 
hepcidin (Figure 3.1). However, we did find evidence for an independent, pleiotropic effect 
of the HFE and TMPRSS6 SNPs on iron parameters and ratios of hepcidin to ferritin and TS.
Our findings confirm the results found by Traglia et al. in an isolated Italian population [3]. 
They replicated associations of HFE rs1800562 with serum iron, transferrin and TS and of 
 TMPRSS6 rs855791 with serum iron and TS in their cohort of 1545 related individuals and 
reported a borderline genome-wide significant association for serum ferritin and HFE 
rs1800562. TMPRSS6 rs855791 association with serum ferritin was only nominally signifi-
cant. Conform our results, Traglia et al. did not find an association of these SNPs with hepci-
din, and use of hepcidin as covariate in their association analysis of the SNPs with the iron 
parameters did not change the associations. In contrast, we observed both for the total 
study population and for the subsets a remarkable stronger association between ferritin 
and the SNPs after adjustment for serum hepcidin, which was not observed in the data of 
Traglia et al. Nevertheless, estimates of regression coefficients were comparable between 
our study and the study of Traglia et al. Finally, Traglia et al. reported that HFE rs1800562 
and TMPRSS6 rs855791 were associated with the ratio of hepcidin to ferritin in subset 1. We 
observed this association both in our total study population and in our two subsets. Traglia 
et al. did not study the ratio of hepcidin to TS.
Our results and the results of Traglia et al. are in contrast to the generally accepted idea that 
HFE and TMPRSS6 affect hepcidin transcription, thereby adapting the hepcidin expression 
in response to the systemic iron concentration. Indeed, there is only limited evidence from 
animal and in vitro studies for a direct relation between the Hfe protein and (intracellular) 
iron homeostasis in different cell types [16,29-32]. For example, it was shown that HFE muta-
tions can directly affect iron accumulation in hereditary hemochromatosis macrophages, 
independently of the presence of hepcidin [29,30]. On the other hand, evidence for HFE and 
 TMPRSS6 affecting hepcidin transcription is abundant. Mice experiments and observational 
studies in humans have shown that defects in HFE result in insufficient expression of hep-
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cidin in the liver and lower serum hepcidin levels relative to the body iron stores, leading 
to the iron storage disorder hereditary haemochromatosis [7-11]. Mutations in TMPRSS6 have 
been associated to inappropriately high urine and serum hepcidin concentration for the 
setting of systemic iron deficiency, which has been suggested to cause iron-refractory iron 
deficiency anemia. Furthermore, a recent in vitro study by Nai et al. showed that the G allele 
of TMPRSS6 rs855791 inhibits hepcidin more efficiently than the A allele [33]. In this same pub-
lication, it was also reported that hepcidin was significantly lower in TMPRSS6 rs855791 GG 
homozygotes than in AA homozygotes in normal subjects after exclusion of iron-deficient 
individuals (serum ferritin <30 ng/mL) and individuals with clinically relevant inflammatory 
conditions (C-reactive protein >1 mg/dL) [33]. We and Traglia et al. did not observe an associ-
ation between hepcidin and TMPRSS6 rs855791 in our data, even though we also excluded 
iron-deficient individuals and individuals with clinically relevant inflammatory conditions 
in subset 1. In addition, the difference in results between Nai et al. and Traglia et al. is striking, 
because Nai et al. used a selection of unrelated individuals (N=545) of the same population 
used by Traglia et al. For HFE rs1800562, van Dijk et al. demonstrated in a small population of 
first-degree family members of clinically diagnosed HFE rs1800562 homozygous probands 
that hepcidin was lower in HFE rs1800562 AA homozygotes compared to AG heterozygotes 
and GG homozygotes combined (p<0.01) [11], but we did not find a significant association be-
tween hepcidin and HFE rs1800562 in our sample of the general population. On the other 
hand, our findings for the ratios of hepcidin to ferritin and hepcidin to TS corroborate with 
the results of both Nai et al. and van Dijk et al. [11,33].
Reasons that may have masked an intermediate role of hepcidin in the association between 
the two SNP variants and iron parameters in our study and that of Traglia et al. include the 
reliance on measurement of hepcidin in serum and the potential omission of environmen-
tal and genetic factors that may cause variation in serum hepcidin levels independent of 
iron regulation. In other words, the hepcidin as measured in our study (by ELISA) and that 
of Traglia et al. (by mass-spectrometry) may not be a correct reflection of the hepcidin that 
is intermediate in the Hfe and MT2 regulation of iron parameters. This could also be true 
for TS as a proxy for circulating iron, as TS does not necessarily reflect the concentration of 
the (putative) hepcidin signaling form of the molecule, i.e. differic transferrin [34]. Besides, we 
used serum levels of hepcidin as well as serum levels of iron and ferritin, but the associations 
that we studied might be cell type or tissue-specific. Hepcidin is predominantly produced in 
hepatocytes [35-37], whereas the Hfe protein is expressed in a whole range of tissues and cell 
types [38,39], and MT2 is expressed primarily in the liver [40]. The identified associations between 
the HFE and TMPRSS6 variants and ratios of hepcidin to ferritin and hepcidin to TS, a better 
reflection of the long-term balance between hepcidin and body iron status, may support 
this hypothesis. Nevertheless, adjustment for the ratio of hepcidin to ferritin in the associ-
ation analyses for the SNPs with iron, TS and TIBC did not change the effects of the SNPs on 
the iron parameters either, indicating an independent, pleiotropic effect of the SNPs on both 
the hepcidin ratios and the iron parameters. 
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In summary, we can confirm that HFE rs1800562 and TMPRSS6 rs855791 are main determi-
nants of HFE and TMPRSS6-related variation in iron, ferritin, TS and TIBC in the gen eral popu-
lation. These SNPs are not associated with serum hepcidin itself, but do influence  ratios 
reflecting hepcidin relative to circulating iron and iron stores, measured by the iron para-
meters TS and ferritin, respectively. Our study can confirm that serum hepcidin,  whether 
corrected for iron stores or not, is not the intermediate variable in the associations of the 
SNPs with the iron parameters, thereby confirming the results of Traglia et al. In addition, 
our data indicate that the SNPs exert a pleiotropic effect on both the hepcidin ratios and 
the iron parameters. Taken together, our study points at a direct SNP effect on certain serum 
iron parameters, rather than an indirect effect entirely dependent upon a change in serum 
hepcidin levels. We call for additional functional studies in a controlled setting that do  allow 
further elucidation of the role of hepcidin in the associations between the SNPs and iron 
para meters, results which will contribute to elucidation of underlying mechanisms and 
which will eventually facilitate the development of interventions for iron disorders.
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ABSTRACT
Serum hepcidin concentration is regulated by iron status, inflammation, erythropoi esis 
and numerous other factors, but underlying pathways are incompletely understood. To 
obtain better insights, we aimed to identify common genetic determinants of serum 
hepcidin in the general population. We meta-analyzed genome-wide association re-
sults on serum hepcidin from three European population-based studies (total N up to 
6,096), the only three cohorts worldwide with both hepcidin measurements and gen-
ome-wide single nucleotide polymorphism (SNP) data. We measured six genetic vari-
ants that were among the top findings in up to 3,826 additional independent samples. 
Our study revealed one interesting locus (linkage disequilibrium region from EML6 to 
SPTBN1 (alias ELF), lead SNP rs354202) potentially associated with serum hepcidin con-
centration (discovery beta (SE)=-0.17 (0.03), p=7.0E-08; in silico replication beta (SE)= 
-0.15 (0.10), p=0.12; discovery and in silico replication combined beta (SE)=-0.17 (0.03), 
p=2.1E-08). The ELF protein is essential in TGF-β signaling by son of mothers against 
decapentaplegic (SMAD) proteins in mice, and the bone morphogenetic protein-SMAD 
pathway is central in hepcidin regulation. The known common variants rs1800562  
(p.Cys282Tyr) in HFE and rs855791 (p.Ala736Val) in TMPRSS6 showed strong associations 
with the ratio hepcidin/ferritin. Our findings for rs354202 and serum hepcidin concen-
tration warrant follow up in additional association studies and functional studies. We 
recommend extension of this study once additional cohorts become available to in-
crease power to identify common variants with small effects on serum hepcidin.  
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Introduction
Iron is an essential trace element for fundamental metabolic processes in humans [1,2]. Iron 
deficiency limits hemoglobin synthesis and leads to anemia, whereas an excess of free iron 
is toxic because it catalyzes the production of free radicals resulting in tissue damage [1,2]. In 
addition, iron imbalances have been associated with other diseases, e.g. diabetes mellitus 
[3,4], inflammation [5] and diseases of aging [6]. Hence, the iron balance in the human body is 
tightly controlled, with hepcidin as key regulator of systemic iron homeostasis [7,8]. Hepcidin 
controls the absorption, storage and tissue distribution of iron by binding to the cellular iron 
exporter ferroportin and inducing its internalization and degradation [9]. In this way, hep-
cidin regulates the uptake of dietary iron from the intestine and the release of iron from 
macrophages involved in recycling of iron from senescent erythrocytes [7,8]. 
In the last few years, several genome-wide association studies have revealed genetic vari-
ants associated with iron status in the general population, including common variants in 
the hereditary hemochromatosis gene (HFE), transferrin gene (TF), transferrin receptor 2 
gene (TFR2) and transmembrane serine protease 6 gene (TMPRSS6). On the contrary, little is 
known about genetic determinants of hepcidin. Mutations in hepcidin antimicrobial peptide 
(HAMP), the hepcidin encoding gene, lead to strongly decreased hepcidin levels and a severe 
juvenile form of the iron storage disorder hereditary hemochromatosis (HH), but HAMP mu-
tations are very rare [10]. In addition, mutations in HFE, TFR2 and TMPRSS6 have been related 
to hepcidin expression [10-16]. Until now, however, no common genetic variants for hepcidin 
have been identified. The only published genome-wide association study (GWAS) on serum 
hepcidin in the Val Borbera genetic isolate was underpowered to find genome-wide signi fi-
cant associations with hepcidin [17]. In addition, the single nucleotide polymorphisms (SNP) 
rs1800562 (p.Cys282Tyr) in HFE and rs855791 (p.Ala736Val) in TMPRSS6, which were thought 
to be associated with hepcidin as an explanation for their effects on iron, ferritin, transfer-
rin and transferrin saturation (TS), did not show association with serum hepcidin in recent 
studies by our groups [17,18]. Nevertheless, these variants did show association with the ratios 
hepcidin/ferritin and hepcidin/TS [17,18], which express the dependence of hepcidin concen-
tration on stored and circulating iron, respectively [1,7,8,19]. 
The aim of the current study was to identify common genetic determinants of serum hep-
cidin in the general population. We studied hepcidin as well as the ratios hepcidin/ferritin 
and hepcidin/TS. We performed a meta-analysis using data from the only three cohorts 
worldwide that have, to the best of our knowledge, both hepcidin measurements and 
 genome-wide SNP data: the Nijmegen Biomedical Study (NBS) (Nijmegen, The Nether-
lands), Prevention of REnal and Vascular ENd-stage Disease (PREVEND) (Groningen, The 
Netherlands) and Val Borbera (VB) (Milan, Italy). This was followed by replication of six top 
hits in additional independent samples of the NBS and PREVEND. 
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Methods
Study populations
In this meta-analysis, we combined genome-wide association results for hepcidin and the 
ratios hepcidin/ferritin and hepcidin/TS based on up to 6,096 individuals from three popula-
tion-based cohorts (Supplemental Table 4.1). Data for replication were obtained from up to 
3,826 additional independent samples from two of the three cohorts. Information on labo-
ratory methods, genotype methods, imputation, quality control, and phenotypes is shown 
in Supplemental Tables 4.2-4.4. All three studies were approved by appropriate ethical com-
mittees, and all participants gave informed consent. 
Genome-wide association analysis
Genome-wide association analyses were performed in each cohort separately according to 
a set protocol. A subset analysis was performed in which individuals with ferritin <30 ng/mL 
and CRP ≥10 mg/L were excluded as to remove individuals with iron deficiency and clinical 
inflammation, which are acquired conditions known to alter iron metabolism [20]. Hepci-
din and the ratios hepcidin/ferritin and hepcidin/TS were log-transformed and thereafter 
adjusted for age and age2, separately for males and females. For NBS, time of blood sam-
pling was used as an additional covariate (three categories: before 12 PM, between 12 and 5 
PM and after 5 PM). For VB, principal components were used to adjust for family structure. 
Sex-specific residuals were calculated and merged into one variable. Outliers, defined as 
values that differed more than four times the SD from the mean, were excluded. The as-
sociation between the single nucleotide variants and the trait was tested using genotype 
probabilities and an additive model on the standardized residuals (Z score). 
Meta-analysis
The GWAS results from the three cohorts were combined in a fixed-effects meta-analysis 
using METAL [21]. The standard-error based approach was used, which weighs effect size es-
timates using the inverse of the corresponding standard errors. Variants with a minor allele 
frequency <1% and a SNPtest info value or MACH RSQR <0.4 were excluded prior to the me-
ta-analysis. Genomic control correction was applied to the individual cohorts. 
Replication
Six SNPs were measured with single SNP assays in additional independent samples from 
PREVEND (N=2,876) and NBS (N=1018). Single-SNP genotyping in PREVEND samples was 
performed by KBiosciences (KBiosciences, Herts, UK) utilizing the SNPline system. Sin-
gle-SNP genotyping in NBS samples was carried out by deCODE Genetics using the Cen-
taurus (Nanogen) platform [22]. The quality of each Centaurus SNP assay was evaluated by 
genotyping each assay on the CEU samples and comparing the results with the HapMap 
data. All assays had mismatch rate <0.5%. One SNP for which the genotyping assay failed 
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both in NBS and PREVEND samples was carried forward to in silico replication in the addi-
tional samples from the NBS that were genotyped with the HumanOmniExpress-12v1-1_B 
(N=524).
 
Results
Combination of GWAS results from three cohorts (Supplemental Tables 4.1-4.4) revealed two 
loci that were genome-wide significantly associated (p<5E-08) with serum hepcidin (Table 
4.1 and Supplemental Figures 4.1-4.8). The first one (rs118031191 on chromosome 10, near-
est gene FOXI2) showed genome-wide significant association in all individuals, but not in 
the subset (p=1.4E-05). The second locus showed genome-wide significant association in 
the subset (four SNPs on chromosome 2 in EML6 with lead SNP rs354202). This latter signal 
 covers a region that also includes SPTBN1, which encodes spectrin, beta, non-erythrocytic 1 
and is the left flanking gene of EML6 approximately 50 kbp away (Supplemental Figure 4.8). 
Conditional analysis in NBS data showed no additional independent signals at the chromo-
some 2 locus after adjustment for rs354202 (Supplemental Figures 4.9-4.10). 
The ratio hepcidin/ferritin in all individuals and in the subset showed genome-wide signi-
ficant association with the previously known genes HFE and TMPRSS6 (Supplemental  Table 
4.5). No novel statistically significant loci for hepcidin/ferritin were identified; the  novel 
locus with the lowest p-value in the subset (rs1594673 on chromosome 5, nearest gene 
PRELID2) also appeared in the top results for serum hepcidin in the subset (Table 4.1). The 
associations of the ratio hepcidin/ferritin with rs354202 and rs118031191 in all individuals 
and in the subset were far from significant (rs354202: p=6.7E-03 and 1.6E-02, respectively; 
rs118031191: p=3.8E-02 and 1.9E-02). However, directions of the effect estimates were the 
same as for the association with hepcidin [beta (SE) rs354202: -0.09 (0.03) in all individuals 
and -0.09 (0.04) in the subset; beta (SE) rs118031191: -0.14 (0.07) in all individuals and -0.18 
(0.08) in the subset]. 
The ratio hepcidin/TS was genome-wide significantly associated with the TMPRSS6 locus 
in the subset, but not with HFE (Supplemental Table 4.6). No novel significant loci were 
found for hepcidin/TS. SNP rs354202 showed the most significant novel signal in the subset 
(p=1.6E-07) and was also among the top results for hepcidin/TS in all individuals (p=3.0E-06). 
Directions of the effect estimate were the same as for the association with hepcidin [beta 
(SE) -0.15 (0.03) in all individuals and -0.18 (0.04) in the subset]. SNP rs118031191 was also 
among the top results for hepcidin/TS in all individuals (p=2.4E-07), but not in the subset 
(p=3.4E-05). Directions of the effect estimate were the same as for the association with hep-
cidin [beta (SE) -0.35 (0.07) in all individuals and -0.32 (0.08) in the subset].
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Six SNPs were brought forward to replication. SNPs rs354202, rs118031191, rs56281245 and 
rs12289793 were selected based on p<1E-06 for association to hepcidin in all individuals 
and/or in the subset. Two additional SNPs were selected, although not present in the top 
with p<1E-06, because they showed hepcidin association p-values close to 1E-06, their MA 
results were based on three cohorts, they lie inside genes, and their MAF is >10%. These were 
rs1835473 (p =1.9E-06 for hepcidin in all individuals), which lies in the gene PKIB  encoding 
 protein kinase (cAMP-dependent, catalytic) inhibitor beta, and rs12441903 (p=4.3E-06 
for hepcidin in all individuals), which lies in the gene LRRK1 encoding leucine-rich repeat 
kinase 1. SNPs rs117568227 and rs141939445 showed p<1E-06 but were not selected because 
the MA results were based on only one or two cohorts, they lie in intergenic regions, and have 
MAF~1%. Replication analysis revealed no significant associations at p=0.05 (Table 4.2). The 
p-value for discovery and replication analyses combined became stronger for rs354202 only.
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Discussion
This is the first meta-analysis of GWAS for serum hepcidin, which is based on analysis of up 
to 9,917 individuals. It revealed a potentially interesting locus on chromosome 2 with lead 
SNP rs354202. 
SNP rs354202 is located on chromosome 6 in an intron of EML6, encoding echinoderm 
micro tubule associated protein like 6. The linkage disequilibrium region of rs354202 
 stretches from EML6 to SPTBN1 [alias ELF (embryonic liver fodrin)], encoding spectrin, beta, 
non-erythro cytic 1. This gene is a member of a family of beta-spectrin genes, which are 
involved in linking the plasma membrane to the actin cytoskeleton. The ELF protein was 
shown to be essential in TGF-β signaling by son of mothers against decapentaplegic (SMAD) 
proteins in mice [23]. Central in hepcidin regulation is the bone morphogenetic protein-SMAD 
pathway [24], and the ELF protein is thus a plausible candidate to influence hepcidin expres-
sion. In addition, a recent genome-wide RNA interference screen provided a large number 
of putative hepatic hepcidin regulators; results also pointed to adaptor proteins as hepcidin 
activators [25]. Based on current knowledge, spectrins could be considered as adaptor pro-
teins [26], but results of the RNA screen did not specifically point to β-spectrins. Furthermore, 
rs354202 showed association with hepcidin in both all study individuals and in the subset, 
suggesting that this signal is not driven by extreme iron deficiency or inflammation. It also 
showed strong associations with the ratio hepcidin/TS, but not with the ratio hepcidin/fer-
ritin. Finally, the direction of effect of rs354202 on all traits was the same, i.e. the A allele of 
rs354202 is associated with a decrease in hepcidin, hepcidin/ferritin and hepcidin/TS. 
We confirmed the association of the ratio hepcidin/ferritin with common variants in HFE 
and TMPRSS6. We previously reported on the associations of rs1800562 in HFE and rs855791 
in TMPRSS6 with the ratio hepcidin/ferritin via independent studies both in the VB and NBS 
population [17,18]. As expected, we further substantiated these associations here and found an 
even stronger signal. The association signal of the ratio hepcidin/TS with common variants 
in HFE and TMPRSS6 was less strong. Of note, the association of rs1800562 in HFE with the 
ratio hepcidin/TS, previously found in the NBS [18], disappeared upon meta-analysis of results 
of NBS, PREVEND and VB in all individuals (p=0.13), but still showed a relatively weak signal 
in the subset (p=3.7E-04). Also rs855791 in TMPRSS6 showed a stronger signal for association 
with the ratio hepcidin/TS in the subset compared to analysis based on all individuals. The 
stronger signal of rs1800562 and rs855791 with the ratio hepcidin/ferritin compared to the 
ratio hepcidin/TS indicates that these SNPs have a larger influence on hepcidin response to 
body iron stores than on hepcidin response to circulating iron. 
Recently, a meta-analysis on iron status in up to 48,972 subjects was completed by the 
Gen etics of Iron Status Consortium, which also incorporated the three cohorts included in 
the current study (Benyamin et al., in press). This meta-GWAS identified 12 SNPs that were 
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significantly associated with one or more of the iron parameters, i.e. serum iron, ferritin, 
transferrin, and TS. Of these 12 SNPs, only rs1800562 and rs1799945 in HFE and rs855791 in 
TMPRSS6 showed association with the hepcidin ratios, whereas the other 9 SNPs did not 
associate with either hepcidin or the hepcidin ratios (p>0.05, data not shown). This is unex-
pected, as hepcidin and iron metabolism are clearly intertwined [1,7,8,19], as also indicated by 
the strong and positive correlation between serum hepcidin and serum ferritin in the NBS 
and the VB population [17,27].
The fact that our meta-analysis revealed only one locus that potentially affects serum hep-
cidin suggests that there are no common variants that explain a large proportion of pheno-
typic variation in serum hepcidin. Indeed, with our N of 6,096 we had 80% and 99.4% chance 
of detecting (at alpha 5E-08) a variant that explains 0.62% and 1% of hepcidin variance, re-
spectively. For comparison, the well-known iron-related SNPs rs1800562 in HFE and rs855791 
in TMPRSS6 explain ~1% of serum iron variation. In addition, (narrow-sense) heritability of 
hepcidin was previously estimated to be 9.8% (non-significant) in the VB population and 
genome-wide SNP explained variance adjusted for age and gender was estimated at ~37% 
(SE~20%) in the NBS (data not shown), suggesting that a large part of hepcidin variability 
is caused by variation in environmental factors. Future studies that aim to detect common 
variants with small effects on serum hepcidin could increase power by further enlarging 
sample size and/or reducing the hepcidin variability by adjustment for non-genetic factors 
associated with serum hepcidin, like we did for age, gender [17,27], and diurnal rhythm [7,28], 
but also for e.g. alcohol consumption [29], and pregnancy [30]. Studies into rare variants using 
 exome or whole genome sequencing and gene-gene and/or gene-environment interactions 
could further increase insights into the genetic etiology of hepcidin.  
In conclusion, our study revealed one interesting locus (lead SNP rs354202) potentially af-
fecting serum hepcidin concentration. Furthermore, our results indicate that there are no 
common genetic variants that explain more than 1% of phenotypic hepcidin variation. We 
recommend to measure rs354202 in additional independent samples in order to confirm its 
association with serum hepcidin and to follow-up this locus with fine mapping and func-
tional studies to obtain insight into the underlying mechanism of association. 
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SUPPLEMENTAL FIGURE 4.7   Regional association plot for rs118031191 with serum hepcidin in all 
individuals. 
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SUPPLEMENTAL FIGURE 4.8  Regional association plot for rs354202 with serum hepcidin in the subset. 
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ABSTRACT
Joint association analysis of multiple traits in a genome-wide association study 
(GWAS), i.e. a multivariate GWAS, offers several advantages over analyzing each 
trait in a separate GWAS. In this study we directly compared a number of multivari-
ate GWAS methods using simulated data. We focused on six methods that are im-
plemented in the software packages PLINK, SNPTEST, MultiPhen, BIMBAM, PCHAT 
and TATES, and also compared them to standard univariate GWAS, analysis of the 
first principal component of the traits, and meta-analysis of univariate results. We 
simulated data (N=1,000) for three quantitative traits and one bi-allelic quantitative 
trait locus (QTL), and varied the number of traits associated with the QTL (explained 
variance 0.1%), minor allele frequency of the QTL, residual correlation between the 
traits, and the sign of the correlation induced by the QTL relative to the residual 
correlation. We compared the power of the methods using empirically fixed sig-
nificance thresholds (α=0.05). Our results showed that the multivariate methods 
implemented in PLINK, SNPTEST, MultiPhen and BIMBAM performed best for the 
majority of the tested scenarios, with a notable increase in power for scenarios with 
an opposite sign of genetic and residual correlation. All multivariate analyses 
 re sulted in a higher power than univariate analyses, even when only one of the 
traits was associated with the QTL. Hence, use of multivariate GWAS methods can 
be  recommended, even when genetic correlations between traits are weak.  
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Introduction
Genome-wide association studies (GWAS) have been very successful in the identification of 
common genetic variants associated with complex traits. Usually, information on a set of 
related traits is collected in populations sampled for GWAS. These traits are typically ana-
lyzed separately, i.e. in a univariate manner, for association to genome-wide DNA markers. 
This is often followed by an informal comparison of evidence for association at particular 
loci across the studied traits (e.g. [1]). However, a joint analysis of multiple, potentially correl-
ated traits, i.e. a multivariate analysis, could be very advantageous for a number of reasons. 
First, a multivariate analysis has increased power in case of presence of genetic correlation 
between the different traits; the extra information that is provided by the cross-trait co-
variance is ignored in univariate analyses [2,3]. Secondly, most multivariate procedures can 
perform a single test for association with a set of traits. This reduces the number of per-
formed tests and alleviates the multiple testing burden compared to analyzing all traits 
separately [2,4]. Finally, in case of presence of pleiotropy, where a single genetic variant is 
associated with multiple traits, a multivariate GWAS is more consistent with biology com-
pared to cross-trait comparison of univariate analyses [5].
A number of methods for simultaneous analysis of multiple traits in population-based 
GWAS have been published (e.g. [4,6-19]). Although a few of the methods have been compared 
to newly proposed methods [12,15] and some of the methods have been compared to univariate 
analysis [4,7,12], little is known about their relative performances. Here, we performed the first 
direct comparison of several multivariate (MV) GWAS methods using simulated data. We in-
cluded six methods, with a focus on methods already implemented in freely available soft-
ware: the multivariate test of association MQFAM implemented in the genetic associ ation 
analysis software PLINK (MV-PLINK) [7], a Bayesian multiple phenotype test implemented in 
SNPTEST (MV-SNPTEST) [20], the R package MultiPhen (MultiPhen) [12], a Bayesian model com-
parison and model averaging for multivariate regression in BIMBAM (MV-BIMBAM) [21,22], the 
Principal Component of Heritability Association Test (PCHAT) [4], and a Trait-based Associ-
ation Test that uses Extended Simes procedure (TATES) [15]. These can be classified into direct, 
indirect and univariate-based methods (Figure 5.1). MV-SNPTEST, MultiPhen and MV-BIM-
BAM are direct MV methods, in which the effects of the genetic variant are modeled directly 
on the traits without changing the general format and nature of the trait data. MV-SNPTEST 
[20] and MV-BIMBAM [22] are both based on a Bayesian multivariate regression analysis, but 
MV-BIMBAM additionally partitions the traits into three groups: 1) traits that are unaffected 
by the genetic variant, 2) traits that are directly affected by the genetic variant, and 3) traits 
that are indirectly affected by the genetic variant through directly affected traits. Multi-
Phen identifies the linear combination of traits most associated with each genetic variant 
by applying a reversed ordinal regression, such that genotype (allele count) is regressed on 
a collection of traits [12]. MV-PLINK [7], PCHAT [4] and UV-PCA are indirect methods based on a 
reduction of the trait dimension. In MV-PLINK the association between a set of traits and a 
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genetic variant is assessed using canonical correlation analysis. Specifically, the linear com-
bination of traits that maximizes the covariance between the genetic variant and all traits 
is extracted. PCHAT is based on extracting the principal component of heritability that is the 
optimal linear combination of the traits from a heritability point of view [4]. In TATES [15], the 
observed correlation structure between the traits is taken into account in the meta-analysis 
approach.
We compared the power of the methods under empirically fixed type I errors to one another 
and to standard univariate (UV) analysis, univariate analysis of the first principal compo-
nent of the traits (UV-PCA), and meta-analysis of univariate results (UV-MA). In UV-PCA, the 
first principal component of a standard principal component analysis is extracted and used 
in a univariate analysis. In UV-MA, p-values obtained in standard UV GWAS analyses are 
combined in a meta-analysis approach. Our goal was to provide researchers with insights 
that will guide the application of the methods to real data. 
 
FIGURE 5.1   Schematic representation of the included methods.  
GV indicates genetic variant; MV, multivariate; PCHAT, Principal Component of Heritability Association Test; T1, trait 1; T2, trait 2; T3, trait 3; TATES, 
Trait-based Association Test that uses Extended Simes procedure; UV-MA, meta-analysis of univariate results; UV-PCA, univariate analysis of first 
principal component.
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Methods
Data simulation
We simulated genotype and phenotype data for 1,000 individuals. Simulations were per-
formed in R.
Genotype data were simulated for one bi-allelic quantitative trait locus (QTL) with minor 
allele frequency q and major allele frequency p. Genotypes were generated by sampling two 
alleles independently from a binomial distribution as 0 or 1, using two trials and a probabil-
ity of success of each trial equal to q. The genotype is the sum of the two alleles, which can 
be 0, 1 or 2. Because alleles were sampled independently, genotypes were in Hardy Weinberg 
equilibrium. 
Phenotype simulation was based on work by Saint-Pierre and colleagues [14]. For each indi-
vidual, three quantitative traits Yj (j=1, 2, 3) were simulated. The trait-specific QTL herita-
bilities (the relative variance of Yj explained by the QTL, h
2
j), MAF of the QTL q, and residual 
correlation between the traits excluding the QTL effect (rEjj) were controlled. 
First, the effect of the QTL on the individual traits, aj, was determined from h
2
j and q using the 
following formula [14]:    aj = √ hj
2 / 2pq
Secondly, the traits were constructed by adding up the trait-specific effect of the QTL and 
a residual component. Here, the trait-specific effect of the QTL was assumed to be additive 
and obtained by multiplying aj with the number of effect (minor) alleles. The residual com-
ponent (e1,e2,e3) was simulated from a multivariate normal distribution with mean zero and 
with variance-covariance structure:  
                        Var
where (1 – h2j) is the trait-specific proportion of the variance not explained by h
2
j and rEjj is 
the residual correlation between the traits excluding the QTL effect. The correlated residuals 
were generated using the function mvrnorm from the R package MASS. Third, all traits were 
centered and scaled to have zero mean and unit variance. 
Application of methods
MV-PLINK: The command used for association testing with MV-PLINK [7,23] (https://genepi.
qimr.edu.au/staff/manuelF/multivariate/main.html) was: plink.multivariate --noweb --file 
geno --mqfam --mult-pheno pheno.phen --out output. We applied an additive model. MV-
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PLINK produces an F-statistic and a p-value per genetic variant analyzed. This p-value of 
multivariate association was extracted from the output. Note that the canonical correlation 
analysis (CCA) applied by MV-PLINK is similar to multivariate analysis of variance (MANOVA) 
as CCA is applied to a single genetic variant at a time.
MV-SNPTEST: The command used to perform additive association testing with 
 MV-SNPTEST [20] (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html# 
multiple_phenotype_tests) was: snptest -data geno.gen pheno.sample -o output -bayesian 1 
-method expected -mpheno T1 T2 T3 -prior_qt_mean_b 0 -prior_qt_V_b 0.02 -prior_mqt_c 4 
-prior_mqt_Q 6.
An inverse Wishart prior [IW(6,4)] was set on the error covariance matrix ∑ and a matrix 
 normal prior [N(0.02,∑)] on the vector of parameters, according to recommendations of 
the authors. Method ‘expected’ was applied, which results in the use of expected genotype 
counts (~dosages) in the analyses. The output file contains a log10 Bayes Factor (BF) per 
 genetic  variant, which was extracted for the purpose of this study. 
MultiPhen: MultiPhen is an R package available from CRAN (http://cran.r-project.org/web/
packages/MultiPhen/MultiPhen.pdf) for the R software (http://www.r-project.org/) [12]. The 
test for association is a likelihood ratio test (LRT) for model fit, testing whether all regression 
coefficients in the model are jointly significantly different from zero. We analyzed the simu-
lation data using the mPhen function, specifying the genotype data, phenotype data and 
JointModel=TRUE. This results in a p-value per trait and a p-value for the LRT. The latter was 
extracted from the output.
MV-BIMBAM: The BIMBAM software [22] can be run in two different ways: 1) using option 
–mph 1, which tests for association between the multivariate traits, all partitioned in the 
group of directly affected traits, and genotype; and 2) using option –mph2, which considers 
all the different possible partitions of traits into the different categories of traits (directly af-
fected, indirectly affected, unaffected). We applied option –mph2 under the additive model 
using the following command: bimbam -g geno.txt -p pheno.txt -o output -f 3 -mph2 -A 0.1 -A 0.2.
According to recommendations of the authors, the prior for the genetic effect A was set at 0.1 
and 0.2. The association results are summarized by a log10 BF that evaluates presence of any 
association between the QTL and the traits averaging over all possible partitions of the traits 
into the different groups. This value was extracted from the output.
PCHAT: In PCHAT [4] (http://www.wpic.pitt.edu/wpiccompgen/PCHAT/PCHAT.htm) the sam-
ple is split in a training set, which is used to construct the optimal linear combination of 
traits from a heritability point of view, and a test set, which is used for association testing 
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between genotype and the optimal linear combination of traits. In this way, use of the same 
data for both estimation of the optimal linear combination of traits and association test-
ing is avoided. In addition, so called ‘bagging’ is performed, in which bootstrap samples are 
drawn from the training sample and the optimal linear combination of traits is averaged 
across bootstrap samples. The null distribution of the test statistic is obtained in the same 
way, using permutation of the data. We applied the additive model and set input parame-
ters to values recommended by the authors: 50 subsets and bagging subsets for the deter-
mination of the distribution of the PCHAT test statistic under the null hypothesis; 200 and 
50 subsets and bagging subsets, respectively, for testing the association of a genetic variant 
with the trait; 150 individuals for the subsets; and 1000 simulations for determination of the 
distribution of the test statistic under the null hypothesis. The option “both” was used for 
the analysis, resulting in a permutation experiment to determine the null distribution of the 
test statistic, after which the association test is performed using the standard deviation and 
degrees of freedom obtained in the permutation test. PCHAT produces 11 output files. In one 
of them, the association result is expressed as a p-value, which was extracted for this study.
TATES: TATES [15] (http://ctglab.nl/software) requires a correlation matrix of the traits and uni-
variate association results as input. Full, symmetrical correlation matrices were generated 
using the corr option in R. UV analyses for the traits were performed by fitting linear models 
using the lm function in R. TATES was run in R using the freely available script specifying 
three traits and one genetic variant. The output contains the TATES trait-based p-value cor-
rected for the correlations between the traits, which was extracted for this study. 
Univariate (UV) analysis, meta-analysis of univariate results (UV-MA) and UV-PCA: UV 
analyses were performed as described under ‘TATES’. Resulting p-values were extracted for 
the purpose of this study. UV-MA was performed with METAL [24] (http://www.sph.umich.
edu/csg/abecasis/Metal/), using univariate results per trait as input files and the analysis 
scheme ‘scheme samplesize’, which uses p-value and direction of effect as input for the MA 
and weighs according to sample size. PCA was performed in R using the princomp com-
mand. UV-PCA was executed using the first principal component (PC) in a univariate ana-
lysis as described above.  
Empirical significance thresholds (H0 simulations) and power
For each simulation scenario (see below) 1,000 datasets were simulated. Empirical signifi-
cance thresholds for all methods were derived based on permutation of the traits generated 
in these simulation datasets, resulting in the null distribution of the test statistic. We gen-
erated 10 permuted datasets per simulation dataset, resulting in a total of 10,000 per muted 
replicates per scenario. These replicates were analyzed with the multivariate methods, 
resulting in a p-value or log10 BF for each replicate per method per scenario. Significance 
thresholds were set in such a way that 5% of the 10,000 replicates per method yielded a 
 significant result (5% false-positive rate). This was done by sorting the 10,000 association 
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measures in ascending (p-values) or descending order (Bayes Factors) and defining the 
 empirical significance threshold as the mean of the 500th and 501st association measure. 
UV analysis results in one p-value per trait. We adjusted the significance thresholds for three 
UV association tests, ensuring that alpha was fixed at 5% for all traits combined. For each 
null model, we first determined which trait was most strongly associated with the QTL per 
replicate, i.e. which trait resulted in the smallest p-value. These 10,000 p-values were sorted 
in ascending order and the mean of the 500th and 501st p-value was set as the threshold.
The power is defined as the percentage of 1,000 replicates for which the extracted p-value 
was smaller or log10 BF was larger than the empirical significance thresholds, ensuring an 
equal type I error rate of 5% for all methods. 
Simulation scenarios
Simulations were focused on three main scenarios in which one, two or three out of the 
three traits were associated with the QTL. Within these main scenarios, data sets were gen-
erated for a given combination of parameter values (rEjj, h
2
j, rG and q) as shown in Table 5.1. 
This resulted in a total of 30 simulation scenarios.
We simulated positive residual correlations between the traits and studied scenarios with a 
relatively high and low residual correlation (rEjj=0.7 and rEjj=0.3, respectively). The QTL was 
fixed to explain 0.1% of the trait variances. By varying the sign of a1, we created a QTL in-
duced correlation (rG) between trait 1 and traits 2 and 3 which was either positive or nega-
tive, enabling us to study the influence of a negative genetic correlation. 
Note that due to the fixed trait-specific QTL heritabilities, the resulting QTL effects on the 
individual traits are larger for smaller q and vice versa. This fits with the scenario one would 
expect in real data [25].
TABLE 5.1  Simulation scenarios.
# traits associated with QTL Heritability (h2j) Effect size (aj) rG rE MAF (q)
1 h21 = 0.1%, h
2
2 = h
2
3= 0 a1>0, a2=a3=0 0 3x0/3x0.3/3x0.7 0.01/0.4
2 h21 = h
2
2 = 0.1%, h
2
3 = 0 a1=a2, a3=0 + 3x0/3x0.3/3x0.7 0.01/0.4
h21 = h
2
2 = 0.1%, h
2
3 = 0 -a1=a2, a3=0 - 3x0/3x0.3/3x0.7 0.01/0.4
3 h21 = h
2
2 = h
2
3 = 0.1% a1=a2=a3 + 3x0/3x0.3/3x0.7 0.01/0.4
h21 = h
2
2 = h
2
3 = 0.1% -a1=a2=a3 - 3x0/3x0.3/3x0.7 0.01/0.4
MAF indicates minor allele frequency; j, trait; QTL, quantitative trait locus; rE, residual correlation; rG, genetic 
 correlation. 
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Results
Empirical significance thresholds
Supplemental Table 5.1 shows the empirical significance thresholds for all methods for 
 every simulation scenario. Thresholds were around 5% for MV-PLINK, MultiPhen, TATES and 
UV-PCA. Significance thresholds for PCHAT were slightly increased to approximately 6%, in-
dicating slight deflation of type I error rate under the null. MV-SNPTEST and MV-BIMBAM 
showed log10 BF significance thresholds between -0.05 and 0.44. Significance thresholds for 
UV-MA were highly dependent on the residual correlation between the traits: around 5% 
for scenarios with uncorrelated traits and 0.2-0.3% for scenarios with high residual correl-
ation, thus indicating high inflation of type I error rate under the null for the latter scenarios. 
Thresholds for UV analysis were around 5%/3=1.7% for scenarios with no residual correl-
ation and slightly increased with increasing residual correlation.
Power comparison
One out of three traits associated with the QTL (Figure 5.2 A)
All MV methods resulted in higher power than UV analysis. Power of MV-PLINK, MV-SNP-
TEST, MultiPhen and MV-BIMBAM was similar: between 10% and 15% for scenarios with a 
residual correlation of 0 or 0.3 and 20-25% for scenarios with rE=0.7. PCHAT outperformed 
MV-PLINK, MV-SNPTEST, MultiPhen and MV-BIMBAM for scenarios with rE=0 and 0.3, but 
not for scenarios with rE=0.7, although power of PCHAT increased for rE=0.7 as well. TATES 
showed a power between 11-14% for all scenarios and performed slightly better than UV-
PCA and UV-MA, which showed a similar performance as UV analysis of trait 1, the trait as-
sociated with the QTL. 
Two out of three traits associated with the QTL (Figure 5.2 B)
MV-PLINK, MV-SNPTEST, MultiPhen and MV-BIMBAM showed the best and similar perfor-
mance, with higher power with increasing residual correlation. This was most noticeable 
when the correlation induced by the QTL was negative.
PCHAT and TATES showed a robust performance relatively independent of the residual 
correlation, but their power never exceeded that of MV-PLINK, MV-SNPTEST, MultiPhen or 
MV-BIMBAM.
UV-PCA and UV-MA showed the same performance for scenarios in which there was a residual 
correlation between the traits. For scenarios with no residual correlation, UV-PCA performed 
better under negative genetic correlation and UV-MA under positive genetic correlation. They 
were outperformed by UV analysis of trait 1 and 2 only in case of a negative genetic correlation.
Three out of three traits associated with the QTL (Figure 5.2 C)
Again, MV-PLINK, MV-SNPTEST, MultiPhen and MV-BIMBAM performed similar and best 
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under simulation scenarios with a negative genetic correlation; in this case, their power in-
creased with increasing residual correlation. However, for scenarios with a positive genetic 
correlation, power of MV-PLINK, MV-SNPTEST, MultiPhen and MV-BIMBAM increased with 
decreasing residual correlation. 
PCHAT and TATES showed a comparable performance over all simulation scenarios. Also 
here, power slightly increased with decreasing residual correlation in case of a positive gen-
etic correlation, and slightly increased with increasing residual correlation for a negative 
genetic correlation. 
Similar to simulation scenarios with two out of three traits associated to the QTL, UV-PCA 
and UV-MA showed comparable power for all scenarios with rE>0. Again, for scenarios with 
rE=0, UV-PCA performed better in case of a negative genetic correlation and UV-MA per-
formed better in case of a positive genetic correlation. UV-MA outperformed all methods 
when rE was 0 and the genetic correlation was positive; for rE=0.3 and a positive genetic 
correlation, UV-PCA and UV-MA performed best of all methods. Power of UV-MA was the 
same as that of UV analysis for all scenarios with a negative genetic correlation.   
FIGURE 5.2   Power of the methods for scenarios with one of three traits associated with the QTL (A), two of three 
traits associated with the QTL (B) and with all three traits associated with the QTL (C).  
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The explained variance of the QTL was fixed at 0.1%. For clarity reasons, we have not provided errors bars. Confidence ranges for the power estimates 
are all between 1 and 5%; exact values are provided in Supplemental Tables 5.3-5.5.
MAF, minor allele frequency; MV, multivariate; PCHAT, Principal Component of Heritability Association Test; QTL, quantitative trait locus; rE, residual 
correlation; rG, genetic correlation induced by the QTL; TATES, Trait-based Association Test that uses Extended Simes procedure; UV-MA, meta-ana-
lysis of univariate results; UV-PCA, univariate analysis of first principal component; UV T1, univariate analysis of trait 1; UV T2, univariate analysis of 
trait 2; UV T3, univariate analysis of trait 3.
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Results for simulation scenarios with different heritabilities for the three traits (h21=0.001, 
h22=0.002, h
2
3 = 0.0005) are comparable to the results presented in Figure 5.2C (Supplemen-
tal Table 5.2). 
Results for MAF=0.25, 0.10, and 0.05 are shown in Supplemental Tables 5.3-5.5. As expected, 
power was similar for all MAF scenarios. Low MAF was not a problem for the methods, ex-
cept for MultiPhen which experienced convergence problems of the underlying R function 
‘polr’ when MAF was equal to or lower than 5%.  
Run time
Run time was measured on a Linux cluster using one core on a node equipped with 24 GB 
RAM and two Intel Xeon L5520 processors running on 2.26 GHz. Time for performing associ-
ation analyses for 1000 subjects and 1000 replicates (similar to 1000 genetic variants in our 
study) was recorded. For TATES and UV-MA, run time also included the time used for UV as-
sociation analyses of the three traits. MV-BIMBAM was the fastest method using 9 seconds, 
while PCHAT needed 437 minutes and 15 seconds. Run times for MV-PLINK, MV-SNPTEST, 
MultiPhen, TATES, UV-PCA and UV-MA were 23 seconds, 1 minute and 10 seconds, 3 minutes 
and 18 seconds, 23 seconds, 23 seconds and 19 seconds, respectively.
Discussion
In this study, we used simulated data to compare the performance of six multivariate 
gen ome-wide association methods (MV-PLINK, MV-SNPTEST, MultiPhen, MV-BIMBAM, 
PCHAT and TATES) and standard univariate analysis, univariate PCA, and meta-analysis of 
univariate analyses. Our results showed that there is not a single method that performed 
best under all simulation scenarios. However, all six multivariate methods resulted in a 
higher power than UV analysis, even when only one of the traits was associated with the 
QTL. UV-MA only outperformed all methods when all traits were associated with the QTL 
and the genetic correlation was positive.
Use of multivariate GWAS can be recommended even when genetic correlations between 
traits are expected to be weak. Indeed, even when only one of the traits was associated with 
the QTL and thus in the absence of genetic correlation and pleiotropy, MV analyses resulted 
in higher power than UV analyses. This was described before by Liu et al. for bivariate ana-
lyses and is due to the differences in the penalty for multiple testing [9]. Note that this penalty 
is commonly not applied in multiple UV analyses of real data. 
The influence of the strength of residual correlation, i.e. the relative amount of shared gen-
etics, and sign of genetic correlation, i.e. difference in sign of QTL effect, on power varied 
across the different methods. For MV-PLINK, MV-SNPTEST, MultiPhen and MV-BIMBAM, 
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higher power was observed with increasing residual correlation in case of a single QTL trait 
and when two or all three traits were associated with the QTL with a negative genetic cor-
relation. The latter is due to the resulting opposite sign of genetic and residual correlation. 
Indeed, we observed a similar increase in power when simulating a positive genetic cor-
relation and negative residual correlation (data not shown). This effect has been described 
before for these and other methods [7,9,12,14] and was demonstrated analytically by Evans for 
bivariate linkage analysis [26]. In contrast, when residual and genetic correlation were in the 
same direction, power of these four methods decreased with increasing residual correlation 
between the traits, which also corroborates previous findings [7,12]. PCHAT and TATES were 
relatively independent of the underlying (genetic) correlations of the traits. For PCHAT, this 
can be explained by the fact that it constructs the optimal linear combination of traits from 
an heritability point of view, thereby essentially removing the influence of residual correla-
tion on power [4]. For TATES, it was described that the power was not influenced by opposite 
effects of the QTL on the traits, because of its reliance on p-value information [15]. UV-MA did 
however severely suffer from a negative genetic correlation between the traits; indeed, in 
this scenario it performed equal or worse than standard UV analysis. These findings are not 
unexpected; a negative genetic correlation between the traits is disastrous for the power of 
a MA, because the direction of effect is taken into account. An alternative meta-analysis ap-
proach is Fisher’s method [27]. As it combines univariate p-values into one test statistic, simi-
lar to TATES, it does not suffer from a differential sign of effect. For scenarios with a negative 
genetic correlation, Fisher’s method performed better than UV-MA and also better than 
TATES, except for scenarios with a residual correlation of 0.7: here it was outperformed by 
TATES but not by UV-MA (data not shown). The reduced performance for an opposite QTL ef-
fect was observed for UV-PCA as well, but not for scenarios with no residual trait correlation. 
In these scenarios, the first PC reflects the negative genetic correlation between the traits. 
Power is thus increased compared to UV since there is no need to multiple testing penalty.
We would like to emphasize that all methods were compared based on empirically derived 
significance levels, adjusting each method to an exact 5% type I error rate. Null simulations 
illustrated that for MV-PLINK, MV-SNPTEST, MultiPhen, MV-BIMBAM, TATES and UV-PCA 
these empirical significance levels were all close to the nominal level of 0.05 for p-values or 
between 0.01-1 for log10 BF
 [28]. PCHAT was slightly conservative based on our observations. 
Thresholds for UV analysis were around 1.7% (i.e. 5 divided by 3) in case of uncorrelated traits, 
which is in line with a Bonferroni correction for three independent tests. As expected, for 
correlated traits the adjusted threshold was less stringent and somewhere between 1.7 and 
5%. We found that significance thresholds for UV-MA were highly dependent on trait cor-
relations with increased stringency with increase in correlation. Trait correlations result in 
longer tails for the test statistic distribution, and therefore a more stringent threshold must 
be applied to keep the type I error at 5%. Thus, use of the UV-MA can potentially lead to 
a high number of false-positive findings if traits are highly correlated and the significance 
threshold is not appropriately adjusted. 
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Some of the methods included in our study have been compared to one another before. MV-
PLINK and MultiPhen were compared by O’Reilly et al. and van der Sluis et al., which showed 
that both methods result in the same power when restricting the analysis to normally dis-
tributed traits [12,15], corroborating our findings. TATES was compared to MANOVA (which is 
similar to MV-PLINK) and shown to be only outperformed by MANOVA in the particular con-
dition that the genetic variant affects only one of multiple strongly correlated traits [15]. In 
contrast, we observed that MV-PLINK outperformed TATES in almost all scenarios. 
In addition to power (and type I errors), there are other characteristics that are important 
to take into account when deciding upon the appropriate multivariate GWAS analysis. 
MV-PLINK output results contain trait loadings, which indicate how much each trait con-
tributed to the multivariate association result [7]. MV-BIMBAM outputs marginal posterior 
probabilities for each trait being unaffected, directly affected or indirectly affected by the 
QTL, conditional on an overall association with at least one trait [22]. PCHAT gives the weights 
for each of the traits included in the analysis which were used to construct the optimal 
linear combination of the traits to detect an association with the QTL [4]. MultiPhen output 
contains the betas and p-values for the association of each trait with the QTL based on the 
joint model including all traits [12]. This additional information, which is not provided by 
MV-SNPTEST and TATES, can be used to obtain insight into underlying biology and facil-
itates the discrimination between independent and pleiotropic QTL effects. Furthermore, 
MV-PLINK, MultiPhen, TATES and UV-MA allow analysis of a combination of quantitative 
and binary (case-control) traits [7,12,15]. MV-BIMBAM and UV-MA can be applied to summary 
data, without access to raw phenotype and genotype data [22]. Also, MV-SNPTEST, MultiPhen, 
TATES, UV-PCA and UV-MA are able to handle genotype probabilities as obtained by impu-
tation while the other methods are not [12,15,20]. Finally, our study showed large differences in 
run time between the methods. 
Our simulations are not exhaustive. Data were simulated for three traits according to an 
additive model, and analyzed accordingly. We did not simulate and analyze other, non-ad-
ditive genetic models and/or (higher-order) interactions, nor did we study scenarios with 
more than three traits. In addition, priors for MV-SNPTEST and MV-BIMBAM and input par-
ameters (e.g. number of (bagging) subsets) for PCHAT were not varied. Also, we did not study 
the effect of missing data. This was explored by Klei et al. for PCHAT who concluded that 
dropping individuals with missing data had a substantial diminishing effect on power of 
the test [4]. In addition, Van der Sluis et al. [15] reported that 10% missingness completely at 
random hardly affected the power to detect QTLs when the QTL affected all traits, but that 
it resulted in a higher power drop for MANOVA compared to TATES when the QTL was only 
associated to one of the traits. Finally, we did not simulate trait outliers in our data. O’Reilly 
showed that this could result in substantial inflation of the statistics for CCA for low fre-
quency variants [12]. However, in our opinion outliers should be handled appropriately prior 
to association analyses. 
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Taken together, our study showed substantial differences in power between the  methods, 
dependent on the simulation scenario. For some of the simulation scenarios, a large in-
crease in power of multivariate compared to univariate analyses was observed, which 
suggests that the multivariate methods might be able to identify genetic variants that are 
currently not identifiable by standard univariate analysis. Overall, MV-PLINK, MV-SNPTEST, 
MultiPhen and MV-BIMBAM performed best for the majority of the tested scenarios, with 
a remarkable increase in power for scenarios with an opposite sign of genetic and residual 
correlation. As a consequence, results of these methods will be biased towards QTLs that 
cause a genetic correlation that is opposite in sign to the residual correlation. PCHAT and 
TATES showed a robust performance over all simulation scenarios and are therefore rec-
ommended to use if one aims to obtain a reflection of the underlying genetic architecture 
of the traits.  
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ABSTRACT
Iron and the iron regulatory hormone hepcidin, major determinant of body iron 
distribution, are hypothesized to play a role in cardiovascular disease. Here, we as-
sess the associations of hepcidin as well as ferritin, iron, total iron binding capacity 
and transferrin saturation (i.e. iron parameters) with non-invasive measurements 
of atherosclerosis (NIMA) in males and females of a population-based cohort. We 
included 766 participants of the Nijmegen Biomedical Study aged 46−67 years for 
whom serum measurements of hepcidin, iron parameters, and NIMA were avail-
able. NIMA were presence of plaque, ankle-brachial index (ABI) and intima media 
thickness (IMT). We performed multivariable logistic and linear regression analyses 
using quartiles of hepcidin and iron parameters. Analyses were stratified by gender 
and adjusted for several demographic, clinical and biochemical determinants, in-
cluding traditional risk factors of cardiovascular disease based on the Framingham 
risk score. Hepcidin and the ratio hepcidin/ferritin, reflecting hepcidin expression 
relative to iron stores, were significantly associated with the presence of plaque 
in females [adjusted odds ratios for quartile 4 vs quartile 1 (95% CIs) of 3.07 (1.36; 
6.90) and 2.31 (1.03; 5.18), respectively]. The hepcidin/ferritin ratio was significantly 
and negatively associated with ABI at rest in males and females [adjusted betas for 
quartile 4 vs quartile 1 (95% CIs) of -0.03 (-0.07; 0.00) and -0.04 (-0.06; -0.01), respec-
tively]. Our results suggest that the body iron distribution as determined by hepci-
din affects the development of atherosclerosis in females. 
112 C H A P T E R  6
Introduction
A few decennia ago, Sullivan proposed the ‘iron hypothesis’, which suggests that iron de-
ficiency plays a protective role against heart disease [1]. With this hypothesis he aimed to 
explain the sex difference in cardiovascular disease (CVD) risk and the increase in CVD in-
cidence among women after menopause. According to the hypothesis, loss of iron with 
menstruation is responsible for the lower risk of heart disease in premenopausal women 
compared to men and postmenopausal women. The original hypothesis was formulated 
without specification of a mechanism. It is proposed that stored iron, which is known to be 
redox-active [2], catalyzes the formation of reactive oxygen species, which oxidize low-dens-
ity lipoprotein (LDL) cholesterol. This has been shown to induce the formation of foam cells 
and ultimately atherosclerosis [3,4]. 
Until now, several epidemiological studies have investigated the associations between 
body iron stores and CVD, most of them using blood donation history as a proxy for body 
iron  levels, but they remain inconclusive. Some studies confirmed the iron hypothesis [5-8], 
whereas Ascherio et al. demonstrated that the number of lifelong blood donations among 
38,244 men was strongly associated with lower plasma ferritin levels, but not with the risk 
of myocardial infarction or fatal coronary heart disease over 4 years of follow-up [9]. Some 
studies reported on the associations between blood donation and (sub)clinical measures of 
atherosclerosis instead of on cardiovascular events and/or deaths [10-12]. Zheng et al. found 
decreased body iron stores, decreased oxidative stress and enhanced vascular function, as 
measured by flow-mediated dilation, in high-frequency blood donors compared to low-fre-
quency  donors [10]. Engberink and colleagues concluded that the intima media thickness 
(IMT) of the common carotid artery was slightly reduced in frequent donors as compared to 
low-frequency donors, although not statistically significant [11]. Finally, Peffer and colleagues 
showed that serum ferritin levels were lower in high-frequency donors compared to low-fre-
quency  donors, but they did not observe clear beneficial effects on measures of subclinical 
atherosclerosis as assessed by IMT, pulse-wave velocity and ankle-brachial index (ABI) [12].
In 2001, a peptide with antimicrobial properties was discovered, named hepcidin [13]. This 
small 25 amino-acid peptide hormone plays a key role in systemic regulation of iron homeo-
stasis [14]. Hepcidin is synthesized by various cell-types, but predominantly by hepatocytes. 
It is upregulated by elevated body iron status and inflammatory cytokines, and decreased 
in iron deficiency and low oxygen tension. Hepcidin binds and subsequently degrades the 
cellular iron exporter ferroportin in the membrane of macrophages, leading to changes in 
body iron distribution by leaving iron trapped inside these iron recycling cells [15]. Hepcidin is 
of additional value when assessing iron status, because of its central role in iron regulation. 
Besides, the ratios of hepcidin to ferritin and hepcidin to transferrin saturation (TS) are in-
formative for assessing iron status, given the dependence of hepcidin expression on stored 
iron and circulating iron, respectively [16,17]. 
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It has been hypothesized that increased hepcidin concentrations may increase cardiovascu-
lar risk, by slowing or preventing the mobilization of iron from macrophages. This iron trap-
ping in macrophages subsequently activates these cells to become more athero genic [18,19]. 
Indeed, there is some evidence for a role of hepcidin in the development of atherosclerosis 
from in vitro studies and studies in patients on hemodialysis [20,24]. However, the association 
of serum hepcidin with atherosclerosis has not been investigated in the general population. 
Here, we studied the associations of serum hepcidin and its ratios to ferritin and TS, as well 
as serum ferritin, serum iron, total iron binding capacity (TIBC; a proxy for transferrin), and 
TS (i.e., iron parameters) with non-invasive measures of atherosclerosis: presence of plaque, 
ABI at rest and after exercise and IMT. We used a well-phenotyped subsample of 766 partici-
pants aged 46-67 years from the Nijmegen Biomedical Study (NBS) and stratified analyses 
by gender in order to account for differences in iron status and CVD risk between males and 
females during life. 
 
Methods
Study population
This study was performed in a subset of participants from the Nijmegen Biomedical 
Study (NBS). Details of the NBS have been described before [25]. Briefly, the NBS is a popula-
tion-based survey conducted by the Department for Health Evidence and the Department 
of Laboratory Medicine of the Radboud university medical center, Nijmegen, The Nether-
lands. In 2002, 22,451 age and sex-stratified randomly selected adult inhabitants of Nijme-
gen, a city located in the eastern part of the Netherlands, received an invitation to fill out 
a postal questionnaire (QN) including questions about lifestyle, health status, and medical 
history, and to donate a blood sample for DNA isolation and biochemical studies. A total 
of 9350 (43%) persons filled out the QN, of which 6468 (69%) donated blood samples. Be-
tween 2005 and 2008, the NIMA (non-invasive measurements of atherosclerosis) substudy 
was performed by the Department of Internal Medicine. In the NBS-NIMA, all NBS partici-
pants aged 50-70 years at that time were re-invited to fill out an additional QN, donate a 
fasting blood sample, and undergo anthropometric measurements and non-invasive meas-
urements of atherosclerosis. A total of 1491 subjects participated in NBS-NIMA (response 
71%). Approval to conduct the NBS and NBS-NIMA study was obtained from the Radboud 
university medical center Institutional Review Board. All participants gave written informed 
consent for participation in the NBS.
Our study is based on 1491 subjects who participated both in the NBS in 2002 (‘baseline’) and 
the NBS-NIMA in 2005 (‘follow-up’). The following data as measured in the NBS in 2002 were 
extracted: hepcidin, ferritin, iron, TIBC, TS, creatinine, C-reactive protein (CRP), total chol-
esterol (TC), high-density lipoprotein (HDL) cholesterol and liver enzyme alanine amino-
transferase (ALT) as measured in non-fasting serum; age at inclusion, length, weight [used 
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to derive body mass index (BMI)], the report of a cerebrovascular accident or myocardial 
infarction, use of antihypertensives, lipid lowering medication or anticoagulants, presence 
of diabetes, smoking, presence of a regular menstruation (used to determine menopausal 
state), use of hormone replacement therapy (HRT), presence of anemia and the report of a 
cerebrovascular accident or myocardial infarction for parents, children, brothers or sisters 
as measured via the QN. The following data were extracted from the NBS-NIMA study: high 
sensitive CRP and folate as measured in fasting serum; systolic blood pressure (SBP) meas-
urements and NIMA (see below); and use of antihypertensives, lipid lowering medication or 
anticoagulants as measured via the QN.
For this study, we excluded subjects without hepcidin measurement (n=329). We also ex-
cluded premenopausal women (n=157) because of the differences in hepcidin level, iron 
status and CVD risk between pre- and postmenopausal women [26]. Furthermore, we ex-
cluded participants with a history of CVD at baseline (2002) (n=52) and persons who used 
anti hypertensives, lipid lowering medication or medication for CVD at baseline (n=187) as a 
proxy for presence of atherosclerosis to obtain an ‘at-risk population’, resulting in a total of 
766 eligible participants. 
Laboratory methods and clinical measurements
The iron parameters, creatinine, CRP and ALT were measured as described recently [26]. 
 Creatinine was used to calculate the estimated glomerular filtration rate (eGFR) as de-
scribed before [26]. Serum hepcidin was measured with an in-house developed and validated 
competitive enzyme-linked immunosorbent assay as described before [26,27]. High sensitive 
CRP was determined by ELISA (Dako, Glastrup, Denmark). Folate was determined by a micro-
biological assay using a colistin-sulfate resistant strain of Lactobacillus leichmanniias as 
 described before [28]. Measurements of SBP, TC, HDL cholesterol and NIMA measurements 
were performed as described before [29]. NIMA measurements used for this study comprise the 
carotid intima media thickness (IMT), presence of plaque and the ankle-brachial index (ABI). 
In short, IMT was measured at the most distal centimeter of both common carotid arteries 
before the bifurcation into the internal and external carotid arteries. Presence of plaque was 
defined as a focal thickening of the arterial wall of at least 1.5 times the mean IMT, as defined 
by the Mannheim Intima-media thickness consensus [30]. Both carotid ar teries (as well as the 
common carotid, internal carotid as the external carotid arteries) were scanned from most 
proximal to most distal to check for focal thickenings. ABI was determined by dividing the 
lowest of two ankle pressures by the highest of two arm pressures, which were measured 
with a hand-held Doppler device. The ABI was measured at rest and after exercise. A lower 
ABI indicates obstruction in the peripheral arteries and thus atherosclerosis. 
Statistical analysis
Statistical analyses were performed with SPSS for Windows, release 20 (IBM Corporation, 
Armonk, NY). 
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Distributions of serum hepcidin, serum ferritin, the ratios hepcidin/ferritin and hepcidin/
TS, high sensitive CRP, ALT and folate were skewed towards higher values and therefore 
transformed with the natural logarithm to normalize their distributions. Outliers, defined 
as  values that differed more than three times the standard deviation (SD) from the mean of 
continuous variables, were reduced to mean ± 3 SD (maximal number of outliers per trait: 13). 
Blood sampling time and CRP were categorized into 3 groups based on clinically relevant 
cutoffs. For blood sampling time, these were before 12 PM, 12 PM to 5 PM, and later than 
5 PM, according to Dutch routine and in line with previously reported hepcidin concentra-
tion patterns throughout the day [26,31,32]. For CRP, cutoffs of less than 5 mg/L, 5 to 20 mg/L, and 
more than 20 mg/L were used [26].
Serum hepcidin, the hepcidin ratios and the iron parameters were transformed into gen-
der-specific quartiles (Q). Parameters that varied over the day, i.e. serum hepcidin, hepcidin/
ferritin, hepcidin/TS, serum iron and TS were first adjusted for time of blood sampling cat-
egories using linear regression analyses. 
To optimize the information on atherosclerosis in a single proxy for the hard endpoint CVD, 
we also constructed one dichotomous measure of atherosclerosis based on measurements 
of presence of plaque, IMT and ABI, using cutoffs from clinical guidelines [33]. The combined 
measure of atherosclerosis was defined as IMT >0.9 mm OR ABI <0.9 OR a difference be-
tween ABI in rest and exercise >0.15 OR presence of plaque. 
Characteristics of the study population were described per quartile of serum hepcidin. For 
all continuous variables, median and 5th and 95th percentiles (P5 and P95, respectively) 
were calculated from original untransformed values. Categorical variables were expressed 
in numbers and corresponding percentages.
Multivariable logistic regression analyses were used to study the associations of presence 
of plaque and the combined measure of atherosclerosis with quartiles of hepcidin and iron 
parameters. Multivariable linear regression analyses were used to study the associations 
of IMT and ABI at rest and after exercise with quartiles of hepcidin and iron parameters. 
We adjusted for the following potential confounding factors: time of blood sampling, CRP, 
high sensitive CRP, BMI, eGFR, ALT, folate, presence of anemia, time between baseline and 
follow-up and traditional risk factors based on the Framingham risk score [34]: age, systolic 
blood pressure, smoking, diabetes, total cholesterol, HDL cholesterol and reported use of 
antihypertensive treatment, lipid lowering medication or anticoagulants in NBS-NIMA. For 
females, we additionally adjusted for the use of HRT. Resulting odds ratios (OR) of logistic 
models express the increase or decrease in odds for presence of plaque relative to Q1. Result-
ing betas of linear models express the increase or decrease in IMT or ABI using Q1 as a refer-
ence, thus Q2 vs Q1, Q3 vs Q1 and Q4 vs Q1. Explained variances (adjusted r2 for linear models 
and Nagelkerke r2 for logistic models) were obtained to indicate the amount of variance in 
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IMT and ABI and in the risk of presence of plaque that was explained by the determinants 
in addition to the variance explained by the potential confounding factors. Note that the 
Nagelkerke r2 is an approximation of explained variance and that comparison of its value for 
different models is only valid if applied to the same set of samples. 
All analyses were stratified by gender.
 
Results
Characteristics of the study population
Characteristics of the subjects included in the study, stratified by gender and hepcidin quar-
tiles, are presented in Table 6.1. A total of 420 participants (55%) was male. Median age at 
inclusion of the male participants was 57 years; that of the females was 56 years. Serum 
hepcidin quartiles were constructed separately for males and females, but the resulting 
concentration ranges per quartile were approximately the same. Serum ferritin concen-
tration was lower in females than in males, whereas the ratios of hepcidin to ferritin and 
hepcidin to TS were higher in females per hepcidin quartile. Both serum ferritin and the 
ratios increased with quartiles of hepcidin. Median iron concentration, TIBC and TS were 
comparable over the quartiles and between males and females. Use of antihypertensives, 
lipid lowering medication and anticoagulants in NBS-NIMA, was higher in males than in 
females. High sensitive CRP increased with quartiles of hepcidin whereas SBP, BMI, TC and 
HDL cholesterol were comparable over hepcidin quartiles for both males and females. 
Association with presence of plaque, IMT and ABI at rest and after exercise
Table 6.2 shows the results of multivariable logistic regression analyses for presence of 
plaque stratified by gender. In females, hepcidin and the ratios hepcidin/ferritin and hep-
cidin/TS were positively associated with the presence of plaque. The strongest associations 
were found for Q4 vs Q1 of hepcidin, hepcidin/ferritin and hepcidin/TS, with adjusted ORs 
(95% CIs) of 3.07 (1.36; 6.90), 2.31 (1.03; 5.18) and 2.22 (0.99; 4.95) and a p for trend of 0.04, 0.03 
and 0.04, respectively. In males, hepcidin showed a positive association with the presence 
of plaque, but this association was weaker than in females [OR (95% CI) Q4 vs Q1 1.89 (0.94; 
3.77), p for trend 0.05]. The ratios hepcidin/ferritin and hepcidin/TS showed some indication 
for positive association with presence of plaque, but ORs did not consistently increase over 
the quartiles.    
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Results of multivariable linear regression analyses for IMT, ABI at rest and ABI after exer-
cise are presented in Tables 6.3-6.5. In males, hepcidin showed an association with IMT [beta 
(95% CI) Q4 vs Q1: -0.03 (-0.06; -0.01), p for trend 0.05]. In females, Q2 and Q3 vs Q1 of iron and 
TS showed a significant and positive association with IMT [betas (95% CIs) Q2 vs Q1: 0.05 
(0.01; 0.08) and 0.04 (0.00; 0.07), respectively; betas (95% CIs) Q3 vs Q1: 0.04 (0.01; 0.08) and 
0.04 (0.01; 0.08, respectively], but not for Q4 vs Q1. IMT was not associated with iron and TS 
in males.
ABI at rest (Table 6.4) showed a negative and significant association with the ratio hepcidin/ 
ferritin, with increasing strength over quartiles of the hepcidin/ferritin ratio: adjusted betas 
(95% CIs) for Q2 vs Q1: -0.01 (-0.04; 0.01), Q3 vs Q1: -0.03 (-0.05; 0.00), Q4 vs Q1: -0.04 (-0.06; 
-0.01), p for trend 0.003. The same trend was observed in males, with a significant associ-
ation for Q4 vs Q1 [beta (95% CI) -0.03 (-0.07; 0.00), p for trend 0.03]. The associ ation results 
of hepcidin/ferritin ratio with ABI after exercise (Table 6.5) were less consistent, but also 
showed some indication for a negative association. 
The combined dichotomous measure of the NIMA showed positive and significant associ-
ations with hepcidin and the ratios hepcidin/ferritin and hepcidin/TS in females [adjusted 
ORs Q4 vs Q1 (95% CIs) 2.20 (1.04; 4.67), 2.60 (1.20; 5.63) and 2.27 (1.06; 4.85), respectively] (Sup-
plemental Table 6.1). 
The regression models including the potential confounders only resulted in explained vari-
ances (Nagelkerke r2) of 18% and 24% for presence of plaque in males and females, respec-
tively. In males, an increase to 20% was seen for inclusion of hepcidin, ferritin, the ratio 
hepcidin/ferritin and iron. In females, inclusion of hepcidin, hepcidin ratios, iron or TS led 
to an increase in explained variance to a maximum of 27%. This increase of maximal 3% 
is relatively large, as the 20 potential confounders together explained 24% of the variance. 
Inclusion of the ratio hepcidin/ferritin in the models for ABI at rest and ABI after exercise 
increased the explained variance with 2% in females. Models for IMT for both genders and 
models for ABI at rest and ABI after exercise in males resulted in a maximum of 1% increase 
in explained variance. 
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Discussion
To our knowledge, this is the first study that investigated the associations between hepci-
din, iron and non-invasive measurements of atherosclerosis in a general population. After 
adjustment for several demographic, clinical and biochemical determinants, we demon-
strated that serum hepcidin and the ratio hepcidin/ferritin were significantly and positively 
associated with the presence of plaque in females. Suggestive evidence for a positive asso-
ciation with presence of plaque was observed for hepcidin and the ratio hepcidin/ferritin 
in males and the ratio hepcidin/TS in females. Furthermore, the hepcidin/ferritin ratio was 
significantly and negatively associated with ABI at rest in males and females. Iron and TS 
showed evidence for a positive association with IMT in females, but the effects did not con-
sistently increase over the quartiles of iron and TS. 
In our study, we used three measures that reflect the presence of atherosclerosis. Presence 
of plaque has been shown to be a better predictor of myocardial infarction risk and the ex-
tent of underlying coronary artery disease than IMT [35]. In addition, ABI is the only of the 
three NIMA that is routinely applied in clinical practice. As hepcidin and the ratio hepcidin/
ferritin showed consistent associations with presence of plaque and ABI, the two most evi-
dent markers of atherosclerosis, our results suggest that hepcidin plays a role in the devel-
opment of atherosclerosis in females. 
Our results confirm several previous studies that investigated serum hepcidin concentra-
tion in relation to cardiovascular or metabolic diseases in patient populations. In patients on 
maintenance hemodialysis, hepcidin was shown to be associated with arterial stiffness and 
fatal and non-fatal cardiovascular events [20,21]. Valenti et al. showed that hepcidin correlates 
with monocyte chemoattractant protein-1 levels in patients with metabolic alterations, 
and that these levels are an independent predictor of the presence of carotid plaques  [36]. In 
 response to this paper, Kroot et al. demonstrated that total hepcidin and hepcidin-25 levels 
were significantly higher in subjects with metabolic syndrome than in age-matched con-
trols in a nested case-control study in the NBS [37]. In another paper, Valenti et al. reported 
that hepcidin-25 was independently associated with carotid plaques in patients with non-
alcoholic fatty liver disease [38]. In addition, hepcidin was reported to increase significantly 
and linearly with increasing number of metabolic syndrome features, paralleling the trend 
of serum ferritin [39]. Finally, increased hepcidin production was observed in patients with 
(low-grade) inflammation, obesity and other metabolic syndrome alterations, which are 
traditionally associated with CVD [40-42]. 
Our findings are in agreement with the hypothesis that hepcidin increases iron deposition 
in macrophages within atherosclerotic plaques with subsequent increased lipid peroxid-
ation and progression to foam cells [18], resulting in an increased risk of atherosclerosis. There 
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is additional evidence for this hypothesis from recent in vitro and mice studies. Saeed et al. 
demonstrated that suppression of hepatic hepcidin production resulted in reduced macro-
phage intracellular iron content, which increased the efflux capacity of cholesterol and 
thereby decreased the formation of foam cells and atherosclerosis [23]. Using human mono-
cytes derived from atherosclerotic plaques, Finn et al. showed that hepcidin increased the 
intracellular iron content, resulting in increased ROS and decreased cholesterol efflux [24]. 
These observations are consistent with those obtained in a mouse model of atherosclerosis 
and in macrophage cell lines, suggesting that the interaction of (locally produced) hepcidin, 
trapped iron, and accumulated lipids is critical for pro-atherosclerotic activation of macro-
phages, contributing to their destabilization [22]. Our results for the hepcidin/ferritin ratio, re-
flecting the amount of hepcidin relative to ferritin as a measure of intracellular iron, match 
with the latter findings, since the ratio hepcidin/ferritin showed significant association with 
the presence of plaque and ABI. This underscores the role of hepcidin in determining the 
body iron distribution and thus the interplay of hepcidin and ferritin levels in the develop-
ment of atherosclerosis. 
Our results might explain the inconsistent results of previous epidemiological studies on 
the association between body iron stores and CVD risk [5-12]. Hepcidin levels were not meas-
ured in these studies, except for the study by Peffer et al. [12] in which a subset (n=269) of 
the NBS-NIMA population was used, but the associations between hepcidin and NIMA 
were not investigated in that study. Furthermore, our results might explain the paradox 
of no obvious increase in atherosclerosis in patients with hemochromatosis gene (HFE)- 
related heredi tary hemochromatosis despite their sometimes significant iron overload: 
hepcidin levels are relatively low, resulting in decreased retention of iron by macrophages 
and therefore a more rapid clearance of iron from arterial lesions [18,19,43]. Interestingly, the 
p.Cys282Tyr  variant (rs1800562) of the HFE gene, that is associated with a decrease in the 
hepcidin/ ferritin  ratio [44,45], has also been associated with decreased levels of LDL and total 
cholesterol  levels [46]. Finally, a lower incidence of coronary artery disease in patients with 
β-thalassemia major and intermedia [47,48] might not only be due to increased cholesterol 
requirements associated with erythroid hyperplasia and therefore relatively low serum 
cholesterol levels [47], but also to relatively low hepcidin levels which might play a role in the 
protection against CVD as well [49,50]. 
Interestingly, the associations of serum hepcidin and the ratio hepcidin/ferritin with pres-
ence of plaque and ABI were far stronger in females compared to males. It is known that 
some of the traditional cardiovascular risk factors have a different impact on males and 
females [51], but the reason for this remains unexplained. Hormones might be responsible 
for gender-related differences, but this is unlikely in our study as we focused on postmeno-
pausal women, who are more similar to men regarding hormonal status, and adjusted for 
the use of hormone replacement therapy. 
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Our study has some limitations. First, we performed several association tests in our male 
and female population separately; replication of the results in other populations will have 
to confirm that our positive findings are not due to chance effects and a relatively small 
sample size. Secondly, it is difficult to draw conclusions about causality based on the re-
sults of our study. The fact that hepcidin and iron parameters were measured in a non-CVD 
population 3 to 5 years prior to the NIMA does however reduce the likeliness of a reverse 
mechanism, where atherosclerosis affects hepcidin levels. Also, NIMA measurements were 
not performed in 2002; we used presence of CVD or use of medication for CVD as a proxy for 
presence of atherosclerosis in order to obtain an at-risk population. In addition, our ana-
lyses rely on one measurement of serum hepcidin, which we used as a proxy for the hepcidin 
concentration in the years before and after this measurement. Hepcidin and TC were meas-
ured in serum collected during the day and not in fasting state, which makes the measure-
ment less precise due to the known circadian rhythm of hepcidin and the influence of food 
intake on hepcidin and cholesterol levels [32,52]. We adjusted our analyses for time of blood 
sampling to reduce the noise caused by this measurement error, but the precision of the 
reported associations might still be decreased. Moreover, we used serum concentrations of 
hepcidin, ferritin and iron, whereas the associations of interest might be cell type or tissue 
specific. Finally, the number of CVD events in our population was too small to analyze the 
associ ation of hepcidin, the hepcidin ratios and the iron parameters with the hard endpoint 
of CVD. Nevertheless, presence of plaque, IMT and ABI have shown to predict CVD, both in 
patients and in the general population [35,53,54].
In conclusion, this epidemiological study is the first to describe associations between 
 hepcidin and presence of plaque, ABI and IMT. Our results indicate that hepcidin and the 
hepcidin/ferritin ratio are associated with atherosclerosis, as measured by the presence of 
plaque and ABI, in postmenopausal women in a general population. Our results suggest 
that it is the body iron distribution as determined by serum hepcidin and its ratio to ferritin 
instead of the total body iron load that plays a role in the development of atherosclerosis. 
We warrant replication of our results in an independent population using hard cardiovas-
cular endpoints and the set-up of functional studies to disentangle causal relationships, in 
addition to  studies that use hard cardiovascular endpoints. Eventually, hepcidin could be a 
novel biomarker and therapeutic target for CVD.  
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ABSTRACT
Previous reports suggested a role for iron and hepcidin in atherosclerosis. Here, we 
evaluated the causality of these associations from a genetic perspective via (i) a Men-
delian randomization (MR) approach, (ii) study of association of atherosclerosis-re-
lated single nucleotide polymorphisms (SNPs) with iron and hepcidin, and (iii) esti-
mation of genomic correlations between hepcidin, iron and atherosclerosis. Analyses 
were performed in a general population sample. Iron parameters (serum iron, serum 
ferritin, total iron-binding capacity and transferrin saturation), serum hepcidin and 
genome-wide SNP data were available for N=1,819; non-invasive measurements of 
atherosclerosis (NIMA), i.e. presence of plaque, intima media thickness and ankle-bra-
chial index (ABI), for N=549. For the MR, we used 12 iron-related SNPs that were pre-
viously identified in a genome-wide association meta-analysis on iron status, and 
assessed associations with NIMA. Other than for rs651007, associated with decreased 
ferritin concentration and decreased atherosclerosis risk, we observed no SNP associ-
ations that fit the hypothesized directions of effect between iron and NIMA. Two of six 
NIMA-related SNPs showed association with the ratio hepcidin/ferritin, suggesting 
that an increased hepcidin/ferritin ratio increases atherosclerosis risk. Genomic cor-
relations were close to zero, except for hepcidin and ferritin with ABI at rest [-0.27 (SE 
0.34) and -0.22 (SE 0.35), respectively] and ABI after exercise [-0.29 (SE 0.34) and -0.30 
(0.35), respectively]. The negative sign indicates an increased atherosclerosis risk with 
increased hepcidin and ferritin concentrations. Our results suggest a potential causal 
role for hepcidin and ferritin in atherosclerosis, but not for the other iron parameters.  
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Introduction
In 1981, the ‘iron hypothesis’ was proposed, stating that iron depletion protects against 
heart disease [1]. According to this hypothesis, premenopausal women have a lower risk of 
heart disease compared to men and postmenopausal women due to loss of iron with men-
struation. The hypothesis was specified without a mechanism, but it is proposed that high 
levels of body iron stores promote cardiovascular disease (CVD) by catalyzing low-density 
lipoprotein (LDL) cholesterol oxidation and thereby atherosclerosis [2,3]. Since the proposal 
of the ‘iron hypothesis’, several epidemiological studies have investigated the associations 
between body iron stores and CVD or (sub)clinical measures of atherosclerosis, but they re-
main inconclusive [4-11]. The inconsistent results might be explained by the fact that it is not 
the total body iron load, but the body iron distribution as determined by serum hepcidin that 
drives the association with atherosclerosis and CVD risk. Hepcidin, key regulator of system-
ic iron homeostasis, has been hypothesized to increase CVD risk by slowing or preventing 
the mobilization of iron from macrophages [12], promoting transformation of these cells into 
foam cells and ultimately atherosclerosis [3,12]. In a recent epidemiological study we demon-
strated that serum hepcidin and the ratio of hepcidin to ferritin, i.e. hepcidin expression rela-
tive to body iron stores, are associated with atherosclerosis in the general population, espe-
cially in postmenopausal women [13]. We did not observe associations of the iron para meters, 
i.e. serum ferritin, serum iron, total-iron binding capacity (TIBC) and transferrin  saturation 
(TS), with atherosclerosis [13]. However, disentangling the specific causal roles of hepcidin and 
iron parameters in atherosclerosis and CVD in observational population  studies is fraught 
with difficulties due to potential for residual confounding, reverse causation, and the exis-
ting phenotypic correlations between iron parameters and hepcidin.
In this study, we aimed to investigate the causal roles of hepcidin, the ratios hepcidin/ 
ferritin and hepcidin/TS, and the iron parameters in atherosclerosis, as measured by non-in-
vasive measurements of atherosclerosis (NIMA), by focusing on their underlying genetics. 
More specifically, we 1) applied a Mendelian randomization (MR) approach, 2) evaluated 
associations of genetic determinants of NIMA with hepcidin and iron parameters, and 3) 
estimated the genomic correlations of hepcidin and the iron parameters with NIMA based 
on genome-wide chip data.
In the MR approach, genetic determinants of the risk factor(s) of interest, in this case iron 
status and hepcidin, are used to estimate the causal effect of the risk factor on a disease 
outcome, in this case NIMA [14]. As genetic variants are randomly distributed in the popu-
lation, this observational design mimics the randomization in a clinical trial and hence 
 allows for assessment of causality. The second step allowed us to evaluate whether pub-
lished NIMA-related genetic variants show cross-trait association with hepcidin and the 
iron parameters. This might indicate presence of pleiotropy, where a single genetic variant 
affects multiple traits independently. It can also indicate a causal relationship between two 
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correlated traits, where a single genetic variant indirectly affects a second trait (i.e. NIMA) 
due to a causal association with a first, intermediate trait (i.e. iron and/or hepcidin). Third, 
the estimation of genomic correlations allowed us to evaluate the extent to which the same 
genetic variants, captured via a genome-wide chip, impact on hepcidin or iron parameters 
and NIMA. Existence of a genomic correlation between two traits can indicate pleiotropy or 
causality, as for cross-trait associations. A positive genomic correlation indicates that the 
same genetic variants influence two traits in the same direction, while a negative genomic 
correlation indicates an opposite direction of effect. 
The boost in the identification of genetic variants for complex traits via genome-wide as-
sociation studies (GWAS) has facilitated the design of MR studies in recent years. For the 
iron parameters, several GWAS have been published [15-20]. Recently, a large meta-analysis of 
GWAS on biochemical markers for iron status was completed by the Genetics of Iron Status 
(GIS) Consortium. The study included 23,986 subjects from eleven population-based studies 
in the discovery phase and up to 24,986 subjects in the replication phase (Benyamin et al., 
in press). This meta-analysis led to the identification of 12 single nucleotide polymorphisms 
(SNPs) statistically significantly associated with at least one of the iron parameters at a 
 genome-wide level (Supplemental Table 7.1), which we used for the current study in the MR 
analysis. 
The complex genetic etiology of hepcidin is relatively unexplored. Traglia et al. published a 
GWAS on serum hepcidin in the genetic isolate Val Borbera, in which no statistically signifi-
cantly associated loci were found [21]. In addition, studies into the SNPs C282Y (rs1800562) 
in the hereditary hemochromatosis gene (HFE) and A736V (rs855791) in the transmembrane 
serine protease 6 gene (TMPRSS6), which have repeatedly been associated with the iron 
 parameters, only associated with the ratios hepcidin/ferritin and hepcidin/TS and not with 
serum hepcidin [22]. Thus, no genetic determinants of hepcidin are currently available. 
There have also been numerous GWAS into genetic determinants of NIMA. Sixteen GWAS 
were combined in a meta-analysis for common carotid intima media thickness (IMT) and 
the presence of carotid plaque (total N=42,484), which revealed three (nearest genes ZHX2, 
APOC1 and PINX1) and two (nearest genes PIK3CG and EDNRA) different SNPs that were 
 statistically significantly associated with IMT and plaque, respectively [23]. A meta-analysis of 
21 GWAS for ankle-brachial index (ABI) (total N=58,409) identified one genome-wide signifi-
cant association with nearest gene CDKN2B [24]. We used these six SNPs to study cross-trait 
associations with iron parameters and hepcidin (Supplemental Table 7.2). 
Here, we studied the roles of hepcidin, the ratios hepcidin/ferritin and hepcidin/TS, and the 
iron parameters in NIMA by an MR approach, cross-trait associations, and genomic correl-
ations. We used a subsample of 1819 participants aged 42–76 years from the Nijmegen 
 Biomedical Study (NBS), a well-phenotyped sample of the general population. 
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Methods
Study population
Details of the NBS have been described before [25]. Briefly, the NBS is a population-based sur-
vey conducted by the Radboud university medical center, Nijmegen, The Netherlands. In 
2002, 22,451 age and sex-stratified randomly selected adult inhabitants of Nijmegen, a city 
located in the eastern part of the Netherlands, received an invitation to fill out a postal ques-
tionnaire (QN) including questions about lifestyle, health status, and medical history, and 
to donate a blood sample for DNA isolation and biochemical studies (NBS-1). A total of 9350 
(42%) persons filled out the QN, of which 6468 (69%) donated blood samples. In 2005 the 
second phase of NBS was started (NBS-2), for which all participants of the first phase were 
re-invited to fill out a second questionnaire. Those who participated in NBS-2 and were aged 
50-70 years at that time were asked to also participate in the NIMA (non-invasive measure-
ments of atherosclerosis) substudy performed by the Department of Internal Medicine. For 
the NBS-2-NIMA study, participants had to fill out an additional QN, donate a fasting blood 
sample, and undergo anthropometric measurements and non-invasive meas urements of 
atherosclerosis. A total of 1491 subjects participated in NBS-2-NIMA (response 71%).  Approval 
to conduct the NBS and NBS-2-NIMA study was obtained from the Radboud university medi-
cal center Institutional Review Board. All participants gave written informed consent. 
Genotype data (Illumina HumanHapCNV370-Duo BeadChip) were available for those 1980 
NBS participants that were selected to serve as controls in GWAS [26]. A total of 1819 sam-
ples passed quality control [sample yield ≥96% (after exclusion of intensity-only markers 
(n=23,573)), Caucasian ancestry ≥90% (based on Structure analysis), SNP yield ≥96%]. Meas-
urements of hepcidin and the iron parameters (iron, ferritin, TS and TIBC) were available for 
all these samples; NIMA for a subset of 549 participants. 
Laboratory methods and clinical measurements
Total serum iron, TIBC, TS and ferritin were measured as described before [27]. Serum hepci-
din was measured with an in-house developed and validated competitive enzyme-linked 
immunosorbent assay [27,28]. We used the following NIMA measurements for this study: IMT, 
presence of plaque and the ankle-brachial index at rest (ABIR) and after exercise (ABIEX). The 
NIMA and total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipo-
protein cholesterol (HDL), and triglycerides (TGC) were measured as described before [13,29].
Selection and measurement of genetic variants
Genome-wide SNP data were used to estimate genomic correlations and were available 
for 1819 NBS participants, as indicated above. SNP quality control [minor allele frequency 
(MAF) ≥1%, and Hardy-Weinberg equilibrium (HWE) p-value >10-6] resulted in availability 
of 323,414 SNPs. Density was increased by imputation, which was performed with 1000- 
genomes phase1 integrated version 3 as a reference sample using IMPUTE v2 software [30]. 
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We used in total 18 SNPs for the MR approach and cross-trait associations: 12 iron- related 
SNPs (Benyamin et al., in press) (Supplemental Table 7.1) and six NIMA-related SNPs [23,24] 
(Supplemental Table 7.2). Five of these SNPs were directly measured (rs1800562, rs855791, 
rs744653, rs9990333, and rs6486121) and 13 SNPs were imputed, all of them with a quality of 
imputation of >0.99 as measured using the SNPtest info measure. 
Statistical analysis
SNP associations
For the MR approach and cross-trait associations, genotype probabilities (P) of the 12 
iron-related and 6-NIMA related SNPs were transformed to dosages, i.e. dosage = PAA*0 + 
PAB*1 +PBB*2; allele B was the effect allele as presented in Supplemental Tables 7.1 and 7.2. 
Hepcidin, the hepcidin ratios and ferritin were log-transformed to normalize their distribu-
tions. For these log-transformed variables and for the other iron parameters, standardized 
residuals adjusted for age, squared age and time of blood sampling were derived. This was 
done separately for men and women to adjust for gender. Outliers that differed more than 
four times the SD from the mean were excluded. SNP associations of the iron-related SNPs 
with NIMA and the NIMA-related SNPs with iron parameters, hepcidin and hepcidin ratios 
were studied using logistic (presence of plaque) and linear (IMT, ABI, hepcidin, hepcidin 
 ratios, iron parameters) regression models. Resulting odds ratios (OR) of logistic regression 
models express the effect of an additional effect allele on risk of presence of plaque, i.e. AB vs 
AA and BB vs AB. Resulting betas of linear models express the effect of an additional effect 
allele on measures of IMT, ABI, and on standardized residuals of iron, TS, TIBC, log-hepcidin, 
log-hepcidin/ferritin, log-hepcidin/TS, and log-ferritin. We also studied the associations be-
tween iron-related SNPs and NIMA with adjustment for the potential confounding factors 
TC, LDL, HDL and TGC, and stratified by gender.   
Estimation of genomic correlations and genome-wide SNP explained variances
We estimated genomic correlations (rG) based on only directly measured autosomal SNPs  using 
the software packages GCTA [31] and Bayz [32]. The use of GCTA to estimate rG using genome- or 
chromosome-wide SNPs for complex traits has been described [33] and applied in  other studies 
before (e.g. [34]). However, recent results of Visscher et al. showed that the statistical power to de-
tect statistically significant rG was limited with a sample size of N=1000 [35]. As our sample size 
for estimation of rG was smaller than 1000, we also estimated rG with a Bayesian multivariate 
model as implemented in the software package Bayz; this Bayesian analysis handles large sets 
of traits in a simultaneous analysis, and therefore we expected Bayz to produce more precise 
estimates compared to GCTA, which is limited to two-trait analysis. 
In GCTA, rG are calculated for pairs of traits using the genetic relationship matrix (GRM) 
and a bivariate restricted maximum likelihood analysis (GREML) [33]. For the estimation of 
the GRM for pairs of individuals we only retained individuals with a pairwise relationship 
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<0.025 to remove cryptic relatedness from the data, as recommended by Yang et al. [36]. This 
resulted in 423 to 431 individuals for the NIMA and 1456 to 1481 individuals for hepcidin and 
the iron parameters. 
In software package Bayz, Bayesian multivariate models including up to 8 traits simultan-
eously were used to estimate rG [32,37]. The genomic model from Janss et al. [32] is based on use 
of an eigenvector decomposition of the GRM in a random regression model; the GRM used is 
the same one as used in GCTA GREML analyses. The multi-trait implementation makes use 
of latent variables to model the covariance [37]. To determine the required number of latent 
variables, the Bayesian Deviance Information Criterion (DIC) [38] was computed. The Bayes-
ian model uses uniform priors for variances to express a-priori ignorance about the model 
parameters. From the Bayesian model, the marginal posterior means for rG are reported. 
The marginal posterior standard deviation expresses uncertainty on the estimate, and, with 
uninformative prior distributions, should be similar to the frequentist SE. For our study, four 
different multivariate models were constructed to prevent simultaneous inclusion of  highly 
dependent and correlated variables. Thus, hepcidin and ferritin were not included in the 
same model as the ratio hepcidin/ferritin, as also holds for serum iron and TIBC with TS, i.e. 
the ratio of serum iron over TIBC. Model 1 included hepcidin, ferritin, iron, TIBC, presence of 
plaque, IMT, ABIR and ABIEX and was used to determine rG for all included variables. Model 
2 included the ratio hepcidin/ferritin, iron, TIBC, presence of plaque, IMT, ABIR and ABIEX, 
model 3 included the ratio hepcidin/TS, ferritin, presence of plaque, IMT, ABIR and ABIEX, and 
model 4 included hepcidin, ferritin, TS, presence of plaque, IMT, ABIR and ABIEX; these latter 
three models were used to estimate rG for the ratio hepcidin/ferritin, the ratio hepcidin/TS, 
and TS, respectively. 
Prior to GCTA and Bayz analyses, the following steps were taken: 1) pairwise LD pruning to 
remove highly correlated SNPs (window size 100, step 5 and r2 0.98) using the software pack-
age PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) [39], resulting in 297,574 SNPs 
for analysis; 2) log-transformation of the variables hepcidin, ferritin and the ratios hepcidin/
ferritin and hepcidin/TS to normalize their distributions; 3) transformation of hepcidin, the 
iron parameters and NIMA to sex-specific residuals using age, squared age and for hepcidin 
and the iron parameters also time of blood sampling as determinants in regression models; 
4) reduction of outliers to mean ± 4SD (maximal number of outliers per trait was six); and 
5) standardization of the traits to zero mean and unit variance. 
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Results
Characteristics of the subjects included in our study are presented in Table 7.1. The percent-
age of males of the total study population was 49% and median age at inclusion was 63 
years. NIMA were available for a subset of 549 participants (49% male) with a median age 
of 59 years.
MR results: associations of iron-related SNPs with IMT, presence of plaque and ABI
Figure 7.1 visualizes the effects of the SNPs on the iron parameters based on the iron meta- 
GWAS of the GIS Consortium. The SNPs are classified into their hypothesized effects on the 
risk of atherosclerosis according to the ‘iron hypothesis’: SNPs that increase serum iron, TS 
and/or ferritin are hypothesized to increase the risk of atherosclerosis, and vice versa. The 
hypothesized effect of rs8177240 is classified as unknown, because the T allele of this SNP 
decreases iron and transferrin and increases TS. The hypothesized effects of rs4921915, 
rs6486121 and rs174577 are also classified as unknown, because these SNPs are only associ-
ated with transferrin. 
Results of the single SNP association analyses are presented in Table 7.2. Only the T allele 
of rs651007, associated with decreased ferritin, showed effects that were consistent with 
TABLE 7.1  Characteristics of the study population.
Variable† Total N Median (P5-P95) or N (%)*
Gender, males 1819 900 (49%)
Age at inclusion, years 1819 62.9 (42.2 - 76.0)
Time of blood sampling 1811
     Before 12:00 pm 374 (21%)
     Between 12:00 pm and 5:00 pm 1165 (64%)
     After 5:00 pm 272 (15%)
Serum hepcidin, nmoles/L 1810 7.5 (0.9 - 22.5)
Serum ferritin, µg/L 1817 120.7 (17.8 - 421.4)
Hepcidin/ferritin, µmoles/µg 1808 60.3 (20.9 - 170.3)
Hepcidin/TS, µmoles/L/% 1791 0.25 (0.04 - 0.96)
Serum iron, µmoles/L 1800 17.0 (9.0 - 27.0)
TIBC, µmoles/L 1800 58.0 (46.0 - 75.0)
TS, % 1800 28.8 (14.1 - 48.1)
IMT, mm 549 0.85 (0.70 - 1.05)
ABI at rest 549 1.10 (0.96 - 1.27)
ABI after exercise 542 1.11 (0.76 - 1.34)
Presence of plaque 549 232 (42%)
ABI indicates ankle-brachial index; IMT, intima media thickness; N, number; P5, fifth percentile; P95, 95th percent-
ile; TIBC, total iron-binding capacity; and TS, transferrin saturation.
* Continuous variables are presented as median (P5-P95). Categorical variables are presented as N (%).
†  Hepcidin, ferritin, hepcidin/ferritin, hepcidin/TS, iron, TIBC, TS and time of blood sampling were measured in 
2002 and presence of plaque, IMT, and ABI at rest and after exercise were measured between 2005 and 2008.
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the hypothesized directions of effects for all NIMA, with nominal significant effects on IMT 
[beta -0.021 (95% CI -0.038; -0.004)] and ABI after exercise [beta 0.034 (95% CI 0.004; 0.063)]. 
SNP rs9990333 showed a nominally significant association with presence of plaque that 
was directionally consistent [OR 1.32 (95% CI 1.03; 1.68)], but this SNP showed inconsistent, 
nonsignificant effects on other NIMA. Two other nominally significant effects were found for 
rs8177240 and rs4921915, but their hypothesized directions of effect were unknown. Adjust-
ment of the associations for TC, LDL, HDL and TGC revealed similar results (Supplemental 
Table 7.3). 
Stratification by gender revealed that effects of rs651007 were consistent with the hypothe-
sized directions of effects for all NIMA in men and for all NIMA except for ABI at rest in 
 women (Supplemental Table 7.4). The effect of rs651007 on IMT was stronger in women, 
whereas the effect of rs651007 on presence of plaque and ABI after exercise was stronger 
in men. In addition to rs651007, rs855791 showed consistent associations with all NIMA in 
men, whereas rs1799945 and rs7385804 showed consistent associations with all NIMA in 
 women. Effect estimates were not systematically higher or lower in men or women. Associ-
ations of the gender-specific results remained similar after adjustment for TC, LDL, HDL, and 
TGC (Supplemental Table 7.5).   
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Association of NIMA-related SNPs with the iron parameters and hepcidin
Associations of top SNPs for IMT, plaque and ABI with hepcidin, the ratios hepcidin/ferritin 
and hepcidin/TS, and the iron parameters are shown in Supplemental Table 7.6. Three nom-
inally significant associations were observed. The IMT-associated SNP rs11781551 showed 
association with TIBC, but the observed direction of effect was opposite to the hypothesized 
direction. This SNP also showed association with the ratio hepcidin/ferritin, in addition to 
the ABI-associated SNP rs10757269, and observed directions of effect were consistent with 
hypothesized directions for both SNPs.  
Genomic correlations
Table 7.3 shows the genomic correlations of hepcidin, the ratios hepcidin/ferritin and hepci-
din/TS, and the iron parameters with NIMA as obtained by GCTA (Table 7.3A) and Bayz (Table 
7.3B). Point estimates of genomic correlations resulting from the two methods were mostly 
dissimilar. A substantial part of the estimates by GCTA resulted in values of 0, -1 or 1, indicat-
ing convergence of the models to extremes, as expected due to our relatively small sample 
size. 
Bayz estimates of genomic correlations with NIMA were close to 0, except for the genomic 
correlation of hepcidin and ferritin with ABI at rest [-0.27 (SE 0.34) and -0.22 (SE 0.35), respec-
tively] and ABI after exercise [-0.29 (SE 0.34) and -0.30 (0.35), respectively]. 
Evidence for and against a role of hepcidin and the iron parameters in atherosclerosis based 
on the results of the current study is summarized in Table 7.4. 
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TABLE 7.3 A  Genomic correlations (SE) estimated with GCTA.
Presence of plaque IMT ABI at rest ABI after exercise
Hepcidin 0.18 (1.48) 0.11 (1.49) 0.01 (1.29) 0.02 (1.40)
Ferritin 0.15 (1.49) -1.00 (4.74) 1.00 (38.1) 0.01 (1.45)
Hepcidin/ferritin -1.00 (4.35) 0.09 (4.35) -1.00 (>4E5) 0.25 (2.39)
Hepcidin/TS -1.00 (15.38) -1.00 (4.87) 0.02 (1.37) 0.01 (1.24)
Iron 0.05 (1.53) 1.00 (4.18) 0.08 (1.05) -1.00 (38.1)
TIBC 1.00 (17.3) 0.04 (1.16) 1.00 (55.5) -1.00 (113.7)
TS 0.06 (1.36) 1.00 (147.7) 0.06 (0.96) 1.00 (>1E5)
ABI indicates ankle-brachial index; IMT, intima media thickness; SE, standard error; TIBC, total iron-binding 
capacity; and TS, transferrin saturation.
TABLE 7.3 B  Genomic correlations (SE) estimated with Bayz. 
Presence of plaque IMT ABI at rest ABI after exercise
Hepcidin* 0.01 (0.27) -0.01 (0.31) -0.27 (0.34) -0.29 (0.34)
Ferritin* -0.03 (0.28) 0.01 (0.32) -0.22 (0.35) -0.30 (0.35)
Hepcidin/ferritin# 0.06 (0.21) -0.02 (0.24) -0.10 (0.27) -0.01 (0.28)
Hepcidin/TS$ 0.12 (0.19) 0.10 (0.21) -0.07 (0.27) 0.03 (0.29)
Iron* -0.04 (0.20) 0.06 (0.21) 0.04 (0.25) 0.09 (0.26)
TIBC* -0.01 (0.14) 0.04 (0.15) -0.08 (0.16) -0.07 (0.17)
TS† -0.01 (0.19) 0.00 (0.19) 0.05 (0.21) 0.04 (0.22)
ABI indicates ankle-brachial index; IMT, intima media thickness; SE, standard error; TIBC, total iron-binding 
capacity; and TS, transferrin saturation.
*  Correlations in these rows come from an 8-trait analysis including hepcidin, ferritin, iron, TIBC, presence 
of plaque, IMT, ABI at rest and ABI after exercise. 
#  Correlations in this row come from a 7-trait analysis including the ratio hepcidin/ferritin, iron, TIBC, 
presence of plaque, IMT, ABI at rest and ABI after exercise.
$  Correlations in this row come from a 6-trait analysis including the ratio hepcidin/TS, ferritin, presence of 
plaque, IMT, ABI at rest and ABI after exercise.
†  Correlations in this row come from a 7-trait analysis including hepcidin, ferritin, TS, presence of plaque, 
IMT, ABI at rest and ABI after exercise.
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Discussion
In this study, we investigated relationships of iron parameters and hepcidin with NIMA in a 
sample of the general population by performing an MR approach, assessing associations of 
NIMA-related SNPs with iron parameters and hepcidin, and studying genomic correlations 
of iron parameters, hepcidin, and hepcidin ratios with NIMA. Overall, the results suggest a 
potential role for ferritin and hepcidin in atherosclerosis, but do not provide evidence for 
causal effects of the other iron parameters on NIMA (Table 7.4). 
The lack of evidence for a causal effect of iron, TIBC and TS on NIMA is in contradiction with 
the ‘iron hypothesis’, but confirms results from our previous observational study in which 
we did not find evidence for an association between iron status and NIMA as well [13]. Results 
of that study indicated that the iron distribution, as determined by serum hepcidin and the 
ratio hepcidin/ferritin, plays a role in the development of atherosclerosis. 
The three different approaches that we used provided weak evidence for a potential  causal 
role for hepcidin, ferritin and the ratio hepcidin/ferritin in atherosclerosis, but resulted 
in a lack of evidence for a causal role of iron, TIBC and TS in NIMA. First, iron-related top 
SNPs were not associated with the NIMA. For all but one of the 12 SNPs, directions of effect 
were inconsistent over the four NIMA and/or inconsistent with the hypothesized direction 
of effect according to the ‘iron hypothesis’. The exception was rs651007, which is uniquely 
associated with a decrease in ferritin concentration and which showed a decreased risk of 
atherosclerosis. However, rs411988, which is also uniquely associated with ferritin with a 
similar effect estimate as for rs651007, showed far weaker or even no associations with the 
NIMA. One would expect similar results for these two SNPs [40], thus the MR approach pro-
vides contradicting evidence for a causal role of ferritin in atherosclerosis. The causal effects 
of hepcidin on atherosclerosis could not be studied by an MR approach, as there have been 
no SNPs identified yet that have been validated for association with hepcidin.
Secondly, the reverse approach of studying associations of NIMA-associated top SNPs with 
the iron parameters, as was previously done for coronary artery disease and IMT [41], pro-
vided additional evidence against a role of iron, TIBC and TS in atherosclerosis. It did also 
not provide evidence for a causal role of ferritin in atherosclerosis. We did not observe any 
significant and consistent associations, thus indicating no intermediate or pleiotropic ef-
fects of these SNPs on all four iron parameters. Furthermore, the nearest genes for NIMA-as-
sociated top SNPs are currently not known to be involved in iron metabolism. In contrast, 
two NIMA-related SNPs showed nominally significant associations with the ratio hepcidin/
ferritin, with consistency in observed and hypothesized directions of effect, indicating that 
the ratio hepcidin/ferritin and thus the body iron distribution might be involved in athero-
sclerosis. Notably, two previous studies reported the SNPs rs12091564 and rs10218795 in the 
hemochromatosis type 2 gene (HFE2) to be associated with coronary artery disease (CAD) 
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based on a two-marker association test and haplotype analysis [42,43]. Defects in HFE2 lead to 
a form of juvenile hemochromatosis, which is characterized by a severe iron overload (high 
serum ferritin, high TS, low hepcidin/ferritin ratio) occurring typically before the age of 30, 
and thus this finding might indicate a link between iron or iron distribution and atheroscle-
rosis. However, the HFE2 gene is also expressed in heart and skeletal muscle, thus the SNPs 
in HFE2 do not necessarily associate with CAD via iron. 
Third, genomic correlations of the iron parameters with the NIMA were close to zero, thus 
indicating that there is no overlap in genetic etiology of the traits. Exception was the modest 
negative genomic correlation of ferritin with ABI at rest and ABI after exercise, indicating 
that genetic variants that increase ferritin cause a decrease in ABI. However, these genomic 
correlations were far from statistically significant and ferritin did not show genomic correla-
tions with other NIMA. In addition, we observed a negative genomic correlation of hepcidin 
with ABI at rest and after exercise. This confirms our previous observational study, in which 
we found the ratio hepcidin/ferritin to be negatively associated with ABI at rest and after ex-
ercise in postmenopausal women [13]. On the contrary, we found a significant association of 
hepcidin and hepcidin/ferritin with presence of plaque in our previous observational study, 
but genomic correlations between these variables in the current study were very weak. 
There are some aspects that hampered our study. First of all, the size of the study population 
was limited, resulting in imprecise estimates of genomic correlations, suboptimal power of 
our MR analysis and low power to identify SNP associations with statistical significance. 
Consequently, we focused on directions of observed effect estimates and their consist ency 
with the hypothesized direction of effect. In addition, the limited sample size decreased the 
power of our gender-stratified MR analyses, which we performed based on our previous 
gender-specific findings [13]. Secondly, our estimation of genomic correlations provided us 
with indirect evidence of a potential causal relation between these traits; strong genomic 
correlations can be the result of pleiotropy and are not evidence for causality per se. Also, 
weak genomic correlations do not exclude causal relationships, as causality can also be the 
result of (shared) environmental factors only. In addition, the genomic correlations that we 
reported were based on measured autosomal and common SNPs only. Finally, causal infer-
ence was limited by the fact that most of the 12 SNPs that we included in our MR approach 
influence more than one of the iron parameters. Furthermore, the SNPs rs1800562 in HFE 
and rs855791 in TMPRSS6 also showed association with the ratios hepcidin/ferritin and hep-
cidin/TS [21,22], and with red blood cell traits (e.g. [44,45]). In addition, four of the loci that were 
found in the iron status meta-GWAS have been reported as lipid loci by the Global Lipids Ge-
netics Consortium [46], i.e. HFE, NAT2, ABO and FADS2. However, performing the MR analyses 
using TC, LDL, HDL and TGC as covariates did not change our conclusions. Still, the overlap 
in iron and lipid loci is substantial and is therefore unlikely to be based on chance only. It 
might indicate causal relationships between iron status and lipid levels and therefore also 
atherosclerosis, although the results of our study do not support this. 
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In conclusion, this study is the first to evaluate the ‘iron hypothesis’ from a genetic point of 
view. Our results do not provide evidence for a role of iron, TIBC and TS in the development 
of atherosclerosis, which confirms the findings from our previous observational study [13]. 
Our results are suggestive for a potential causal role of hepcidin and ferritin in atheroscle-
rosis. Thus, our study is in line with the hypothesis that it is the body iron distribution as 
determined by hepcidin and its ratio to ferritin instead of the absolute amount of body iron 
that is involved in the development of atherosclerosis. We warrant future studies to exploit 
any new genetic variants that are found to be associated with serum hepcidin in an MR ap-
proach. In addition, we emphasize follow-up of the current study in a larger series including 
multiple study populations. 
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CHAPTER 8
General discussion
This research project started almost a decade after the discovery of hepcidin [1,2], when 
knowledge on hepcidin function and regulation was mainly based on in vitro and animal 
experiments. There were only a few studies on hepcidin in humans; these were based on 
relatively small groups of healthy subjects or patients, the latter mostly in the context of 
iron disorders [3]. In this thesis, we presented population-based studies on serum hepcidin 
concentrations. We 1) aimed to identify biochemical correlates and genetic determinants 
of serum hepcidin, and 2) studied the effects of hepcidin on atherosclerosis as determined 
by non-invasive measurements of atherosclerosis (NIMA). In this chapter, we describe the 
inferences from our studies together with directions for future research.
Serum hepcidin concentrations should be evaluated in the context of serum ferritin
Based on our study of associations of serum hepcidin with a selection of (biochemical) 
 parameters (chapter 2), serum ferritin appeared to be the strongest correlate of serum hep-
cidin concentration. This association was robust to adjustment for other iron parameters 
and biochemical variables that we tested, e.g. C-reactive protein (CRP), body-mass index 
(BMI), and age. The other iron parameters showed far less strong associations with serum 
hepcidin. 
The strong association that we found between hepcidin and ferritin was reported before; 
correlation estimates based on studies in smaller populations and without adjustment for 
other biochemical variables varied between 0.63 and 0.76 [4-6]. The correlation was later also 
confirmed in the Italian Val Borbera population, although less strong with estimates of 0.32 
and 0.53 for men and women, respectively [7]. The question remains whether the relation be-
tween serum hepcidin and ferritin is causal, and if so, whether it reflects a response of hep-
cidin to body iron stores [8,9] or vice versa, the response of ferritin to ferroportin degradation 
by hepcidin [10]. 
Several observations indicate that it is the balance between these processes, reflected by the 
hepcidin/ferritin ratio, that may be of utmost importance in view of human health and dis-
ease. For example, in patients with hereditary hemochromatosis (HH) due to homozygosity 
for C282Y, hepcidin concentrations are only slightly lower than in controls [11-13], but the ratio 
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hepcidin/ferritin is clearly decreased compared to controls [12,13]. Also, the ratio hepcidin/fer-
ritin was demonstrated to be a potential biomarker for cirrhosis [14]; it was significantly lower 
in chronic liver disease patients compared with healthy controls, whereas serum hepcidin 
was not. Furthermore, the ratio hepcidin/ferritin declined progressively with increasing fi-
brosis in chronic liver disease patients, and was shown to be a significant and independent 
predictor of cirrhosis [14]. In addition, the ratio hepcidin/ferritin was suggested to be helpful 
in distinguishing dysmetabolic hyperferritinemia/dysmetabolic iron overload syndrome 
from other iron overload disorders, in which hepcidin is inappropriately low [15]. Finally, evi-
dence for the importance of evaluation of serum hepcidin concentrations relative to other 
(iron) parameters is also provided by an increased value for the ratio of hepcidin to TS in the 
diagnosis of iron-refractory iron deficiency anemia (IRIDA) due to defects in the TMPRSS6 
gene in the absence of inflammation [16].  
The importance of the ratio hepcidin/ferritin is also supported by our findings in chapters 6 
and 7. The ratio hepcidin/ferritin showed statistically significant associations with presence 
of plaque in women, the ankle-brachial index (ABI) at rest in men and women, and ABI after 
exercise in women, whereas hepcidin was only statistically significantly associated with pres-
ence of plaque in women (chapter 6). Finally, the ratio hepcidin/ferritin was the only variable 
that showed nominally significant associations with NIMA-related SNPs (chapter 7).
In view of the increased insights into the potential importance of the ratio hepcidin/ferri-
tin, we provided reference ranges for the ratio hepcidin/ferritin in men and pre- and post-
menopausal women on the website www.hepcidinanalysis.com, in addition to the refer-
ence ranges for serum hepcidin that we provided in chapter 2. It is important to note that 
these reference ranges are assay-specific. A recent effort to harmonize the different hep-
cidin assays resulted in the construction of hepcidin consensus (HEPCON1) values, which 
allow cross-method comparison of absolute hepcidin values [17]. Furthermore, we included 
the ratio hepcidin/ferritin in subsequent association studies (chapter 3 and 4) and would 
advise future studies on iron parameters and serum hepcidin concentration to do the same. 
If the ratio hepcidin/ferritin proves to be of importance in future studies on human health 
and disease, we recommend to investigate which factors influence the ratio, like we did for 
serum hepcidin in chapter 2. 
Neither a candidate gene approach nor a meta-analysis of GWAS based on all cohorts 
available worldwide resulted in identification of common genetic variants associated 
with serum hepcidin yet: the search should continue
We used two approaches to search for common variants associated with serum hepcidin. 
In a candidate-gene study, we focused on the most important genetic variants of two very 
strong candidate genes, i.e. rs1800562 in HFE and rs855791 in TMPRSS6. SNP rs855791 was 
previously found to be strongly associated with serum iron, transferrin, and transferrin sat-
uration (TS); rs1800562 with these three parameters and serum ferritin [18-22]. It was common-
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ly thought that these associations could be explained by an intermediate effect on serum 
hepcidin based on knowledge from knockout mice models and mutations in patients [13, 23-25]. 
However, both Traglia et al. [7] and our group unexpectedly did not observe associations of 
these variants with serum hepcidin, but only with the ratio hepcidin/ferritin and to a less-
er extent with the ratio hepcidin/TS. Adjustment for hepcidin or the ratio hepcidin/ferritin 
did not decrease the strength of the SNP–iron parameter associations. This indicates that 
rs1800562 and rs855791 influence iron uptake and/or export via an unknown mechanism, 
which could potentially involve a different, and currently unidentified, intermediate fac-
tor than hepcidin. The fact that ferroportin is found in vertebrates and hepcidin is not [26,27], 
provides support for a hepcidin-independent mechanism. Notably, the new insights that 
our study and that of Traglia provided, in addition to the knowledge based on laboratory 
experiments and patient series, underscores the added value of findings in (replicated) 
population-based studies. It also emphasizes the importance of candidate-gene studies to 
learn more about mechanisms behind SNP associations. Hence, we recommend to zoom in 
on associations of iron-related genes with hepcidin and the ratio hepcidin/ferritin in future 
candidate-gene approaches.
In addition to the candidate-gene study, we performed a meta-analysis of genome-wide 
 association studies (meta-GWAS) to search for genetic determinants of serum hepcidin 
and its ratios in a hypothesis-free manner. Our meta-GWAS included all currently available 
 cohorts worldwide that have both hepcidin measurements, iron parameters and genotype 
data for their samples. This resulted in a sample of over 6,000 individuals. It provided us with 
80% power to discover variants that explain 0.62% and 0.78% of hepcidin variation, assum-
ing respectively perfect LD between the SNP marker and the causal variant (best case scen-
ario) and an imperfect LD of r2=0.8 [28]. Still, our meta-GWAS yielded only one potential locus 
that affects serum hepcidin concentrations. This suggests that the heritability of hepcidin 
cannot be explained by common genetic variants with a moderate to large effect, but rather 
by common variants with small effects and/or rare variants with large or small effects. Also, 
we did not find novel genome-wide statistically significant loci for the ratio hepcidin/ferri-
tin. Replication of the most significant novel top findings for the ratio hepcidin/ferritin, as 
we initiated for serum hepcidin, should be considered for future studies. 
As discovery of common genetic variants for serum hepcidin and its ratio to ferritin is rele-
vant for elucidation of biology and identification of biomarkers and therapeutic targets, 
performance of more powerful GWAS is valuable. There are several possible approaches to 
increase the power to identify these variants via GWAS. The first option is to get more out of 
the currently available data by application of a multivariate (MV-) GWAS on serum hepcidin 
and (a selection of) the iron parameters. We invested in a methodological study comparing 
a selection of MV-GWAS methods (chapter 5), which showed that MV-GWAS can provide 
additional power compared to univariate analyses, even when the genetic correlations 
 between traits are weak. The iron parameters are measured in all three cohorts that are in-
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cluded in the current meta-GWAS on serum hepcidin. It is thus relatively easy and cheap to 
perform a MV-GWAS in the three cohorts and combine results in a meta-analysis, as we did 
for the univariate GWAS. Interpretation of these multivariate association results, though, is 
not straightforward: a multivariate association can be driven by one of the traits, a subset of 
the traits, or even by all traits. New signals from a MV analysis should therefore be studied 
for association with the individual traits, and interesting signals should be replicated in in-
dependent samples using both multivariate and univariate analysis. 
The second option would be to increase the sample size of the current meta-analysis. The 
development of an affordable and precise high-throughput method for serum hepcidin 
measurement, as offered by our recently developed ELISA mimetic assay [29], will facilitate 
the addition of a substantial number of extra samples. 
Also, power could be gained by reducing non-genetic sources of variation of serum hepcidin 
concentration. Pre-analytical variation could be decreased by reducing the time between 
blood sampling and freezing of the sample, and by minimizing the number of freeze-thaw 
steps and pipetting steps. Day-to-day differences within individuals are large and were 
shown to range from 3.9% to 15.9% [30]. To reduce this biological variation, it could be con-
sidered to perform multiple hepcidin measurements a few days in a row for every partici-
pant. As hepcidin has a circadian rhythm (chapter 2 and [31,32]), these measurements should 
be performed approximately at the same time every day. Finally, variation in  hepcidin 
concentration could be reduced by adjustment for non-genetic determinants of serum 
 hepcidin or performance of analyses in homogeneous subsets. We included age, gender and 
time of blood sampling in our analyses (chapters 3, 4, 6 and 7), and excluded participants 
from analyses as to reduce the influence of inflammation (C-reactive protein ≥10 mg/L) and 
iron deficiency (ferritin <30ng/mL) (chapter 3 and 4), but other factors, e.g. alcohol con-
sumption [33], and pregnancy [34], could be included as well. The potential gain in power by 
ana lyzing a subset, despite the decrease in sample size, was demonstrated by the smaller 
p- values found for rs354202 in the subset-analysis of our meta-GWAS (chapter 4). 
Low frequency (1-5% frequency) and rare (<1% frequency) genetic variants are not (or poor-
ly) captured by the genome-wide SNP arrays due to their low correlation with common 
SNP markers present on these chips. Application of newer techniques such as exome or 
whole-genome sequencing will enable actual measurement of uncommon single nucleo-
tide and structural variants and assessment of their association with serum hepcidin and 
iron parameters. These rare variants are expected to have relatively large effects, and might 
therefore be present in individuals in the tails of the hepcidin distribution, i.e. among indi-
viduals with the highest and lowest hepcidin concentrations. Identification of these rare 
variants might therefore not only be useful to increase insight into hepcidin regulatory 
mechanisms, but may also be useful for future selection of individuals that could profit from 
(preventive) hepcidin-targeting therapies. Sequencing data could also help to pinpoint the 
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causal variant of a region identified by GWAS, whether common or rare. However, applica-
tion of sequencing techniques in large cohorts is currently still very expensive, and there are 
big challenges associated with data storage, quality control, and analysis [35]. To efficiently 
identify associations with rare variants on short term, it will be more feasible to apply 
 so-called exome-chips, which allow the measurement of over 200k low-frequency and rare 
gen etic variants in the human exome. Downside of this chip is that the non-coding part of 
the DNA is ignored, and that it may not include population-specific variants, as selection 
of the variants on the chip was based on their occurrence in a set of ~12,000 sequenced 
 genomes from both the general population and case series.  
Our studies indicate that the body iron distribution as determined by serum hepcidin 
and the ratio hepcidin/ferritin may affect the development of atherosclerosis, but 
 further studies are needed before hepcidin or its ratio to ferritin could be considered 
as therapeutic target for cardiovascular disease
Our studies into the roles of hepcidin and iron parameters in atherosclerosis (chapter 6 and 
7) are to our knowledge the first that are based on data in an unselected general population, 
and are complementary to the work that has been done using patient series and in vitro and 
animal models. Results of our studies suggest that it is not the absolute amount of body iron 
that increases the risk of atherosclerosis, which is in contrast to the original ‘iron hypoth-
esis’ proposed by Sullivan in 1981 [36], but rather the body iron distribution as determined by 
serum hepcidin and its ratio to ferritin. This confirms a publication by Sullivan in 2007, in 
which he stated an additional mechanism by which iron depletion could protect against 
atherosclerotic lesion progression involving hepcidin [37]. It provides also an explanation for 
the fact that HH patients with iron overload do not show an increased incidence of athero-
sclerosis, as their hepcidin levels are relatively low, resulting in decreased retention of iron 
by macrophages [38].
Our results are in agreement with findings on the role of hepcidin in patient populations [15, 
39-47] and results from in vitro and mice studies [48-50], but are discrepant with two studies [51,52] 
(summarized in Table 8.1). Notably, the reliability of some of the hepcidin assays used in 
these studies is doubtful (indicated in Table 8.1), as full validation reports are not available. 
The role of the ratio hepcidin/ferritin in atherosclerosis was not investigated before.
The first discrepant study is a case-control study (N=75) from 2006 in which serum hepci-
din levels were measured by a commercially available prohepcidin ELISA kit and compared 
between healthy controls and patients who had previously experienced an atherosclerotic 
event [52]. Prohepcidin levels among both groups were similar, but potential confounding 
factors were not taken into account. More importantly, prohepcidin levels do not correlate 
with serum hepcidin, neither do they respond to relevant physiological stimuli, nor is pro-
hepcidin able to degrade ferroportin [53-56]. Thus, this study does in fact not contribute any 
evidence against a role of serum hepcidin in atherosclerosis. 
164 C H A P T E R  8
The second discrepant study is a recently published mouse study by Kautz et al., which 
 argued against a significant role of macrophage iron in atherosclerosis progression [51]. 
 Results of the study by Kautz et al. indicate that increased macrophage iron as a result of 
a ferroportin mutation, which replicates the effect of increased hepcidin concentration, 
does not promote atherosclerosis. They support their results by stating that macrophages 
are highly resistant to iron-induced damage, and that systemic inflammation is not an 
 invariant feature of atherosclerosis [51]. Nevertheless, their findings do not corroborate with 
results from two experimental studies based on a similar mouse model by Saeed et al. and 
Li et al. [48,50]. Kautz et al. explain their discrepant findings with the study by Saeed et al. by 
suggesting that the effect of macrophage iron on atherosclerosis could be so small that 
 contradictory conclusions might be reached due to differences in study design. Kautz et al. 
do not mention the study by Li et al. The latter study found that hepcidin overexpression 
did not change plaque size, which corroborates results by Kautz et al., but rather plaque 
composition, increasing plaque destabilization, which was not studied by Kautz et al.  
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The evidence for a (causal) role of hepcidin and the ratio hepcidin/ferritin in atherosclerosis 
in the general population is not very strong. Although we had the availability of a unique 
dataset containing data on both hepcidin concentration and NIMA and also genotypes for 
a subset of this group, our sample size was limited. This led to suboptimal power, resulting 
in wide confidence intervals for the associations, genomic correlations and SNP effects esti-
mated in chapter 6 and 7. Furthermore, we observed inconsistent associations of hepcidin 
and the hepcidin ratios for the different NIMA (chapter 6), that each reflect the presence of 
atherosclerosis. In addition, we were unable to study causal effects of hepcidin on NIMA by 
an MR approach due to lack of genetic determinants for hepcidin (chapter 4). The 12 genetic 
variants associated with iron status that we used for our MR, were not perfect as proxies for 
the different iron parameters due to their pleiotropic character, i.e. they influence more than 
one iron parameter, or even show association with other, potentially confounding, traits. 
Four of the 12 SNPs have been reported for association with lipid traits, which are known 
to be associated with atherosclerosis, but including the lipid traits as covariates in our MR 
analyses did not change the conclusions based on unadjusted results. Finally, the estimates 
of genomic correlations and cross-trait associations of NIMA-related SNPs with hepcidin 
and iron parameters provided additional evidence for a role of hepcidin and ferritin in 
 atherosclerosis, but the resulting associations and correlations do however not necessarily 
reflect causal relations, as they might also be a result of pleiotropy.
Taken together, our studies combined with results from previous efforts still provide only 
limit ed evidence for a causal role of hepcidin and the ratio hepcidin/ferritin in atherosclero-
sis  (Table 8.1). To increase knowledge on the hepcidin-atherosclerosis relation in humans, we 
first of all call for studies that replicate our findings in independent populations with a larger 
sample size. These studies could be improved by relying on multiple serum hepcidin measure-
ments over time. We also recommend to extend our MR analysis with genetic determinants for 
serum hepcidin and the ratio hepcidin/ferritin. This is dependent on actually finding variants 
and their suitability for disentangling causal effects of hepcidin and its ratio to ferritin versus 
effects of the iron parameters. The variants should either specifically associate with hepcidin 
or the ratio hepcidin/ferritin and not with the iron parameters, or they should influence these 
traits in an opposite direction. Application of a MV-GWAS could be used in order to find the lat-
ter type of variant, especially by using the methods MV-PLINK, MV-SNPtest, MV-BIMBAM and 
MultiPhen, as we found that these methods show a notable increase in power for scenarios 
with a positive residual and negative genetic correlation (chapter 5). Furthermore, future MR 
studies could consider application of a factorial MR (Burgess et al., submitted), which enables 
estimation of the causal effect of a specific risk factor using pleiotropic genetic variants. This 
could be used to estimate the causal effects of the individual iron parameters using the cur-
rent set of 12 mostly pleiotropic SNPs, which we were unable to do due to our limited sample 
size and resulting extremely wide confidence intervals. Finally, we recommend to study the 
association of hepcidin and the iron parameters with the hard(er) endpoint of clinical disease, 
i.e. occurrence of a cardiovascular event or coronary heart disease. 
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Besides population-based studies, we warrant additional functional studies to test for caus-
ality of the role of hepcidin and the ratio hepcidin/ferritin in atherosclerosis in an experi-
mental setting. These studies could investigate effects of hepcidin agonists, compounds 
that mimic the function of hepcidin or stimulate its endogenous synthesis, and hepcidin 
antagonists, which decrease hepcidin production or block its function [57-59]. There are cur-
rently several efforts ongoing to develop these compounds, and to test them in preclinical 
studies in the context of iron disorders [58,59]. Some of them have even been moved forward to 
phase I and II clinical trials in the context of cancer-related anemias [58]. These studies might 
also differentiate between systemic hepcidin levels, i.e. serum hepcidin levels, and local cell 
or tissue-specific concentrations of hepcidin, which might be of importance in the context 
of atherosclerotic plaques, as also mentioned by Kautz et al. [51].
 
G E N E R A L  D I S C U S S I O N   169
References
1 Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized 
in the liver. J Biol Chem 2001;276:7806-10.
2 Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human 
peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-50.
3 Piperno A, Mariani R, Trombini P, et al. Hepcidin modulation in human diseases: from 
research to clinic. World J Gastroenterol 2009;15:538-51.
4 Swinkels DW, Girelli D, Laarakkers C, et al. Advances in quantitative hepcidin 
measurements by time-of-flight mass spectrometry. PLoS One 2008;3:e2706.
5 Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 
2008;112:4292-7.
6 Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive 
to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-81.
7 Traglia M, Girelli D, Biino G, et al. Association of HFE and TMPRSS6 genetic variants 
with iron and erythrocyte parameters is only in part dependent on serum hepcidin 
concentrations. J Med Genet 2011;48:629-34.
8 Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of Mammalian iron 
metabolism. Cell 2010;142:24-38.
9 Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012;366:348-59.
10 Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to 
ferroportin and inducing its internalization. Science 2004;306:2090-3.
11 Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated 
haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 
2003;361:669-73.
12 Piperno A, Girelli D, Nemeth E, et al. Blunted hepcidin response to oral iron challenge in 
HFE-related hemochromatosis. Blood 2007;110:4096-100.
13 van Dijk BA, Laarakkers CM, Klaver SM, et al. Serum hepcidin levels are innately low in 
HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated 
and normal ferritin levels. Br J Haematol 2008;142:979-85.
14 Tan TC, Crawford DH, Franklin ME, et al. The serum hepcidin:ferritin ratio is a potential 
biomarker for cirrhosis. Liver Int 2012;32:1391-9.
15 Martinelli N, Traglia M, Campostrini N, et al. Increased serum hepcidin levels in subjects 
with the metabolic syndrome: a population study. PLoS One 2012;7:e48250.
16 Donker AE, Raymakers RA, Vlasveld LT, et al. Practice guidelines for the diagnosis and 
management of microcytic anemias due to genetic disorders of iron metabolism or heme 
synthesis. Blood 2014;123:3873-86.
17 Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin 
methods: first steps toward harmonization. Am J Hematol 2012;87:977-83.
18 Benyamin B, Ferreira MA, Willemsen G, et al. Common variants in TMPRSS6 are 
associated with iron status and erythrocyte volume. Nat Genet 2009;41:1173-5.
170 C H A P T E R  8
19 Benyamin B, McRae AF, Zhu G, et al. Variants in TF and HFE explain approximately 40% of 
genetic variation in serum-transferrin levels. Am J Hum Genet 2009;84:60-5.
20 Middelberg RP, Ferreira MA, Henders AK, et al. Genetic variants in LPL, OASL and TOMM40/
APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC 
Med Genet 2011;12:123.
21 Pichler I, Minelli C, Sanna S, et al. Identification of a common variant in the TFR2 
gene implicated in the physiological regulation of serum iron levels. Hum Mol Genet 
2011;20:1232-40.
22 Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron 
concentrations. Blood 2010;115:94-6.
23 Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron 
deficiency. Science 2008;320:1088-92.
24 Ahmad KA, Ahmann JR, Migas MC, et al. Decreased liver hepcidin expression in the Hfe 
knockout mouse. Blood Cells Mol Dis 2002;29:361-6.
25 Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-
refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-71.
26 Hilton KB, Lambert LA. Molecular evolution and characterization of hepcidin gene 
products in vertebrates. Gene 2008;415:40-8.
27 Ganz T. Systemic iron homeostasis. Physiol Rev 2013;93:1721-41.
28 Feng S, Wang S, Chen CC, et al. GWAPower: a statistical power calculation software for 
genome-wide association studies with quantitative traits. BMC Genet 2011;12:12.
29 Grebenchtchikov N, Geurts-Moespot AJ, Trentmann S, et al. Engineered Human Lipocalin 
as an Antibody Mimetic: Application to Analysis of the Small Peptide Hormone Hepcidin. 
Clin Chem 2014;60:897-9.
30 Murphy AT, Witcher DR, Luan P, et al. Quantitation of hepcidin from human and mouse 
serum using liquid chromatography tandem mass spectrometry. Blood 2007;110:1048-54.
31 Schaap CC, Hendriks JC, Kortman GA, et al. Diurnal rhythm rather than dietary iron 
mediates daily hepcidin variations. Clin Chem 2013;59:527-35.
32 Kemna EH, Tjalsma H, Podust VN, et al. Mass spectrometry-based hepcidin 
measurements in serum and urine: analytical aspects and clinical implications. Clin 
Chem 2007;53:620-8.
33 Bridle K, Cheung TK, Murphy T, et al. Hepcidin is down-regulated in alcoholic liver 
injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 
2006;30:106-12.
34 van Santen S, Kroot JJ, Zijderveld G, et al. The iron regulatory hormone hepcidin 
is decreased in pregnancy: a prospective longitudinal study. Clin Chem Lab Med 
2013;51:1395-401.
35 Bush WS, Moore JH. Chapter 11: Genome-wide association studies. PLoS Comput Biol 
2012;8:e1002822.
36 Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
G E N E R A L  D I S C U S S I O N   171
37 Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med 
(Maywood) 2007;232:1014-20.
38 Sullivan JL. Do hemochromatosis mutations protect against iron-mediated 
atherogenesis? Circ Cardiovasc Genet 2009;2:652-7.
39 Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-alpha are significant 
predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial 
Transplant 2011;26:2663-7.
40 van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related to cardiovascular 
events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;28:3062-71.
41 Valenti L, Dongiovanni P, Motta BM, et al. Serum hepcidin and macrophage iron 
correlate with MCP-1 release and vascular damage in patients with metabolic syndrome 
alterations. Arterioscler Thromb Vasc Biol 2011;31:683-90.
42 Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular 
damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 
2011;21:568-75.
43 Kroot JJ, van Dijk BAC, Laarakkers CMM, et al. Serum hepcidin levels are elevated in the 
metabolic syndrome. Arterioscler Thromb Vasc Biol Published online April 29, 2011.
44 Ulu SM, Yuksel S, Altuntas A, et al. Associations between serum hepcidin level, FGF-21 level 
and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol 2014.
45 Samouilidou E, Pantelias K, Petras D, et al. Serum hepcidin levels are associated with 
serum triglycerides and interleukin-6 concentrations in patients with end-stage renal 
disease. Ther Apher Dial 2014;18:279-83.
46 Malyszko J, Malyszko JS, Pawlak K, et al. Hepcidin, an acute-phase protein and a marker of 
inflammation in kidney transplant recipients with and without coronary artery disease. 
Transplant Proc 2006;38:2895-8.
47 Abdel-Khalek MA, El-Barbary AM, Essa SA, et al. Serum hepcidin: a direct link between 
anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid 
arthritis. J Rheumatol 2011;38:2153-9.
48 Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases 
macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. 
Arterioscler Thromb Vasc Biol 2012;32:299-307.
49 Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs macrophage differentiation 
and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol 
2012;59:166-77.
50 Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating 
macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol 2012;32:1158-66.
51 Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a mouse model of 
atherosclerosis. Cell Rep 2013;5:1436-42.
52 Oguz A, Uzunlulu M, Hekim N. Hepcidin is not a marker of chronic inflammation in 
atherosclerosis. Anadolu Kardiyol Derg 2006;6:239-42.
172 C H A P T E R  8
53 Kemna EHJM, Kartikasari AER, van Tits LJH, et al. Regulation of hepcidin: Insights from 
biochemical analyses on human serum samples. Blood Cells Mol Dis 2008;40:339-46.
54  Kemna E, Pickkers P, Nemeth E, et al. Time-course analysis of hepcidin, serum iron, and 
plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-6
55 Roe MA, Spinks C, Heath AL, et al. Serum prohepcidin concentration: no association with 
iron absorption in healthy men; and no relationship with iron status in men carrying HFE 
mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or 
pregnant women. Br J Nutr 2007;97:544-9.
56 Gagliardo B, Kubat N, Faye A, et al. Pro-hepcidin is unable to degrade the iron exporter 
ferroportin unless maturated by a furin-dependent process. J Hepatol 2009;50:394-401.
57 Kroot JJ, Tjalsma H, Fleming RE, et al. Hepcidin in human iron disorders: diagnostic 
implications. Clin Chem 2011;57:1650-69.
58 Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends 
Pharmacol Sci 2014;35:155-61.
59 Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. 
Haematologica 2013;98:1667-76.
  173
Summary
Hepcidin is the key molecule of systemic iron homeostasis. It is known to regulate the 
amount of circulating iron by controlling two processes: (i) the uptake of iron from the in-
testine, and (ii) the release of iron from macrophages that recycle iron from senescent 
erythrocytes. Hepcidin thus determines body iron distribution, i.e. an increased serum hep-
cidin concentration leads to a decrease in serum iron and an increase in the amount of iron 
trapped inside the reticulo-endothelial macrophages, and vice versa. Hepcidin is involved in 
various iron disorders, with hepcidin deficiency leading to iron overload and hepcidin excess 
resulting in low circulating iron and consequently iron-restricted anemia. Hepcidin has also 
been associated with iron disorders related to other diseases, e.g. chronic kidney disease, 
cancer, and the metabolic syndrome. It is also suggested to play a role in the development 
of atherosclerosis, finally leading to cardiovascular disease (CVD). Manipulation of hepcidin 
concentrations is thus potentially useful in clinical practice, and an improved understand-
ing of hepcidin regulation will contribute to the potential of using hepcidin as a therapeutic 
target. 
Although hepcidin was discovered more than 10 years ago, at the beginning of the 21st cen-
tury, our understanding of regulation of hepcidin production is still incomplete. Most  studies 
focused on in vitro or animal models, and only a few explored hepcidin concentrations in 
patient groups or small series of healthy individuals. In this thesis, we focused on serum 
hepcidin concentrations in the general population and aimed to identify biochemical cor-
relates and genetic determinants of serum hepcidin using epidemiological studies (Part I). 
Secondly, we investigated hepcidin as a potential determinant of atherosclerosis and aimed 
to elucidate its effect on non-invasive measurements of atherosclerosis (NIMA) (Part II). 
Chapter 1 provides a general introduction on this thesis. It includes an overview of the cur-
rent knowledge on hepcidin regulation and of the suggested relation between iron, hepci-
din and atherosclerosis. The objectives and outline of this thesis are given as well as a de-
scription of the Nijmegen Biomedical Study (NBS), since all studies in this thesis are based 
on data from this unselected sample of the inhabitants of the municipality of Nijmegen.  
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PART I: Determinants of serum hepcidin
Chapter 2 describes a study in which we constructed reference ranges for serum hepcidin 
and investigated (biochemical) correlates of serum hepcidin in almost 3,000 participants 
of the general population. Reference ranges were assessed in a subset from which we ex-
cluded persons with characteristics evidently influencing serum hepcidin concentration. 
We demonstrated that serum hepcidin concentrations are lower for premenopausal than 
for postmenopausal women but are constant over age in men. Furthermore, we observed 
a trend of increasing hepcidin concentration during the day. We applied regression ana-
lyses to study associations of hepcidin with the iron parameters [serum ferritin, serum iron, 
total iron-binding capacity (TIBC), transferrin saturation (TS)], body-mass index (BMI), ala-
nine aminotransferase (ALT) as a marker of liver damage, estimated glomerular filtration 
rate (eGFR) as a marker of kidney function, and the inflammatory marker C-reactive protein 
(CRP). This revealed that serum ferritin is the strongest correlate of serum hepcidin in both 
men and women, explaining approximately 60% of serum hepcidin variance. Additional 
significant, though less strong, associations were observed for CRP and TIBC in men and for 
TIBC, ALT, and eGFR in women.
In chapter 3, we performed a candidate-gene association study focusing on HFE and 
 TMPRSS6. The single nucleotide polymorphisms (SNPs) rs1800562 in HFE (p.Cys282Tyr) and 
rs855791 in TMPRSS6 had previously been associated with iron, and it was commonly be-
lieved that these associations could be explained by the intermediate effect on hepcidin 
concentration. However, the results of an Italian study did not support an intermediate role 
for hepcidin in the SNP–iron parameter associations. We replicated this finding in the NBS. 
We showed that rs1800562 and rs855791 are not associated with serum hepcidin, but did 
find evidence for associations of these SNPs with the ratios hepcidin/ferritin and hepcidin/
TS. The ratios hepcidin/ferritin and hepcidin/TS reflect the amount of hepcidin relative to 
iron stores and circulating iron, respectively. Adjustment for hepcidin or the ratio hepcidin/
ferritin did not decrease the strength of associations of the SNPs with iron, suggesting that 
these SNPs exert a pleiotropic effect on the iron parameters and hepcidin ratios. This unex-
pected finding in the Italian as well as our Dutch study indicates that there are hepcidin-in-
dependent mechanisms that are responsible for the associations of rs1800562 and rs855791 
with iron. 
The aim of chapter 4 was to identify genetic determinants of serum hepcidin to obtain bet-
ter insights in its regulation. We performed a genome-wide association study (GWAS) on 
serum hepcidin in the NBS and combined the results with the GWAS results from two other 
cohorts in a meta-analysis. These three cohorts are the only three cohorts worldwide that 
have both genome-wide single nucleotide polymorphism (SNP) data and serum hepcidin 
measurements. In total, we included 6,096 samples. We replicated six genetic variants in up 
to 3,826 additional independent samples from two of the three cohorts. Our study revealed 
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one interesting locus (linkage disequilibrium region from EML6 to SPTBN1 (alias ELF), lead 
SNP rs354202) potentially associated with serum hepcidin concentration. The ELF protein 
is essential in TGF-β signaling by son of mothers against decapentaplegic (SMAD) proteins 
in mice, and the bone morphogenetic protein-SMAD pathway is central in hepcidin regu-
lation. The effect estimates and p-values of the associations of rs354202 with the ratios 
hepcidin/ferritin and hepcidin/TS were not genome-wide significant. The common variants 
rs1800562 (p.Cys282Tyr) in HFE and rs855791 (p.Ala736Val) in TMPRSS6 showed strong associ-
ations with the ratio hepcidin/ferritin but not with hepcidin.  
In conclusion, we warrant follow-up of rs354202 in additional association studies and rec-
ommend to start functional studies if the association of rs354202 with serum hepcidin has 
been clearly established. 
In chapter 5, we presented the results of a comparison study of a selection of multivariate 
(MV) GWAS methods. In a MV-GWAS, multiple traits are analyzed for their association with 
genetic variants jointly. The goal of this study was to guide researchers in their choice of an 
appropriate MV-GWA method with respect to their research question and data, aiming to 
increase the appropriate use of MV-GWAS. We focused on a selection of six methods that 
are readily available as free software packages. We used simulated data to compare the 
 methods, and we determined empirical significance thresholds to fix type I errors at α=5% 
and allow for a fair power comparison. We simulated data for 1000 participants, three quan-
titative traits and one quantitative trait locus (QTL). Our results showed that all methods 
can increase power compared to a univariate analysis that has appropriately been adjusted 
for testing multiple traits, even when only one of the traits is associated with the QTL. Four 
of the methods showed similar performance across all simulation scenarios: MV-PLINK, 
MV-SNPTEST, MV-BIMBAM and MultiPhen. These methods performed best over almost 
all of the simulation scenarios, with a sharp increase in power for scenarios with a  genetic 
correlation that was opposite in sign compared to the residual correlation. The two other 
 methods, TATES and PCHAT, showed a more constant performance over the simulation 
scen arios, but always resulted in lower power than the other four methods. In conclusion, 
we recommend to apply MV-GWAS methods, because it increases power to identify genetic 
determinants of the trait(s) of interest, even when genetic correlations between the traits 
are weak.  
PART II: Effects on atherosclerosis
In chapter 6, we assessed the associations of hepcidin and the iron parameters with 
non-invasive measurements of atherosclerosis (NIMA) in men and women separately. 
NIMA were presence of plaque, intima-media thickness, and ankle-brachial index at rest 
and after exercise. We included 766 NBS participants for which we had measurements of 
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hepcidin, iron parameters, NIMA and potential confounding factors. Associations were 
studied using  multivariable logistic and linear regression analyses using quartiles of hepci-
din and iron parameters. We adjusted for the following potential confounding factors: time 
of blood sampling, CRP, high sensitive CRP, BMI, eGFR, ALT, folate, presence of anemia, time 
between baseline and follow-up and traditional risk factors based on the Framingham risk 
score, i.e. age, systolic blood pressure, smoking, diabetes, total cholesterol, HDL cholesterol 
and reported use of antihypertensive treatment, lipid lowering medication or anticoagu-
lants. For females, we additionally adjusted for the use of hormone replacement therapy. 
Hepcidin and the hepcidin/ferritin ratio were significantly associated with the presence of 
plaque in women. The hepcidin/ferritin ratio was significantly and negatively associated 
with  ankle-brachial index at rest in men and women. Our results indicate that the body iron 
distribution as determined by hepcidin and the ratio hepcidin/ferritin plays a role in athero-
sclerosis in women and to a lesser extent in men. 
In chapter 7, we studied the associations of hepcidin and the iron parameters with NIMA 
from a genetic perspective. We aimed to shed light on causality of the associations that we 
identified in chapter 6 by use of a Mendelian randomization (MR) approach. For this, we 
used 12 genetic variants that were among the top results of a recent meta-analysis of GWAS 
on iron status. We could not perform a MR analysis for hepcidin due to the lack of estab-
lished genetic determinants for serum hepcidin. We also studied associations of athero-
sclerosis-related SNPs with iron and hepcidin. Finally, we estimated genomic correlations 
of hepcidin and the iron parameters with atherosclerosis. Other than for rs651007, associ-
ated with decreased ferritin concentration and decreased atherosclerosis risk, we observed 
no SNP associations that fit the hypothesized directions of effect between iron and NIMA. 
 Associations of the six NIMA-related SNPs with hepcidin and iron parameters revealed two 
nominally statistically significant and directionally consistent associations with the ratio 
hepcidin/ferritin. The associations of these two SNPs with NIMA corroborate with an in-
creased risk of atherosclerosis, and they associated positively with hepcidin/ferritin. The 
estimated genomic correlations were all close to zero , except for hepcidin and ferritin with 
ABI at rest and ABI after exercise for which we found non-significant negative correlations. 
These negative correlations indicate that increased hepcidin and ferritin concentrations 
are associated with decreased ABI, which corresponds to an increased risk of atheroscle-
rosis. Taken together, our results indicate a potential causal role for hepcidin and ferritin in 
 atherosclerosis, but not for the other iron parameters. 
In conclusion, our population-based studies have led to new insights into biochemical and 
genetic determinants of serum hepcidin and its effects on atherosclerosis in humans. We 
revealed that ferritin is the most important correlate of serum hepcidin, and that the other 
iron parameters showed a less strong association with serum hepcidin. The importance of 
the balance between hepcidin and ferritin is demonstrated by studies in which the ratio 
hepcidin/ferritin was reported to be a biomarker for disease, as was shown for hereditary 
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hemochromatosis and for our studies regarding atherosclerosis. Our candidate-gene ap-
proach, focusing on plausible genes, did not reveal genetic determinants of serum hepcidin, 
but it learned that previously identified associations of common variants in these genes 
with the iron parameters are independent of serum hepcidin and the ratio hepcidin/ferritin. 
Our meta-analysis of GWAS including all currently existing cohorts with both genotype data 
and hepcidin measurements did result in identification of one common variant potentially 
associated with serum hepcidin. In this respect, application of a multivariate GWAS for hep-
cidin and (a selection of) the iron parameters might be valuable, especially since it does not 
require additional investments given that the data are already available. Our studies into 
the role of hepcidin in atherosclerosis showed that hepcidin and the ratio hepcidin/ferritin 
are associated with NIMA, and provided indications that these associations are causal. The 
evidence that we provided is however weak, so we warrant follow-up of these studies in 
larger and independent populations. 
Chapter 8 contains a general discussion of the studies described in this thesis and provides 
directions for future research. 
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Samenvatting
Hepcidine speelt een sleutelrol in de systemische ijzerhomeostase. Het reguleert de hoe-
veelheid circulerend ijzer via beïnvloeding van twee processen: (i) de opname van ijzer uit 
de darm, en (ii) de afgifte van ijzer uit macrofagen die ijzer van verouderde erytro cyten 
 recyclen. Hepcidine bepaalt dus de distributie van ijzer over het lichaam, waarbij een ver-
hoogde concentratie van serum hepcidine leidt tot een afname van serum ijzer en een 
toename van de hoeveelheid ijzer opgeslagen in de reticulo-endotheliale macrofagen, en 
vice versa. Hepcidine speelt een rol bij verschillende aangeboren ijzerstofwisselingsziektes, 
waarbij hepcidine-deficiëntie leidt tot een ijzeroverschot en hoge serumspiegels van hepci-
dine resulteren in een lage concentratie van circulerend ijzer en daardoor een ijzergebreks-
anemie. Daarnaast hangt de hepcidine concentratie samen met ijzerstofwisselingsziektes 
die kunnen ontstaan als gevolg van andere ziektes, zoals chronische nierziekten, kanker, en 
het metabool syndroom. Er is eerder beschreven dat hepcidine een rol speelt in de ontwikke-
ling van atherosclerose, uiteindelijk leidend tot hart- en vaatziekten (HVZ). Manipulatie van 
de concentratie van serum hepcidine kan dus mogelijk waardevol zijn voor toepassing in de 
kliniek. Er is echter eerst meer inzicht nodig in de regulatie van serum hepcidine voordat het 
eventueel in de toekomst als therapeutisch target gebruikt kan worden. 
Alhoewel hepcidine aan het begin van de 21e eeuw en dus meer dan 10 jaar geleden is ont-
dekt, is de huidige kennis over de regulatie van de productie van hepcidine nog steeds in-
compleet. De meeste studies die tot nu toe zijn uitgevoerd, waren gebaseerd op gebruik van 
in vitro en diermodellen. Bij de start van dit onderzoek waren er slechts enkele studies uit-
gevoerd die concentraties van hepcidine in patiëntengroepen of kleine aantallen gezonde 
individuen hebben bestudeerd. In dit proefschrift hebben we ons gericht op concentraties 
van serum hepcidine in de algemene populatie met als doel biochemische en genetische 
determinanten van serum hepcidine te identificeren, gebruikmakend van epidemiologische 
studies (Deel I). Ten tweede hebben we de rol van hepcidine als potentiële determinant van 
atherosclerose onderzocht; meer specifiek is gepoogd de effecten van serum hepcidine op 
non-invasieve metingen van atherosclerose (NIMA) op te helderen (Deel II). 
Hoofdstuk 1 bevat een algemene introductie van deze thesis. Het geeft een overzicht van 
de huidige kennis over regulatie van hepcidine en over de veronderstelde relatie tussen ijzer, 
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hepcidine en atherosclerose. De doelen en de inhoud van dit proefschrift worden beschre-
ven. Tevens wordt een beschrijving van de Nijmegen Biomedische Studie (NBS) gegeven, 
aangezien alle studies in dit proefschrift zijn gebaseerd op data van deze steekproef van 
inwoners van de gemeente Nijmegen.
Deel I: Determinanten van serum hepcidine
Hoofdstuk 2 beschrijft een studie waarin we referentiewaardes voor serum hepcidine heb-
ben geconstrueerd en waarin we de samenhang hebben onderzocht tussen biomarkers in 
het bloed en serum hepcidine in een steekproef van bijna 3000 individuen uit de algemene 
populatie. Referentiewaardes werden bepaald in een subset van deze groep, waaruit we 
personen hebben geëxcludeerd met kenmerken die volgens eerdere studies de concentratie 
van serum hepcidine beïnvloeden. We toonden aan dat concentraties van serum hepcidi-
ne lager zijn in premenopausale dan in postmenopausale vrouwen, maar constant blijven 
met toenemende leeftijd in mannen. Daarnaast vonden we een trend van toenemende con-
centraties van hepcidine gedurende de dag. We hebben regressieanalyses toegepast om de 
associaties van serum hepcidine met de ijzerparameters [serum ferritine, serum ijzer, totale 
ijzerbindingscapaciteit (TIBC), transferrinesaturatie (TS)], body-mass index (BMI), alanine 
aminotransferase (ALAT) als een marker van leverschade, geschatte glomerulaire filtratie-
rate (eGFR) als een marker van nierfunctie, en de ontstekingsmarker C-reactief proteïne 
(CRP) te onderzoeken. Hieruit bleek dat serum ferritine het sterkst samenhangt met serum 
hepcidine in zowel mannen als vrouwen. Serum ferritine verklaarde ongeveer 60% van de 
totale variantie in de concentratie van serum hepcidine. Daarnaast observeerden we signi-
ficante associaties met hepcidine, alhoewel minder sterk, voor CRP en TIBC in mannen en 
voor TIBC, ALAT en eGFR in vrouwen. 
Hoofdstuk 3 beschrijft een kandidaatgen associatiestudie waarbij we ons hebben gericht 
op de genen HFE en TMPRSS6. De single nucleotide polymorfismen (SNPs) rs1800562 in HFE 
(p.Cys282Tyr) en rs855791 in TMPRSS6 zijn eerder geassocieerd met ijzer en de gedachte was 
dat deze associaties verklaard konden worden door een intermediair effect van deze SNPs 
op de concentratie van serum hepcidine. De resultaten van een Italiaanse studie leverden 
 echter geen bewijs voor een intermediaire rol voor hepcidine in de SNP–ijzerparameter 
associaties. Wij repliceerden deze bevinding in de NBS. We toonden aan dat rs1800562 en 
rs855791 niet zijn geassocieerd met serum hepcidine, maar we vonden bewijs voor asso-
ciaties van deze SNPs met de ratio’s hepcidine/ferritine en hepcidine/TS. De ratio’s hepci-
dine/ferritine en hepcidine/TS reflecteren de hoeveelheid hepcidine ten opzichte van res-
pectievelijk de ijzervoorraad in het lichaam en de hoeveelheid circulerend ijzer. Correctie 
voor hepcidine of de ratio hepcidine/ferritine leidde niet tot een afname van de sterkte van 
het effect van de associaties van de SNPs met ijzer, hetgeen suggereert dat de SNPs een 
 pleiotroop effect uitoefenen op de ijzerparameters en de hepcidine ratio’s. Deze onverwach-
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te bevinding in zowel de Italiaanse als onze Nederlandse studie wijst erop dat de associa-
ties van rs1800562 en rs855791 met ijzer via mechanismen lopen die onafhankelijk zijn van 
 serum hepcidine. 
Het doel van hoofdstuk 4 was om genetische determinanten van serum hepcidine te iden-
tificeren om meer inzicht te verkrijgen in de regulatie van serum hepcidine. We hebben 
een genoomwijde associatiestudie (GWAS) uitgevoerd voor serum hepcidine in de NBS en 
we hebben de resultaten hiervan gecombineerd met de GWAS resultaten van twee andere 
 cohorten in een meta-analyse. Deze drie cohorten zijn de enige cohorten wereldwijd die zo-
wel genoomwijde SNP data als metingen van serum hepcidine hebben. In totaal hebben we 
6096 samples geïncludeerd. We hebben zes genetische varianten die een sterke associatie 
vertoonden met serum hepcidine gemeten in 3826 additionele, onafhankelijke monsters af-
komstig uit twee van de drie cohorten. Op basis hiervan werd één interessante locus gevon-
den (linkage disequilibrium regio van EML6 tot SPTBN1 (alias ELF), sterkst geassocieerde SNP 
rs354202) die potentieel geassocieerd is met de serum hepcidine concentratie. Het ELF eiwit 
is essentieel voor TGF-β signalering door son of mothers against decapentaplegic (SMAD) 
eitwitten in muizen, en de bone morphogenetic protein-SMAD pathway speelt een cen-
trale rol in hepcidineregulatie. De effectschattingen en p-waardes van de associaties van 
rs354202 met de ratio’s hepcidine/ferritine en hepcidine/TS waren niet genoomwijd statis-
tisch significant. De polymorfismen rs1800562 (p.Cys282Tyr) in HFE en rs855791 (p.Ala736Val) 
in TMPRSS6 vertoonden sterke associaties met de ratio hepcidine/ferritine, maar niet met 
hepcidine. We pleiten voor follow-up van rs354202 in additionele associatiestudies en beve-
len de start van functionele studies aan als de associatie van rs354202 met serum hepcidine 
overtuigend is aangetoond.
In hoofdstuk 5 presenteren we de resultaten van een studie waarin we een selectie van 
multivariate (MV) analysemethoden voor GWAS hebben vergeleken. In een MV-GWAS wor-
den meerdere traits tegelijkertijd geanalyseerd om hun gezamenlijke associatie met gene-
tische varianten te onderzoeken. Het doel van onze studie was om onderzoekers te onder-
steunen in hun keuze van de meest geschikte MV-GWAS methode met betrekking tot hun 
vraagstelling en data. We focusten op een selectie van zes methoden die beschikbaar zijn 
als gratis softwarepakketten. We gebruikten gesimuleerde data om de methoden te verge-
lijken, waarbij we empirisch de significantieniveaus hebben bepaald zodat de type I fout op 
α=5% werd gefixeerd voor alle methoden. Op deze manier hebben we ervoor gezorgd dat de 
power van de methoden eenduidig vergeleken kon worden. We hebben data gesimuleerd 
voor 1000 personen, drie quantitative traits en één quantitative trait locus (QTL). Onze resul-
taten tonen aan dat alle methoden de power kunnen verhogen vergeleken met een univa-
riate analyse die op de correcte manier is gecorrigeerd voor het testen van meerdere traits, 
zelfs als slechts één van de drie traits is geassocieerd met de QTL. Vier van de methoden 
presteerden vergelijkbaar voor alle geteste simulatiescenario’s: MV-PLINK, MV-SNPTEST, 
MV-BIMBAM en MultiPhen. Deze methoden presteerden het beste voor bijna alle simula-
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tiescenario’s, waarbij ze een sterke toename in power lieten zien voor simulatiescenario’s 
met een genetische correlatie die een tegengestelde richting had vergeleken met de resi-
duele correlatie. De twee andere methoden, TATES en PCHAT, presteerden meer constant 
over alle simulatiescenario’s, maar ze resulteerden altijd in lagere power dan de andere vier 
methoden. Kortom, we bevelen het gebruik van MV-GWAS methoden aan, omdat het de po-
wer voor identificatie van genetische determinanten van de trait(s) van interesse vergroot, 
zelfs als genetische correlaties tussen de traits laag zijn. 
Deel II: Effecten op atherosclerose
In hoofdstuk 6 hebben we de associaties van hepcidine en de ijzerparameters met niet-in-
vasieve metingen van atherosclerose (NIMA) onderzocht in mannen en vrouwen apart. 
NIMA waren: aanwezigheid van plaque, dikte van de intima media, en de enkel-arm-index 
bij rust en na inspanning. We includeerden 766 NBS deelnemers voor wie metingen van 
hepcidine, ijzerparameters, NIMA en potentiële confounders beschikbaar waren. Multi-
variabele logistische en lineaire regressieanalyses werden toegepast om de associaties te 
bestuderen, gebruikmakend van kwartielen van hepcidine en de ijzerparameters. We heb-
ben gecorrigeerd voor de volgende potentiële confounders: tijd van bloedprikken, CRP, hoog 
sensitief CRP, BMI, eGFR, ALAT, folaat, aanwezigheid van anemie, tijd tussen baseline en 
follow-up, en traditionele risicofactoren gebaseerd op de Framingham risicoscore, namelijk 
leeftijd, systolische bloeddruk, roken, diabetes, totaal cholesterol, high-density lipoprotein 
cholesterol, en gerapporteerd gebruik van antihypertensiva, lipidenverlagende medicatie of 
anticoagulantia. De analyses voor de vrouwen hebben we daarnaast nog gecorrigeerd voor 
het gebruik van hormoonvervangende therapie. Hepcidine en de ratio hepcidine/ferritine 
waren statistisch significant geassocieerd met de aanwezigheid van plaque in vrouwen. De 
ratio hepcidine/ferritine was significant en negatief geassocieerd met de enkel-arm-index 
bij rust in mannen en vrouwen. Onze resultaten suggereren dat de distributie van ijzer over 
het lichaam zoals bepaald door hepcidine en de ratio hepcidine/ferritine een rol speelt in 
atherosclerose in vrouwen en in mindere mate in mannen. 
In hoofdstuk 7 hebben we associaties van hepcidine en de ijzerparameters met NIMA van-
uit een genetisch perspectief bestudeerd. Het doel was om de causaliteit van de associaties 
geïdentificeerd in hoofdstuk 6 te bestuderen door een Mendeliaanse randomisatie (MR) 
benadering toe te passen. Hiervoor hebben we 12 genetische varianten gebruikt die tot de 
topresultaten van een recente meta-analyse van GWAS voor ijzerstatus behoorden. We 
konden geen MR analyse uitvoeren voor hepcidine, omdat er tot op heden geen gene tische 
determinanten voor serum hepcidine bekend zijn. Daarnaast hebben we de associaties van 
atherosclerose-geassocieerde SNPs met ijzer en hepcidine bestudeerd. Tot slot hebben we 
genetische correlaties geschat van hepcidine en de ijzerparameters met atherosclerose. Be-
halve voor rs651007, geassocieerd met een afname in de ferritineconcentratie en een ver-
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laagd risico op atherosclerose, observeerden we geen SNP associaties die overeenkomen 
met de veronderstelde richting van het effect tussen ijzer en NIMA. Associatieanalyse van 
de zes NIMA-geassocieerde SNPs met hepcidine en ijzerparameters liet zien dat twee van 
deze zes SNPs nominaal statistisch significant zijn geassocieerd met de ratio hepcidine/fer-
ritine. De richtingen van het effect van deze SNPs op hepcidine/ferritine waren positief, en 
de associaties van deze SNPs met NIMA komen overeen met een verhoogd risico op atheros-
clerose. Alle geschatte genetische correlaties waren bijna nul, behalve die van hepcidine en 
ferritine met de enkel-arm-index bij rust en na inspanning. Hiervoor vonden we negatieve 
correlaties, alhoewel niet significant. Deze negatieve correlaties wijzen erop dat verhoogde 
hepcidine- en ferritineconcentraties zijn geassocieerd met een verlaagde enkel-arm-index, 
hetgeen overeenkomt met een verhoogd risico op atherosclerose. Onze resultaten suggere-
ren een potentieel causale rol voor hepcidine en ferritine in atherosclerose, maar niet voor 
de andere ijzerparameters. 
Samengevat, onze populatiestudies hebben geleid tot nieuwe inzichten in biochemische 
en genetische determinanten van serum hepcidine en de effecten van hepcidine op athero-
sclerose in de algemene populatie. We ontdekten dat van alle ijzerparameters ferritine het 
sterkst samenhangt met hepcidine. Het belang van de balans tussen hepcidine en ferriti-
ne wordt aangetoond door studies waarin de ratio hepcidine/ferritine wordt gerappor-
teerd als biomarker voor ziekte, zoals bijvoorbeeld voor hereditaire hemochromatose en 
voor onze studies met betrekking tot atherosclerose. Onze kandidaatgen associatiestudie, 
waarin we ons richtten op de biologisch plausibele genen HFE en TMPRSS6, leidde niet tot 
de ontdekking van genetische determinanten voor serum hepcidine. We leerden er wel van 
dat de eerder geïdentificeerde associaties van polymorfismen in deze genen met de ijzer-
parameters onafhankelijk zijn van serum hepcidine en de ratio hepcidine/ferritine. Onze 
meta-analyse van GWAS, waarin we alle momenteel bestaande cohorten met zowel geno-
type data als metingen van serum hepcidine includeerden, resulteerde in identificatie van 
één poly morfisme dat potentieel is geassocieerd met serum hepcidine. Met betrekking tot 
identificatie van genetische determinanten voor serum hepcidine kan toepassing van een 
MV-GWAS voor hepcidine en (een selectie van) de ijzerparameters waardevol zijn, vooral 
omdat geen additionele investeringen nodig zijn daar de data daarvoor reeds beschikbaar 
zijn. Onze studies naar de rol van hepcidine in atherosclerose toonden aan dat hepcidine en 
de ratio hepcidine/ferritine zijn geassocieerd met NIMA. We vonden aanwijzingen dat deze 
associaties causaal zijn. Het bewijs hiervoor is echter niet sterk, daarom bevelen we vervolg-
onderzoek van onze studies aan in grotere en onafhankelijke populaties. 
Hoofdstuk 8 bevat een discussie van de studies beschreven in dit proefschrift en mogelijk-
heden voor vervolgonderzoek.  
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Ongeveer vijf jaar geleden kwam ik in aanraking met de vacature voor het promotieonder-
zoek dat heeft geresulteerd in dit proefschrift. Ik heb destijds lang getwijfeld of ik ervoor 
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ziende blik! En wat heb ik veel van je kunnen leren! Jouw efficiëntie, planmatigheid en pro-
fessionaliteit zijn bewonderenswaardig en je scherpe en gerichte vragen hebben me altijd 
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van mijn wetenschappelijke kennis en capaciteiten, maar ook voor mijn ontwikkeling als 
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mijn zelfvertrouwen doen groeien. Ook de gesprekken over persoonlijke zaken, al dan niet in 
relatie tot de wetenschap, heb ik heel erg gewaardeerd. Het was fantastisch om samen met 
jou de brug tussen biologisch en (genetisch) epidemiologisch denken te bouwen!
Bart, ik wil jou graag bedanken voor je frisse en kritische blik op mijn manuscripten. Ik sta 
nog steeds versteld van de snelheid waarmee ik je feedback op mijn manuscripten ontving, 
waarbij je altijd precies de vinger op de zere plek(ken) wist te leggen. Ook wil ik je bedanken 
voor het feit dat ik de praktische coördinatie van de Nijmegen Biomedische Studie (NBS) op 
me heb mogen nemen, want ik heb er veel van geleerd. Ik ben blij dat ik als postdoc in de 
kankerepidemiologiegroep kan blijven werken en zie uit naar onze samenwerking op het 
gebied van de urologische tumoren. 
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Luc, jij was betrokken bij hoofdstuk 5 en 7 van mijn proefschrift. Ik herinner me nog goed hoe 
ik in mijn eerste jaar flink heb zitten oefenen met de door jou ontwikkelde software ‘Bayz’. 
Jouw deur stond altijd open voor vragen, live en via skype en e-mail, en je geduld daarbij is 
heel waardevol voor mij geweest. Ook bedankt voor alle keren dat je naar Nijmegen bent 
gekomen om live analyses en resultaten te bespreken. 
Alejandro, jij hebt me begeleid tijdens mijn eerste stapjes in de wondere linux-wereld. Ik 
heb twee jaar met veel plezier onder jouw begeleiding gewerkt bij Genetica en veel van je 
geleerd. Ik ben je dankbaar voor je continue support en meedenken.
Beste co-auteurs van de artikelen in mijn proefschrift, ook jullie wil ik graag bedanken. Ik 
stel jullie bijdrage, van het uitvoeren van de metingen in het lab tot het geven van input op 
inhoudelijk en methodologisch gebied, enorm op prijs. Daarnaast wil ik de deelnemers van 
de NBS heel hartelijk bedanken voor het afstaan van bloed, het invullen van vragenlijsten 
en het ondergaan van de NIMA-metingen. En ik bedank graag het NBS stuurteam voor het 
opzetten van deze prachtige biobank.  
Beste collega’s van HEV, ik wil jullie heel graag bedanken voor jullie professionele input, col-
legialiteit en gezelligheid! Ik heb me altijd heel erg thuis gevoeld op de afdeling en op ‘de 3e’, 
en ik heb genoten van de gezellige pauzes vol geklets, de grappen op de gang, en de vele soci-
ale activiteiten die we buiten werktijd in diverse samenstellingen hebben gedaan: borrelen, 
het fameuze bowlen (hopelijk blijft mijn topscore nog lang staan ), etentjes, pubquizzen, 
sportactiviteiten, feestjes, karaoke-, stap- en dansavondjes (en nachten ), etc.! 
Beste collega’s van de ijzergroep en leden van de statistical genetics groep, ook jullie wil ik 
bedanken voor jullie waardevolle input op mijn presentaties en de nuttige besprekingen (en 
de gezellige congressen met de ijzergroep ). 
In June 2013, I spent one month at the University of Cambridge, UK. Prof. Willem Ouwehand, 
dr. Augusto Rendon and dr. Emanuele Di Angelantonio, thank you very much for your warm 
welcome, it was a very inspiring stay and it really meant a lot to me. Stephen Burgess, thank 
you for your time to discuss Mendelian randomization. Dear Tiphaine and Ernest, thank you 
very much for introducing me in Cambridge social life in the most pleasant month of the 
year!
Lieve vrienden en vriendinnen, ook jullie hebben aan dit boekje bijgedragen! Ik ben jullie 
heel erg dankbaar voor jullie vriendschap, jullie zijn allemaal heel bijzonder en speciaal voor 
mij op jullie eigen manier, zie de persoonlijke boodschap voorin jullie boekje .
Lieve Anne en Loek, wat ben ik blij dat jullie mijn paranimfen willen zijn! Met jullie aan mijn 
zijden moet het goed komen! En ik ben blij dat we een noodplan hebben, mocht ik flauw-
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vallen: Loek, jij weet mij vast weer snel bij mijn positieven te brengen (zing gewoon een lied-
je ) en Anne, ik heb het volste vertrouwen in jou om mij te vervangen voor het beantwoor-
den van de vragen!  
Lieve Sterre en Maris, mijn lieve grote kleine zusje en grote kleine broertje, volgens mij heb-
ben jullie flauw idee waar dit boekje over gaat, maar jullie hebben er met jullie liefde aan 
bijgedragen en ik ben heel blij met jullie!
 
Lieve papa en mama, ik wil jullie bedanken voor jullie onvoorwaardelijke liefde en steun, ik 
kan me geen lievere ouders wensen! Jullie hebben me het leven gegeven, dat is het mooiste 
cadeau ooit!
En tot slot wil ik nog heel graag kwijt dat ik de afgelopen jaren voor geen goud had willen 
missen, wat heb ik geleefd! Work hard, play hard! En wat heb ik een zin in de toekomst! 
Op het leven!
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